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Abstract 
 
 
STUART SCOTT DUNN: Shape-Specific Hydrogel Nanoparticles with Defined 
Composition and Surface Properties for Gene Silencing 
(under the direction of Prof. Joseph M. DeSimone) 
  
 
Diseases and disorders may be treated through RNA interference (RNAi), a natural 
post-transcriptional gene silencing event. Synthetic small interfering RNAs (siRNAs) may be 
designed to target specific genes for down-regulation in RNAi therapies. In the delivery of 
siRNA to target cells in vivo, numerous challenges are encountered such as susceptibility to 
degradation by RNases, clearance by the reticuloendothelial system, low internalization by 
cells, and endosomal escape. siRNA may be chemically modified or associated with lipid- or 
polymer-based particulate vehicles to enhance in vivo stability, increase bioavailability, 
improve transfection, facilitate accumulation in particular tissues, and enable cell-specific 
gene silencing. Independent control over the physicochemical properties of nanoparticles in 
the delivery of siRNA was enabled through a particle molding process that is a unique off-
shoot of soft lithography known as PRINT
®
 (Particle Replication in Non-wetting Templates) 
technology. Cationic hydrogel nanoparticles were tested using biocompatible poly(vinyl 
pyrrolidone)- and poly(ethylene glycol) (PEG)-based matrices for their ability to physically 
encapsulate and deliver siRNA to target cells. Effective gene silencing was observed in vitro 
using PEGylated hydrogel nanoparticles without inducing cytotoxicity. Functionalization of 
particles with maleic anhydride-derivatized ligands was pursued to produce a wholly acid-
iii 
 
labile system capable of targeting the transferrin receptor, endosomal escape, and delivery of 
siRNA.  
To maximize retention of siRNA within hydrogel nanoparticles during systemic 
administration or functionalization with ligands, a pro-drug strategy was sought for covalent 
incorporation and triggered intracellular release of siRNA. Gene silencing efficiency and 
biocompatibility were optimized in the pro-drug siRNA system by screening the amine 
content of nanoparticles. When control cargos were implemented in the preparation of 
hydrogels, only target-specific, releasable siRNA cargo elicited gene knockdown. In effort to 
treat liver diseases, nanoparticles were functionalized with ligands targeting hepatocytes, 
cells of liver parenchyma implicated in diseases. Ligand-decorated nanoparticles were 
selectively internalized by hepatocytes in vitro and accumulated in hepatocytes in vivo. 
Hydrogel nanoparticles coated with ligands reduced target liver gene expression after 
administration to mice. Further investigation and exploration of this system will hopefully 
enable efficacious in vivo RNAi therapies in the treatment of numerous diseases. 
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CHAPTER 1 
INTRODUCTION TO GENE THERAPY AND RNA INTEFERENCE 
1.1 Introduction to gene therapy and RNA interference 
1.1.1 Gene therapy and background on nucleic acids 
Diseases and cancers may be treated with gene therapy through the introduction of 
nucleic acids into target cells to modulate gene expression and remedy cellular 
malfunctioning. When errors arise in the production or processing of nucleic acids, 
propagation of genetic mutations can lead to diseases that pose serious threats to health. 
Cancer has received the most attention in clinical trials worldwide, comprising 64.7% of all 
trials while the next most commonly treated diseases are monogenic (8.5%) and 
cardiovascular (8.4%).
1
 Examples of monogenic diseases include cystic fibrosis, 
haemophilia, and severe combined immunodeficiency disorder. In addition to monogenic and 
polygenic (e.g. cancer) diseases, gene therapy efforts have been focused on infectious 
diseases (HIV/AIDS), Alzheimer’s disease, and Parkinson’s disease in clinical trials. 
 Before delving into gene therapy endeavors in detail, an overview of basic biological 
processes should provide a foundation for understanding the mechanisms and motivations 
behind different therapeutic nucleic acids. To begin, nucleic acids are the fundamental 
building blocks of living organisms that provide the blueprints for protein production and 
cellular functions through genetic sequences. Instructions for the development and operations 
of inherited and environmentally influenced traits are contained within the code. Nucleic 
2 
 
acids are polynucleotides (linear polymers of nucleotides) linked 3’ to 5’ via phosphodiester 
bridges (Figure 1.1). There are five bases present in nucleic acids, where one is unique to 
DNA (thymine) and the other to RNA (uracil). The bases provide inter-chain hydrogen 
bonding that dictate structure, e.g. the double helix. DNA and RNA are the two natural forms 
of nucleic acids that are responsible for 
information storage (due to greater stability) 
and expression of the code (due to catalytic 
capabilities), respectively. An exception to this 
statement can be noted in some viruses that 
store their genetic information as RNA.  
DNA has one critical biological role: 
carry and protect genetic code in chromosomes 
to provide information for generating all 
biofunctional macromolecules. Conversely, 
RNA can be seen in multiple copies, forms, 
and functions with one crucial role being the 
transfer of DNA to protein. Nucleic acid 
processing involves intricate pathways (Figure 
1.1),
1
 which play a role in essentially all 
cellular metabolic processes. DNA replication 
may yield an identical molecule, e.g. during 
cell division, while transcription is carried out 
by RNA polymerase to create complementary 
 
Figure 1.1 Biological processes for the 
synthesis of proteins from DNA.
1
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base sequences to DNA in a single-stranded messenger RNA (mRNA). Three-base codons 
on mRNA define a particular amino acid and the sequence of a protein through translation. 
Transfer RNAs carry amino acids and recognize the mRNA codons for synthesis of proteins 
in the ribosome. Biological processes proceed through the transfer of information, starting 
from DNA, moving to mRNA, and then to protein, that governs biological behaviors and 
functions. 
1.1.2 Nucleic acids for gene therapy 
 To fix malfunctions in genetic processing, nucleic acids may be delivered to restore 
normal cellular behavior that alleviates the disease. Currently, some of the most commonly 
delivered nucleic acids are plasmid DNA (pDNA), antisense oligonucleotides (AONs), and 
small interfering RNA (siRNA), each with unique repairing mechanisms. First, pDNA is an 
extrachromosomal form of DNA that generally exists as double stranded and ranges from 1-
200 kilobase pairs, adopting open circular, linear, or supercoiled conformations. Once inside 
the cytoplasm, pDNA must travel to the nucleus by crossing the nuclear pore membrane for 
its expression. In therapeutic applications, pDNA must efficiently insert the critical genes to 
be expressed at specific chromosome locations within the genome to ultimately produce 
desired proteins. Several gene therapies based on plasmids have been approved and are in 
clinical trials, some designed to cure severe combined immunodeficiency, neuroblastoma, or 
cystic fibrosis by replacing or repairing defective genes while cancer may be treated through 
expression of tumor suppressing genes.
2
  
Expression of genes may also be directly modified by introducing exogenous nucleic 
acids with the first example dating back to 1977 where single-stranded DNA was found to 
inhibit translation of a complementary RNA in a cell-free system.
3
 Work continued in this 
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area with the discovery of the natural role of antisense RNA in gene regulation and 
modification, thereby promoting its potential to be harnessed for therapeutics.
4
 Antisense 
therapies can be envisioned to take action at the gene or mRNA level. Single stranded triple-
helix-forming oligodeoxynucleotides (TFOs) are an example of gene level regulators: they 
halt transcription by binding to the major groove of duplex DNA through Hoogsteen bonds 
(Figure 1.2) in purine- or pyrimidine-rich sequences, ultimately preventing the unwinding of 
DNA. TFOs can also induce mutations that repair an inherited or acquired defective gene by 
activating the cellular nucleotide excision repair system.
5,6
 A requirement for successful TFO 
targeting and hybridization is that 10-30 nucleotide stretches of pyridines on one strand with 
pyrimidines on the other must be present, which makes TFO methods less appealing.  
 
Figure 1.2 Gene level triple-helix formation to impede transcription through introduction of 
TFO, which binds to a Watson-Crick paired duplex.
7
 
  
Another approach to take action at the gene level is to use short DNA or RNA decoy 
molecules that compete for transcription factor complexes.
8
 In sequestering the transcription 
factors, the production of undesired mRNA may be arrested. Aptamers are a common 
example of RNA decoy molecules (25–40 nucleotides long) that display highly organized 
tertiary structures and provide specific, high-affinity binding to their target.
9
 With many 
attractive features such as ease of production, low immunogenicity, and long-term storage,
10
 
aptamers are a very promising therapeutic with many potential targets like transcription 
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factors or proteins
11
 involved in diseases. However, aptamers are sometimes limited by the 
requirement for local administration: systemic in vivo delivery would impair proteins in 
untargeted organs; still, there is hope with new delivery technologies. 
 Now, therapeutics working at the mRNA level will be addressed: stoichiometrically, 
it seems less effective than attacking the genetic “source” (DNA); however, mRNA is more 
susceptible to attack since it is single-stranded and unprotected in transcription, transport 
from nucleus to cytoplasm, and translation. Once again, decoys (RNA now) may be 
employed to compete with protein binding sites that serve as translational activators or 
mRNA stabilizers.
12,13
 Consequently, decoys can prevent translation or induce mRNA 
instability, leading to its degradation. More commonly, antisense approaches are taken to 
interfere with gene expression by providing a nucleic acid with a complementary sequence to 
the mRNA of interest for hybridization and subsequent treatment. Direct sequence-specific 
cleavage of transcripts may be achieved with ribozymes or DNAzymes that bind to target 
RNA through Watson-Crick base pairing and contain a catalytic moiety that cleaves the 
hybrid.
14,15
 
 Still targeting mRNA, AONs have evolved from generation to generation, enhancing 
stability and efficiency. First, the backbone of AONs was modified by replacing one of the 
free oxygen atoms on the phosphate group with sulfur, leading to the name phosphorothioate 
deoxyoligonucleotide. Stable to nuclease degradation and effective in targeting mRNA for 
cleavage by RNAse H (a ribonuclease that cleaves the phosphodiester bond), these 
phosphorothioate oligonucleotides showed success;
16
 however, they can bind nonspecifically 
to serum proteins, leading to toxicity and side effects.
17
 Next, alkyl modification were made 
to the ribose ring at the 2’ position to yield 2’-O-methyl or 2’-O-methoxy-ethyl RNA that are 
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less toxic and show high targeting specificity.
18
 Nevertheless, degradation of mRNA through 
RNAse H cannot be triggered and translation of mRNA is generally blocked by duplex 
formation; therefore, silencing efficiency is relatively low. Not directly binding mRNA, 
antisense 2’-O-methylribooligonucleotides can be targeted against specific mutated 
sequences in pre-mRNAs to restore correct splicing of RNAs in vitro; this has been seen in 
targeting β-globin pre-mRNA to treat β-thalassemia and prevent anemia.19 
micro RNA have only limited complementarity (in the seed region) to the target 
mRNA, resulting in repression of translation and non-sequence-specific mRNA 
degradation.
20
 Design of AONs is constantly improving as can be seen with recent 
developments of peptide nucleic acids
21
 and morpholino deoxynucleotides,
22
 which have 
significant modifications to the backbone and nucleotide structures (bases are maintained). 
These highly derivatized AONs exhibit complete nuclease resistance and a translation-
blocking mechanism of the target instead of activating RNAse H for target degradation.  
Direct gene silencing may be achieved efficiently with siRNA, which are short (20–
25 nucleotides), double-stranded RNA, that play crucial biological roles, especially in RNAi. 
Phase I clinical trials for treating age-related macular degeneration have shown that siRNA is 
well tolerated and has desirable pharmacokinetic properties for gene therapy.
23
 Naturally or 
synthetically produced, the antisense strand of siRNA is targeted to a specific gene, which 
has a complementary sequence. Once recognized by the RNA-induced silencing complex 
(RISC), a ribonucleoprotein complex in the cytoplasm, siRNA is unwound and incorporated 
into RISC to locate and bind to its target mRNA sequence. After siRNA binds to the 
complementary mRNA strand, RISC activates a ribonuclease that cleaves and degrades the 
duplex; thus, expression of the target gene is prevented using the natural pathway of RNAi. 
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Regardless of the therapeutic nucleic acid identity and function, the cargo must be delivered 
to the cells of interest, which often proves to be a challenge. To facilitate delivery of 
therapeutic payloads into target tissues, cells, and intracellular compartments, delivery 
vehicles or external devices are often implemented. 
External devices that utilize electric currents include electroporation, which involves 
applying an electric field to permeabilize cell membranes, and iontophoresis, which uses a 
small electric current to deliver charged molecules through skin and tissue. Ultrasound 
therapy has been used along with microbubbles in sonoporation to permeabilize membranes 
for gene delivery. The gene gun was invented to transfect DNA-coated nanoparticles into 
cells to express genes, which has been used in vaccine and plasmid delivery. 
Delivery vehicles may include viruses or nanoparticles for encapsulating the cargo, 
protecting it from degradation, targeting receptors on cells of interest, and releasing the cargo 
in specific extracellular or intracellular locations. Viral vectors are the most commonly used 
delivery vehicle as they demonstrate extremely high transfection efficiency since the 
nanoparticle assembly has evolved over time to transfect genetic material efficiently. The 
process of delivering nucleic acids to target cells, known as transfection, faces challenges in 
vivo and in vitro. When nucleic acids are administered systemically via intravenous injection, 
nucleic acids (in particular, RNAs) are subject to degradation by nucleases, clearance by the 
reticuloendothelial system, and protein fouling. Internalization of nucleic acids by cells may 
not proceed efficiently since the highly charged nucleic acid is generally repelled by the 
negatively charged cell membrane. After uptake of nucleic acids by cells, they must travel to 
specific intracellular locations, such as the cytoplasm or endocytic vesicles for 
oligonucleotides and the nucleus for plasmid DNAs.  
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1.1.3 RNAi for silencing expression of genes in cells 
After covering different therapeutic nucleic acids and their functions for regulating 
gene expression, notable highlights for siRNA include simple delivery to the cytoplasm 
(instead of the nucleus), harnessing the natural pathway of RNA interference (RNAi), high 
potency with catalytic activity, minimization of adverse side effects (that could be caused 
with drugs), and the ability to theoretically target any gene of interest. Avoiding delivery to 
specific intracellular compartments (e.g. vesicles or the nucleus) enables rather facile 
intracellular delivery of siRNA. The post-transcriptional gene regulating phenomenon known 
as RNAi provides innate defense against invading viruses and transposable elements.
24
 In 
1998, Fire and Mello discovered RNAi in the nematode Caenorhabditis elegans
25
  for which 
they received the Nobel Prize in Physiology or Medicine in 2006. Next, Tuschl and 
coworkers demonstrated that synthetic, 21- to 22-nucleotide long double-stranded RNAs are 
sequence-specific mediators for RNAi.
26
  
 
Figure 1.3 Illustration of intracellular gene silencing mechanism mediated by exogenously 
introduced synthetic siRNAs incorporated into the RNA-Induced Silencing Complex (RISC). 
Adapted from Alnylam, Inc. 
  
Synthetic siRNAs can be designed to target a specific gene with minimal off-targeting 
effects. After introduction into the cytoplasm of a cell, siRNA becomes incorporated into the 
CytoplasmExtracellular
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RNA Induced Silencing Complex (RISC), which unwinds the double-stranded siRNA such 
that the antisense strands then targets its complementary mRNA sequence (Figure 1.3). Once 
the antisense strand of siRNA binds to mRNA in the RISC, the mRNA is degraded in the 
cell, preventing its translation and the expression of a target protein. siRNA acts catalytically 
by incorporating into the RISC, whose endonuclease activity is directed by the siRNA, and 
should minimally shutdown off-target genes due to the extensive complementarity required 
between the mRNA and siRNA.
27
 Multiple siRNA libraries exist in literature and industry for 
addressing different gene families and functions. 
1.2 RNAi for therapeutic applications and targeting diseases  
1.2.1 Design of siRNA for effective gene knockdown  
Antisense siRNA sequences may be systematically screened for triggering 
degradation of mRNA from target genes. Characteristics of the siRNA have been shown to 
influence potency for gene silencing. For example, low G/C content, lack of inverted repeats, 
and sense strand preferences were identified to play key roles in siRNA functionality as 
determined in a comprehensive analysis of 180 siRNAs targeting mRNA of two genes.
28
 
Establishing siRNA candidates is a multi-step process, taking into account roles in 
functionality such as single nucleotide polymorphisms as well as mismatch target site 
tolerance and discrimination to produce allele-specific siRNAs.
29
 Dharmacon, Inc., a leader 
in RNAi technology, offers SMARTselection, which is an 8-step process that identifies ideal 
sequences for siRNAs targeting specific genes. Minimizing off-targeting effects and 
expanding knowledge of silencing specificity will further the evolution of effective RNAi 
therapies with increased potency. 
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  Modifications to siRNA and antisense oligonucleotides have been explored to alter 
bioavailability, serum stability, and transfection. Chemical structures of different 
oligonucleotide chemistries focus on backbone and substituent modifications (Figure 1.4). 
For example, phosphorothioate (PS) backbones and 2’-O-methyl substituents increase 
resistance to degradation by nucleases and enhance binding to target RNAs.
30
 Locked nucleic 
acids (LNA) also increase binding to target mRNA and phosphorodiamidate morpholino 
oligomers (PMO) yield neutral oligonucleotide analogs that are extremely stable in the 
presence of nucleases. Positively charged piperazine, amino, and arginine-containing PMOs 
offer enhanced cellular internalization and transfection. Modifications to siRNA that enhance 
resistance to nuclease stability may not increase the duration of gene silencing, but rather 
protect siRNA from degradation in the extracellular environment.  
 
Figure 1.4 Structures of oligonucleotide derivatives for enhanced stability, mRNA binding, 
and intracellular delivery.
30
 
  
Unmodified siRNAs exhibit intracellular stability in living cells, suggesting that 
siRNAs are largely degraded in the extracellular environment.
31
 Kinetics of gene silencing 
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really depend on cell division: unmodified siRNA achieved gene silencing that lasted roughly 
a week in rapidly dividing cells while knockdown persisted for a month in slowly dividing 
fibroblast cells.
32
 To confirm gene silencing kinetic mechanisms, cells with low proliferation 
were investigated: prolonged RNAi was observed in primary macrophages
33
  and mammalian 
cells.
34
 After optimizing sequence specificity and stability of siRNAs, in vivo efficacy mainly 
depends on effective delivery to the target tissue and cell. Design of delivery vectors and 
devices plays a crucial role in influencing biodistribution, cell uptake, and delivery to the 
cytoplasm. First, one must begin with the disease at hand to develop delivery systems before 
determining the best route of administration. 
1.2.2 Targeted diseases in the clinic for RNAi  
Since RNAi offers the ability to theoretically target any gene by using the appropriate 
sequence to silence translation of a given mRNA, several types of diseases have been 
investigated in the clinic with RNAi such as ocular and retinal disorders, cancer, kidney 
disorders, infectious diseases, and liver diseases. Select clinical trials utilizing siRNA for 
different applications are listed in Table 1.1.
35
 For example, in collaboration with siRNA 
therapeutics, Allergan pursued intravitreal injection of siRNA targeting vascular endothelial 
growth factor receptor 1 (VEGF1) to treat age-related macular degeneration choroidal 
neovascularization. Administered siRNA was well-tolerated without dose-limiting toxicity. 
Stabilization and improvement in visual acuity and foveal thickness was noted for patients 
treated with RNAi therapy.
36
 Chronic myeloid leukemia (CML) was tackled by Hadassah 
and the Department of Defense with a S40 lentiviral vector encapsulating siRNA targeting 
one of the two fusion genes in CML patients. The S40 pseudoviral vector was noted to be 
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efficient in gene transmission into human hematopoietic cells, resulting in inhibited cell 
growth and increased sensitivity to imatinib, a tyrosine kinase inhibitor.
35
  
For the injury of kidney acute renal failure, Quark Pharmaceuticals intravenously 
injected naked siRNA (I5NP) to inhibit the expression of the pro-apoptotic protein, p53. 
Dose-dependent attenuation of apoptotic signal was observed where analysis of renal 
histology and apoptosis revealed improved injury scores in both cortical and 
corticomedullary regions. Furthermore, this siRNA to p53 was also effective in a model of 
cisplatin-induced kidney injury.
37
 
Table 1.1 Clinical trials for RNAi therapies.
35
 
Disease Sponsor Drug Target Status 
Macular 
degeneration 
Opko Health, 
Inc. 
Bevasiranib VEGF Phase II 
Glaucoma Sylentis SYL040012 
β2 adrenergic 
receptor 
Phase II 
Solid tumor Calando Pharm. CALAA-01 RRM2 Phase I 
Metastatic 
melanoma 
Duke University NCT00672542 
LMP2, LMP7, 
and MECL1 
Phase I 
Liver cancer NCI TKM-080301 
PLK1 gene 
product 
Phase I 
Hepatitis B 
virus 
Nucleonics, 
Alnylam Pharm. 
NUC B1000 HBV mRNA Phase I 
Hepatitis C 
virus 
Santaris Pharma SPC3649 miR-122 Phase II 
Respiratory 
syncytial 
virus 
Alnylam Pharm. ALN-RSV01 RSV N-gene  Phase II 
Kidney injury 
Quark Pharm, 
Inc. 
QPI-
1002/I5NP 
p53 Phase I 
  
Opko Health, Inc. sought to treat diabetic macular edema through intravitreal 
injection of Cand5, a siRNA that targets VEGF. At multiple dose levels in patients with wet 
age-related macular degeneration, Cand5 was found to be well-tolerated, but the siRNA only 
blocked production of new VEGF (not pre-existing forms); therefore, desirable efficacy was 
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not attained. Baseline treatment with VEGF may be required first to take care of pre-existing 
VEGF to realize therapeutic value for Cand5.
38
 To attain RNAi efficacy in clinical trials, 
platform technologies are under development to enhance delivery of siRNA. 
1.3 Platforms for RNAi therapies 
1.3.1 Route of administration for delivery of RNAi therapeutics  
Accessibility to diseased tissue by siRNA determines the route of administration, 
which broadly includes local, topical, and systemic. Localized delivery of siRNA involves 
direct application to the accessible tissue of interest. Administration of siRNA to the skin 
comprises topical modes of delivery. In tissues which are not accessible directly or through 
topical application of RNAi therapies, systemic administration becomes necessary. Systemic 
delivery concerns the intravenous injection of therapeutics, which take on the intravascular 
journey, encountering in vivo barriers en route to the target tissue and cell. Select in vivo 
studies implementing local, topical, and systemic delivery approaches are outlined as 
therapeutic interventions in Table 1.2. 
Table 1.2 Different routes of administration for RNAi therapies. 
Route of 
administration  
Disease Organ siRNA target 
Electroporation
39
 Cancer Prostate VEGF 
Iontophoresis
40
 Atopic dermatitis Epidermis IL-10 
Ultrasound
41
 Yolk sac carcinoma Tumor MDR1 
Topical
42
 Inflammatory bowel  Rectum CCR5 
Inhalation
43
 Cancer Lung PI 3-kinase, NF-κB 
Topical
44
 Angiogensis Eye TLR3 
Intracranial
45
 Alzheimer Brain BACE1 
Systemic
46
 Ewing’s sarcoma Metastasized tumors EWS-FLI1 
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As a form of local delivery, electroporation involves application of controlled electric 
fields to permeabilize cells for the introduction of siRNA. Implementing “plate and fork” 
electrodes, efficient delivery of siRNA in vivo through electroporation was achieved to 
suppress growth of prostate cancer tumors.
39
 Application of ultrasound to gas-encapsulated 
microbubbles enables sonoporation (permeabilization of cells with sound), which can be 
harnessed for gene therapy. Perfluoropropane gas-encapsulated, PEGylated bubble liposomes 
were combined with siRNA and ultrasound was applied to enable gene silencing in vitro and 
in vivo.
47
 Inhalation of RNAi therapies offers a unique way to reach previously untreatable 
respiratory conditions. Inflammatory and immune conditions, cystic fibrosis, infectious 
diseases, and cancer may be tackled with RNAi therapies through inhalation.
48
  
Alnylam has completed Phase 2b clinical trials on a novel RNAi antiviral therapeutic 
directed against respiratory syncytial virus. Developing systemically-administrable siRNA 
delivery platforms that enable tissue- and cell-targeting capabilities without immunogenicity 
or toxicity should offer translation to other routes of administration. In search of robust RNAi 
delivery platforms, nanoparticles present opportunities to enhance stability, increase 
bioavailability, target tissues and cells, and optimize transfection through combinatorial 
material screening. 
1.3.2  In vivo barriers to systemic delivery of siRNA  
Although nanoparticles may offer beneficial features to enhance RNAi therapies, 
several challenges are still encountered during the in vivo journey after systemic injection. 
Delivery is the key challenge to successful RNAi in vivo. As illustrated in Figure 1.3, 
systemic delivery begins with intravenous injection of an aqueous dispersion containing 
nanoparticles. Hurdles encountered in effective systemic delivery of siRNA include (A) 
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filtration, phagocytosis, and degradation in the bloodstream, (B) extracellular matrix 
diffusion, (C) cellular receptor targeting and uptake, (D) endosomal escape, (E) siRNA 
release or dissociation from the carrier, and (F) intracellular trafficking to the RISC to 
degrade mRNA as illustrated in Figure 1.5. Delivery of naked siRNA may be performed; yet, 
it is highly susceptible to rapid clearance and nuclease degradation, showing low cell uptake 
in systemic delivery.  
 
Figure 1.5 In vivo barriers to systemic delivery of siRNA-containing nanoparticles. 
Administration of nanoparticles, which must: A, avoid clearance and degradation in serum; 
B, travel across the vascular endothelium; C, diffuse in the extracellular matrix to target cells 
for receptor-mediated endocytosis; D, escape endosomal vesicles; E, release siRNA in the 
cytoplasm; F, halt expression of target proteins and degrade mRNA. 
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Hydrodynamic injection of naked nucleic acids may overcome some barriers by using 
a large volume of high pressure solution; however, potential side effects like high blood 
pressure, low heart rate, and death tarnish the appeal. Encapsulation of siRNA in delivery 
vehicles may allow for improved efficiency, stability, and cell specificity while avoiding 
immune responses. Methods to obtain proper packaging of siRNAs, stability, resistance to 
nuclease degradation, and efficient transfections are constantly being developed. Ideal 
nanoparticle features for RNAi in liver or tumor targets include small size (< 150 nm), 
effective siRNA loading and stability, surface decorations like PEG and targeting ligands, 
dispersion stability in serum, endosomolytic (endosome lysing) behavior, and effective 
unpackaging of siRNA cargo in the intracellular environment. 
In the first step of the journey, siRNA may avoid degradation by nucleases through 
appropriate chemical conjugation and/or inclusion within a protective delivery vector. 
Prolonged serum circulation may be achieved by mimicking biological features of red blood 
cells such as with low modulus hydrogel microparticles.
49
 To minimize filtration, 
nanovectors should be greater than 5-10 nm in diameter to avoid kidneys.  PEGylation of 
nanoparticles has been demonstrated to play a crucial role in minimizing clearance by the 
immune system, specifically phagocytic cells of the mononuclear phagocytic system, which 
excels in clearing foreign entities, providing immunity, and clearing nanoparticles. PEG 
provides a stealth-like hydration layer around particles to prevent absorption of serum 
proteins and opsins, which would trigger clearance from the bloodstream. Given appropriate 
time and nanoparticle sizes, diffusion across the extracellular milieu to the target cell may be 
governed by biophysical properties of the delivery vehicle. For instance, liver parenchyma 
(Figure 1.6) consist of 150 nm fenestrations in their sinusoids that present a size restriction 
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upon nanoparticles, which must be below the size of fenestrations to effectively reach liver 
parenchymal cells (hepatocytes).  
After diffusing through extracellular space to the target cell, ligand-conjugated 
nanoparticles may bind to receptors to undergo receptor-mediated endocytosis whereby the 
cell internalizes the vector into an endocytic vesicle. Depending on the cell line and 
individual species, approximately a thirty minute window exists for the nanoparticle to 
escape the endocytic vesicle before lysosomal fusion occurs in which degradation of contents 
by proteases and nucleases will occur. Often amine-containing materials are implemented in 
nanoparticle formulations to escape the endosome by harnessing the so-called “proton 
sponge effect”. Progression of the endosomal vesicle over time is accompanied by decreasing 
pH, proceeding from physiological values to ca. pH 5.5 at the late-stage of the endosome’s 
lifetime. Ionizable groups that have pKa values ranging from physiological to endosomal 
values are capable of buffering the decreasing pH of the endosome, resulting in an influx of 
protons and chloride ions to maintain the pH of the endosome. Resulting, osmotic pressure 
may increase such that the endosome becomes unstable and ruptures, releasing its contents 
into the cytoplasm. Alternatives to exploiting the “proton sponge effect” include use of 
membrane-lysing or -fusing species as well as pore-forming peptides. In the process of or 
after endosomal escape, nanoparticles may release siRNA into the cytoplasm where it 
incorporates into the RISC to silence gene expression by binding to and triggering 
degradation of target mRNA. 
    
Figure 1.6 Hepatic liver sinusoids with ca. 150 nm fenestrations.
50
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1.3.3 Viral vectors for gene therapy in vivo 
 Produced by nature, viruses are highly evolved nanoparticles of uniform size that are 
coated by a protein shell and contain RNA- or DNA-based genes, which are responsible for 
diseases ranging from minor afflictions such as chickenpox or cold sores to major ones like 
acquired immune deficiency syndrome or severe acute respiratory syndrome. The distinct 
shapes (e.g. icosahedral, helical, or enveloped) and sizes of viruses provide superior abilities 
to infect organisms. Noting their efficiency for inducing disease, viruses may be captured and 
modified to create viral vectors or studied to design synthetic vectors, both aimed in 
opposition to the purpose of viruses: curing disease.  
 
Figure 1.7 Structure of adenovirus with knobs as cell receptor binding agents, spheres as 
proteins, and duplexes as nucleic acids inside.
51
 
 
 Viral vectors are self-assembled particles (~ 100 nm in diameter) and are generally 
composed of lipids, proteins, and nucleic acids. Several types of these vectors exist: one is 
the retrovirus, which protects nucleic acids in a lipid bilayer, while an adenovirus (Figure 
1.7) separates nucleic acids from the environment by a set of tightly packed coat proteins. 
Crucial viral proteins are (a) capsids for nucleic acid condensation, (b) envelopes for cell 
receptor binding, and (c) enzymes for releasing and integrating their cargo into the cell.
52
 
Interestingly, retroviruses can only enter the cell nucleus during mitosis whereas 
adenoviruses bear nuclear localization signals on surface proteins that facilitate their entry 
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through the nuclear pore complex.
53
 A lentiviral vector was created for delivery of siRNA 
targeting BACE1 in a transgenic model that ameliorated Alzheimer disease neuropathy.
45
  
 Considering the aforementioned viral characteristics, viral vectors can overcome the 
major biological hurdles; however, significant drawbacks still are present. Specifically, they 
can be difficult to mass-produce, immunogenic (toxic), and limited to low cargo capacity.
54
 
Some have been noted for their potential to induce mutagenic integration.
55
 Tragically, viral 
vector gene therapies have resulted in death: the first was in 1999 with a patient suffering 
from the inability to metabolize ammonia where the vector triggered an immune response 
that led to multiple organ failure and brain death;
56
 another involved the treatment of a 
healthy patient for rheumatoid arthritis in 2007.
57
 Serious risks are present in gene therapy; 
still, instead of these tragedies being research deterrents, they may be viewed as warnings to 
proceed with extreme caution before implementing a system that has not been rigorously 
tested. Furthermore, viral vectors may be investigated to understand how tragedy may be 
prevented while extracting their features for delivery. An alternative to viral vectors for 
delivery of therapeutics involves synthetic vectors. 
1.3.4 Non-viral, synthetic vectors for RNAi  
 For synthetic delivery vehicles, immune responses may be avoided while repeated 
administration, large-scale production at low cost, and complete control over composition 
may be realized.
58
 Since synthetic vehicles may not be composed entirely of biological 
molecules, the first assessment of efficacy resides in biocompatibility, which has been 
broadly defined as “the ability of a material to perform with an appropriate host response in a 
specific application”.59 Evaluating toxicity is crucial in determining the applicability of a 
material for in vivo delivery, which has been extensively reviewed
59,60
  and will be discussed 
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later. Some of the most common carrier molecules for condensing and protecting siRNA are 
cationic lipids and polymers, which yield lipoplexes and polyplexes, respectively. One of the 
most commonly employed polycations for nucleic acid delivery is poly(ethylene imine) 
(PEI), illustrated in Figure 1.8, due to its high gene transfection activity. Molecular weight 
and structure (linear or branched) of PEI substantially impact toxicity and transfection.
61
 The 
mechanism for transfection by PEI has been attributed to the ‘proton sponge effect’: amine 
groups provide pH buffering in the endosome to maintain neutrality and the influx of ions 
causes osmotic swelling and bursting of the endosome, resulting in a release of its contents 
into the cytosol. Thereafter, the polyplex may dissociate so that the polymer may be 
processed while siRNA incorporates into the RISC. 
 
Figure 1.8 Chemical structures of cationic polymers used for siRNA delivery. 
 
 Nucleic acid condensation (or compaction), protection, and transfection may be 
optimized with polycations using computer simulations. For example, considering DNA as a 
semiflexible polymer, a coil-globule transition exists between the elongated and “liquid-
drop-like” compact states. With condensing agents like polyethyleneimine (PEI), the nature 
of the folding transition of DNA governs the final state: a continuous transition yields a 
globule whereas a nano-ordered crystalline state is produced in a discrete transition. The 
globule size is larger, more swollen, and loosely-packed than the ordered crystal.
62
 
Consequently, unique shapes may be observed such as toroids and rods, which can be 
harnessed for effective nucleic acid delivery. The degree of packing may heavily influence 
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protection of the nucleic acid and dissociation of the polyplex in systemic delivery. Studies 
may be performed to identify the best-suited polycation structure for delivering a particular 
nucleic acid or siRNA as a polyplex. Commonly used cationic polymers for transfection are 
illustrated in Figure 1.9 where amine functionality seems to be a common feature, providing 
complexation to nucleic acids, cellular uptake, and endosomal escape. 
 
 
Figure 1.9 Non-viral polycation systems for effective in vivo RNAi. 
 
 Notable cationic polymer-based delivery vehicles are illustrated in Figure 1.7 along 
with details regarding the nanoparticle characteristics, in vivo models, and efficacy. PEI was 
functionalized an RGD ligand, targeting integrins on tumor endothelium, through a PEG 
spacer to provide a functional cationic polymer capable of condensing, protecting, and 
delivering siRNA to target cells while exhibiting colloidal stability and reduction of surface 
charge and aspecific cellular uptake.
63
 Cyclodextrin-containing polycations featuring amidine 
and imidazole ionizable groups were mixed with adamantane-terminated PEG, PEG-
transferrin, and siRNA to produce nanoparticles capable of effective RNAi in vivo, 
demonstrating the first gene silencing in human subjects with melanoma.
64
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amphipathic amino poly(alkyl vinyl ether)s were pursued for establishing endosomolytic 
materials capable of transfection.
65
 After determining the ideal alkyl chain length in 
amphipathic polycations, an approach to mask the membrane-lytic behavior was established 
by reversibly conjugating maleic anhydride derivatives.
66
 Subsequently, conjugation of 
siRNA through a labile bond to amphipathic polycations functionalized with PEG and 
ligand-functionalized PEG enabled in vivo RNAi in mice liver toward the reduction of serum 
cholesterol.
66
 
 
Figure 1.10 Structures of DOPE and DOTAP lipids as well as an illustration of a 
multilamellar lipoplex with nucleic acid sandwiched between bilayers.
67
 
 
 Lipoplexes are generally prepared from cationic liposomes to obtain desirable 
encapsulation efficiency of the siRNA. Cationic liposomes can be generated by dispersing 
cationic and neutral lipids, which contain a polar headgroup and hydrophobic tail, in aqueous 
solution, resulting in the formation of spherical bilayered liposomes. Common cationic and 
neutral lipids employed are N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethyl-
ammoniumchloride (DOTAP) and dioleoylphosphatidylethanolamine (DOPE), shown in 
Figure 1.10. Here, DOTAP serves to bind the negatively charged nucleic acid while DOPE, a 
cone-like lipid, promotes endosomal escape by adopting a hexagonal phase that disrupts the 
membrane.
68
 Lipoplexes are spontaneously formed through electrostatic interactions between 
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the nucleic acid and cationic liposome, leading to self-assembly of lipid bilayers between 
which the nucleic acid is present for multilamellar lipoplexes
 
(Figure 1.10).
69
 
 Lipid-like materials have been most commonly pursued for the effective in vivo 
delivery of siRNA. In Figure 1.11, efficacious in vivo RNAi therapies using lipid-based 
delivery vehicles are illustrated. Cationic or neutral lipids are often formulated with 
cholesterol to enhance bilayer stability and PEGylated lipids to provide the hydrophilic 
stealth-like qualities for prolonged circulation. The rational design of lipids involved pursuit 
of liposomal structures that would undergo an inverted hexagonal phase in the endosome to 
fuse with endosomal membranes in a flip-flop manner to release cargo into the cytosol.
70
 
Ionizable cationic lipids with secondary amine functionality were screened with different 
linkers to observe the influence on RNAi in vivo. An acid-sensitive acetal linker in 1,2-
dilinoleyloxy-3-dimethylaminopropane (DLinDMA)-based lipids was found to enable low 
dose activity in rodents and non-human primates.
71
 A novel lipid (DSGLA) containing 
guanidinium, primary amine, and quaternary ammonium functionality was incorporated into 
lipid-polycation-DNA nanoparticles grafted with an anisamide ligand to facilitate effective 
gene silencing in non-small cell lung adenocarcinoma in vivo.
72
 Stable nucleic acid lipid 
particles were formulated with DLinDMA, cholesterol, PEGylated lipid, and 1,2-distearoyl-
sn-glycero-3-phosphocholine to enable RNAi-mediated liver target gene silencing in non-
human primates.
73
 Combinatorial libraries of lipid-like materials have been synthesized using 
robotic automation to produce lipidoids by reacting alkyl epoxides or acrylics with amines.
74–
77
 Lipid-like materials, when formulated with cholesterol and PEGylated lipids, have 
demonstrated the ability to silence multiple genes simultaneously in vivo at unprecedentedly 
low doses.
75
 The formation of polyplex and lipoplex nanoparticles proceeds through self-
24 
 
assembly, which can depend on several factors such as siRNA content, material identity, and 
concentrations. Conversely, top-down approaches to the fabrication of nanoparticles defines 
biophysical and dimensional properties, which may be tuned to provide efficacious siRNA 
delivery vehicles. 
 
Figure 1.11 Lipid-based delivery vectors for effective RNAi in vivo. 
 
1.4 PRINT technology and application to RNAi 
1.4.1 Background to PRINT technology and applications in materials and life sciences 
Adapting lithographic techniques from the semiconductor industry, PRINT is a top-
down, versatile technology that allows for the preparation of monodisperse particles of 
distinct size, shape, and composition.
78
 PRINT was developed in the DeSimone Lab, from 
which a start-up company was spun-out, namely Liquidia Technologies, to commercialize 
the technology. Depicted in Figure 1.12, a silicon wafer is etched with micro- or nano-scale 
features through traditional photolithography to which a photocurable perfluoropolyether 
(PFPE) resin (Fluorcur
TM
) is applied, completely wetting the surface. The low surface energy 
of PFPE enables complete wetting of the template, after which it is photochemically cured to 
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yield a crosslinked elastomeric mold with shape- and size-specific cavities. Furthermore, the 
low interfacial tension of PFPE provides direct filling of micro- or nano-scale cavities using 
organic liquids without wetting area around the features. As a result, distinct particle are 
fabricated without an interconnecting “scum layer”. Chemical resistance of PFPE also 
prevents its swelling by the liquid precursor, unlike with poly(dimethyl siloxane) molds,
79
 
maintaining the cavity features and allowing virtually any composition to be used.  
 
Figure 1.12 Illustration of PRINT process: a nano- or micro-patterned silicon wafer is 
fabricated through traditional photolithography; PFPE (green) is spread on the template and 
photochemically cured to yield an elastomeric mold; a film (red) may be prepared from a 
pre-particle solution containing various materials; the mold is married to the film through a 
laminator nip, using elevated temperatures if necessary to fill the mold cavities, which are 
then solidified; filled molds may be laminated against a sacrificial harvesting layer (yellow) 
to adhere the harvesting film to the particles; after adhesion, particles may be removed, 
yielding an array of monodisperse particles that may be harvested by passing the particle 
array-covered film through a nip containing a bead of solvent that will dissolve the sacrificial 
polymer to yield a dispersion of monodisperse particles. 
   
The mold cavities may be filled with a monomer liquid precursor through capillary 
forces or a variety of materials through melt-fill processes. For materials below their glass 
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transition or melting temperature, a film of material may be prepared, married to the mold, 
and passed through a heated laminator to flow material into mold cavities. Subsequently, 
particles may be solidified through photochemical crosslinking, vitrification, or 
crystallization. Particles in the mold may be extracted by laminating the mold to a sacrificial 
harvesting layer, using heat if necessary, to promote adhesion. The harvesting film may be 
delaminated from the mold, revealing an array of particles on a sacrificial layer. The particle 
array-covered harvesting layer may be passed through a laminating nip containing a bead of 
appropriate solvent to dissolve the adhesive and yield a dispersion of monodisperse PRINT 
particles. 
Figure 1.13 Range of particle shapes, sizes, and compositions accessible with PRINT. (a) 
Low modulus hydrogel microparticles; (b) 3x1 µm silver particles; (c) 7 µm pollen particles. 
 
Examples of particles with different dimensions, compositions, and deformability 
produced via PRINT illustrate the versatility of the technology (Figure 1.13). Biologically-
relevant cargos may be incorporated in the liquid precursor ranging from nucleic acids and 
proteins to magnetic resonance contrast agents for life science applications. The preparation 
of particles with controlled composition, shape, size, and surface functionalization
80
  enables 
exploration in life sciences and materials science endeavors. For example, application of 
electric fields to anisotropic PRINT particles with unique shapes resulted in alignment of 
particles and crystallization.
81
 Superparamagnetic and ferromagnetic magnetite nanoparticles 
were incorporated into PRINT particles to yield unique magneto-polymer composite particles 
(a) (b) (c)
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with a range of geometries.
82
 Multiphasic and regio-specifically functionalized particles were 
prepared to enable two compositionally different chemistries for Janus particles with particle 
end-labeling via post-functionalization.
83
 By geometrically controlling the chemical 
composition distribution during the fabrication process, amphiphilic block microparticles 
were prepared with high aspect ratio (Figure 1.14). Resulting, a series of di-block, tri-block, 
and multi-block particles were synthesized, exhibiting end-to-end assembly when dry or self-
assembly at oil-water interfaces.
84
 Amphiphilic high aspect ratio particles may find 
applications in the P-N junctions of semiconductors for electronics. 
 
Figure 1.14. Array of 20 x 20 x 240 μm rod particles on harvesting film with tunable 
dimensions in ABA triblock structures. (A) One component hydrophobic particles. (B) One 
component hydrophilic particles. (C-F) ABA triblock particles with different 
hydrophilic/hydrophobic/ hydrophilic ratios corresponding to the four HP4MA concentrations 
of (C): 10, (D): 20, (E): 30, and (F): 50 wt %. C-F were captured by overlaying the images 
under red and green channels.
84
 
 
The physical dimensions of drug delivery vectors have been noted to impact the 
kinetics and mechanism of cell uptake via PRINT technology. For instance, positively 
charged cylindrical particles (diameter = 150 nm, aspect ratio = 3) were taken up by a cancer 
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cell line the most rapidly of eight PEG-based hydrogels having different sizes (0.1 – 5 µm) 
and shapes (cylinders and cubes).
85
 Furthermore, the higher aspect ratio particles were 
internalized through multiple endocytotic routes simultaneously relative to the other particles 
in the study, accounting for their rapid uptake kinetics. The surface charge of particles has 
been observed to play a key role in cellular uptake as well. Acetylating primary amines on 
cationic particles rendered the ζ-potential negative and significantly decreased the amount of 
particles internalized by HeLa cells. Intravenous administration of highly crosslinked 200 nm 
PEG particles to mice indicated accumulation notably in the liver and spleen, accompanied 
by fast clearance (apparent distribution half-life of 17 min followed by slow redistribution 
with a half-life of 3.3 h). The rapid clearance rate of these particles, which is comparable to 
that of non-PEGylated liposomes, may be due to a non-ideal steric layer from low molar 
mass PEG in the particle matrix.  
Toward synthetic blood substitutes exhibiting prolonged circulation times, 
biocompatible red blood cell mimetic (RBCMs) hydrogel microparticles with tunable 
modulus were explored to match the morphology and deformability of erythrocytes
49
  (Figure 
1.15). The deformability of RBCMs was evaluated in vitro in a microfluidic system 
containing narrow channels where low-modulus particles were able to deform and pass 
through slits while high-modulus particles could not effectively translocate. In vivo testing of 
PRINT-based RBCMs demonstrated the impact of RBCM modulus on circulation time, 
ranging from hours for stiff particles to days (half-life = 93 d) for highly-deformable, soft 
particles. Furthermore, the biodistribution of these particles following intravenous injection 
indicated a substantial decrease in lung filtration and a corresponding increase in splenic 
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accumulation over a 24 h period, which was attributed to the long residence time of these 
particles in the vasculature. 
 
Figure 1.15 (a) Representative SEM image showing 96 wt% PEGDA 80 × 5000 nm 
particles. Several particles have detached from the PET sheet and display some flexibility. 
Inset: a fluorescence microscope image of the harvested particles shown in the SEM image. 
Scale bars for both images are 5 μm.87 (b) Fluorescent micrograph of a dispersion of RBCM 
microparticles. Scale bar = 20 μm.49 
  
The ability of PRINT particles to extravasate through nanopores was tested using a 
series of high aspect ratio hydrogel nanoparticles (Figure 1.15).
87
 Filamentous particles 
(except 80 x 5000 nm worms with high cross-link density) were able to translocate across a 
porous membrane, providing promise for high-aspect ratio particles to extravasate through 
pores in biological environments under systemic circulation. Looking at another approach to 
particle delivery, high-performance aerosol particles were pursued for inhalation therapies 
via PRINT technology. Aerodynamic properties were tuned by controlling the size and shape 
of aerosol microparticles, leading to enhanced aerosolization and differential lung deposition 
in vivo.
88
 Different particle compositions were explored for PRINT aerosols using biologics, 
fillers, and pure drugs. The first demonstration of nano-molding of protein particles was 
carried out using neat insulin and albumin in the PRINT process along with therapeutic 
cargos including siRNA and paclitaxel.
89
 In addition to controlling the composition of 
(a) (b)
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PRINT particles, the surface density of antibody ligands was investigated through well-
defined conjugation chemistries to yield insight on the complex role of multivalency in 
targeting the transferrin receptor with nanoparticles toward cancer therapies.
90
 Particles 
labeled with transferrin receptor antibody or human transferrin showed minimal toxicity to 
solid tumor cells lines; however, in Ramos B-cell lymphoma, particles activated apoptotic 
pathways leading to programmed cell death.  
1.4.2 Incorporation of biologically-relevant cargos into PRINT particles for drug 
delivery 
Drugs and biologics have been incorporated into PRINT particles toward therapeutic 
applications to elicit cellular responses. First, doxorubicin, a DNA-intercalating 
anthracycline, was encapsulated into reductively-labile PRINT microparticles for triggered 
intracellular release and induction of cell death in human cervical carcinoma cells.
91
 
Docetaxel, a taxane chemotherapeutic that interferes with cell division, was charged into 
poly(lactic-co-glycolic acid) (PLGA) particles with exceptionally high cargo loading. Dose-
dependent death of ovarian cancer cells was elicited by docetaxel-loaded PLGA PRINT 
particles in vitro.
92
 Controlling the release rate of chemotherapeutics or other biologics could 
be crucial in minimizing off-targeting effects and induction of cell death in healthy cells as 
well as achieving sustained release of drugs in relevant diseases for long-term therapy. A 
family of bifunctional silyl ether crosslinkers were synthesized to produce acid-sensitive 
PRINT particles with controlled rates of degradation.
93
 Varying the size of the alkyl 
substituent on the silicon atom influenced the rate of degradation since the access of water 
and acid to the silyl ether linkages will be governed by the degree of hydrophobicity and 
sterics.  
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Figure 1.16 Controlled release of drugs from silyl ether prodrug-conjugated nanoparticles.
94
 
 
A series of silyl ether prodrugs derived from chemotherapeutics bearing pendant 
alcohols were synthesized for controlled release under intracellular acidic conditions from 
PRINT nanoparticles (Figure 1.16).
94
 The release rate of drug from nanoparticles could be 
controlled by varying the alkyl substituent on the silicon atom. Asymmetric bifunctional silyl 
ether prodrugs enabled controlled release of chemotherapeutics from particles and induced 
death in cancer cells in vitro. Moving to another set of cargos, the controlled release of 
biologics from PRINT particles was engineered by transiently rendering protein-based 
particles insoluble in aqueous environments through crosslinking.
95
 A novel disulfide 
crosslinker was used to render bovine serum albumin (BSA)-based particles insoluble under 
physiological conditions where controlled dissolution would then occur under the reducing 
intracellular environment with the rate of dissolution depending on the degree of 
crosslinking. RNA Replicon, an autonomously replicating RNA, was incorporated into 
crosslinked BSA particles for intracellular delivery and expression of protein. In contrast to 
inducing expression of protein, particles encapsulating oligonucleotides have been explored 
to silence expression of proteins. Multiple siRNAs were encapsulated into PLGA rice-shaped 
nanoparticles for gene silencing in prostate cancer cells.
96
 siRNA-loaded PLGA 
nanoparticles were coated with cationic lipids to enable gene silencing and induction of cell 
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death with siRNA targeting KIF11, which is known to cause mitotic arrest and apoptosis in 
cancer cell lines. 
1.4.3 Design of particles for gene silencing  
Given the ability to tune particle characteristics with PRINT technology, different 
particle dimensions with tailored chemical composition, surface functionality, and cargo 
release profiles may be engineered toward the development of nanoparticles for gene 
silencing. Shape has been seen to play a role in gene silencing efficiency where high-aspect 
ratio polystyrene and shape-shifting PLGA nanoneedles enhanced gene knockdown relative 
to spherical microspheres.
97
 The composition of delivery vectors plays one of the most 
important roles in achieving transfection with siRNA. Features of particles that protect 
siRNA under physiological conditions and enable cell uptake, efficient endosomal escape, 
and release of siRNA are essential to an efficacious platform for RNAi. The structures of 
amine-containing monomers have been explored to optimize gene silencing efficiency in 
nanoparticles self-assembled from polymers and lipids. Applied to PRINT technology, 
different amine-containing monomers and endosomolytic species may be incorporated into or 
coated on particles to bestow gene silencing capabilities.  
Functionalization of particle surfaces with stealthing and targeting ligands may enable 
receptor-mediated endocytosis for transfecting specific cells. Chemical or physical 
approaches taken in functionalization of particle surfaces may influence corresponding 
endosomolytic activity of nanoparticles. Reversibly conjugating or coating ligands to 
nanoparticles, with dissociation of ligands under slightly acidic environments, may enable 
effective gene silencing activity by revealing bare particles with lytic activity in the 
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endosome. Controlled release of siRNA from the particle may be pursued by controlling 
particle charge density, degree of porosity, and method of cargo encapsulation, whether 
through physical entrapment or chemical conjugation. Aforementioned particle 
characteristics may be explored in the PRINT process to provide RNAi therapies toward the 
treatment of diseases. 
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CHAPTER 2 
HYDROGEL NANOPARTICLES FOR TARGETED DELIVERY OF SMALL 
INTERFERING RNA TO CANCER AND LIVER CELLS 
2.1 Introduction to hydrogels for delivery of siRNA 
 Hydrogel particles, comprised of water-loving materials, can be prepared via physical 
self-assembly through secondary interactions or via formation of chemical bonds, leading to 
covalently crosslinked networks. The affinity of hydrogels for water promotes swelling, 
which depends on the degree of crosslinking or identity of chemical groups, e.g. ionizable 
carboxylic acid groups. With desirable features for delivery of siRNA such as 
biocompatibility and potential for loading cargos, hydrogel nanoparticles are mechanically 
robust and may allow for facile tuning of particle composition toward gene silencing.  
Cationic dextran micro- and nanogels have been pursued as biodegradable particles 
for loading siRNA post-fabrication to enable time-controlled delivery of siRNA.
1,2
 Enhanced 
Green Fluorescent Protein (EGFP) was used as the reporter gene in a human hepatocellular 
carcinoma cell line to evaluate gene knockdown efficacy of dextran-based particles. When 
hepatocytes were dosed with microgels and PEGylated nanogels containing siRNA against 
EGFP, gene knockdown was achieved, exhibiting efficacy similar to the commercial 
transfection reagent, RNAiMAX. A straightforward, scalable protocol for preparation of 
amphiphilic nanogels of poly(N-isopropylmethyacrylamide) (NIPAM) as the core component 
was established for “breathing-in” siRNA where lyophilized nanogels were re-suspended in 
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an aqueous solution containing the siRNA.
3
 Poly(NIPAM) exhibits thermoresponsive 
behavior, undergoing a coil-to-globule transition around 43 ºC, and may allow for thermally-
triggered release of cargo. Bare and peptide-functionalized poly(NIPAM) nanogels silenced 
EGFR expression in human ovarian carcinoma cells. Cationic core-shell gel particles were 
prepared for absorption of siRNA post-fabrication and subsequent transfection of African 
green monkey kidney epithelial (BSC-40) cells.
4
 Core-shell particles silenced expression of 
cyclophilin B at the mRNA level as determined by reverse transcriptase polymerase chain 
reaction (RT-PCR).  
A unique approach to deliver siRNA from biopolymer hydrogel scaffolds containing 
cells and siRNA was carried out to provide a minimally invasive, injectable administration 
route.
5
 Macroscopic biopolymer hydrogels encapsulating siRNA were fabricated in transwell 
membranes with 0.4 µm pore size. Ionic- and photo-crosslinking of alginate as well as 
thermal gelation of collagen were explored to synthesize biodegradable hydrogel matrices. 
Green fluorescent protein (GFP)-positive human embryonic kidney (HEK 293) cells were 
cultured with siRNA-loaded alginate and collagen biopolymer hydrogels. Substantial GFP 
knockdown was observed for cells cultured in hydrogel scaffolds after 72 h incubation.  
PRINT technology enables control over the encapsulation of siRNA in hydrogels, 
either through direct physical entrapment or covalent incorporation of siRNA during particle 
fabrication. Additionally, post-fabrication loading of siRNA may be pursued through 
electrostatic attraction; however, the surface properties of particles may be altered and the 
association of cargo with particles may be dynamic. In addition to allowing for control over 
the approach to load siRNA in hydrogels, PRINT allows for the incorporation of relevant 
functional monomers to be carried out in a plug-and-play manner, e.g. implementing 
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monomers with endosomolytic activity, reactive handles, dyes, and triggered degradation. 
Many vinyl-based monomers may undergo photoinitiated free-radical polymerization using 
UV light in a matter of minutes. Rapid production of monodisperse, shape-specific particles 
with tailored key design features may enable gene silencing for a broad range of applications. 
2.2 Cationic poly(vinyl pyrrolidone)-based, degradable hydrogel nanoparticles for 
delivery of siRNA 
As a water-soluble, FDA-approved pharmaceutical excipient with biocompatibility, 
poly(vinyl pyrrolidone) (PVP) is a non-ionic, neutral polymer that has been explored as a 
hydrophilic component of nanoparticles for gene therapy. Although PVP may not condense 
nucleic acids through electrostatics, PVP can interact with DNA base-pairs through hydrogen 
bonding in the major groove in a mildly acidic environment.
6
 DNA plasmids have been 
formulated with PVP for injection into the muscle of rats for expression of β-galactosidase as 
a reporter gene.
7
 Improved tissue dispersion and cellular uptake of pDNA using PVP and 
poly(vinyl alcohol) (PVA) after injection into muscle was attributed to potential osmotic 
effects. For targeted transfection of hepatocytes with plasmid DNA, galactosylated chitosan-
graft-PVP (GCPVP) was implemented in vitro.
8
 Negligible cytotoxicity and transfection was 
encountered for HepG2 cells dosed with GCPVP as noted by minimal cell death and 
appearance of EGFP expression. 
With PVP as the hydrophilic, biocompatible linear polymer of hydrogels, a 
degradable crosslinker was desired for the triggered release of particle contents under 
intracellular conditions. Disulfide-based carriers have attractive qualities for the delivery of 
nucleic acids, which often require localization in the cytoplasm or nucleus of cells for 
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transfection.
9
 The redox gradient that exists between extracellular milieu and the intracellular 
cytoplasm may be exploited for the triggered degradation of disulfide-based carriers after 
internalization by cells due to the inherent intracellular reducing environment. Self-
assembled polymersomes formed from disulfide-linked poly(ethylene glycol)-poly(propylene 
sulfide) block copolymers exhibited disruptive properties after internalization by cells,
10
 
suggesting potential for cytoplasmic delivery of biomacromolecules.  
Dissolution of nanogels synthesized via atom transfer radical polymerization (ATRP) 
for a disulfide-containing crosslinker with oligo(ethylene oxide) monomethoxy methacrylate 
allowed for reductively-triggered degradation (dissolution) and release of a drug 
(doxorubicin) to invoke cell death in a human cervical carcinoma (HeLa) cell line.
11
 
Similarly, Trojan horse PRINT microparticles were prepared for the intracellular delivery of 
doxorubicin using a disulfide-based crosslinker for triggered release of cargo and induction 
of cell death.
12
 Gene transfection was observed for polyplexes prepared from poly(amido 
amine)s containing bioreducible disulfide units that were complexed with plasmid DNA in 
African Green Monkey fibroblast-like kidney (COS-7) cells.
13
 Core-shell type polyplexes 
were fabricated from PEG and PEG-poly(L-lysine) block copolymers with disulfide 
crosslinked cores for effective in vivo gene delivery using plasmid DNA
14
 to mice livers.  
Designing cationic hydrogels has been realized through incorporation of amine-
containing monomers. pH-independent, positively charged particles have been developed by 
incorporating quaternary ammonium-containing monomers, such as 2-[2-(acryloyloxy) 
ethyl]trimethyl ammonium chloride (AETMAC). Cationic polymeric nanogels were 
synthesized via inverse microemulsion polymerization using PEG diacrylate and AETMAC 
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for loading oligonucleotides and DNA.
15
 Uptake of nanogels by HeLa cells and 
corresponding biocompatibility was observed at different N/P ratios. 
In the first generation of PRINT hydrogels for the delivery of siRNA to cells, PVP 
was implemented as the primary hydrophilic component of the particle matrix. The precursor 
monomer to PVP is N-vinyl-2-pyrrolidone (VP), which is a liquid monomer that may be 
polymerized through a photoinitiated free radical mechanism. To provide triggered 
intracellular degradation of hydrogels for release of siRNA cargo, a disulfide-containing 
crosslinker was synthesized and incorporated in particles. Disulfide bonds may be cleaved in 
the intracellular milieu by reducing enzymes while the integrity of disulfide bonds is largely 
maintained in normal extracellular environments.
16,17
 The quaternary ammonium-containing 
monomer, AETMAC, can instill electrostatic attraction between the cationic nanoparticle 
matrix and the negatively charged siRNA. Additionally, the positive charge from AETMAC 
enables non-specific interaction with cells, which have negatively charged membranes, 
resulting in endocytosis, a pathway by which cells internalize molecules, proteins, or 
particles. High charge density of nanoparticles can induce lysis of membranes, which is 
necessary after endocytosis for endosomal escape to effectively deliver siRNA to the 
cytoplasm of cells and avoid degradation in lysosomal vesicles. Incorporation of 
fluorescently-tagged monomers (e.g. fluorescein o-acrylate, FOA) into the hydrogel matrix 
allows for evaluation of cell internalization of particles using flow cytometry. PRINT molds 
filled with pre-particle solutions may be rapidly cured through incorporation of UV-
absorbing photoinitiators that will promote quick free radical photopolymerization under 
exposure to UV light.  
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2.2.1 Experimental 
2.2.1.1 Materials 
Monomers and reagents were purchased from Sigma Aldrich. Molecular biology 
grade solvents (and DEPC-treated water, Ambion, Inc.) were used when mixing components 
with siRNA and they were obtained from Thermo Fisher Scientific, Inc. siRNA was 
purchased from Dharmacon, Inc. with anti-firefly luciferase sequence: 5’-
GAUUAUGUCCGGUUAUGUAUU-3’; anti-sense: 5’-P-UACAUAACCGGACAUAAUC-
UU-3’. The pre-particle solution consisted of dissolving solid and liquid monomers with 
sparse addition of DMSO to provide a homogenous solution. siRNA was dissolved in DEPC-
treated water at 50 mg/mL. The composition of the pre-particle solution was (wt%): N-vinyl-
2-pyrrolidone (VP) (57), bis(ethylene acrylate) disulfide (30), AETMAC (10), FOA (1), 1-
hydroxycyclohexyl phenyl ketone (HCPK) (1), and siRNA (1) with the addition of 10 wt% 
DMSO. A custom-designed, double-nip laminator was implemented for preparing PVP 
particles. PRINT molds were graciously supplied by Liquidia Technologies. 
2.2.1.2 Synthesis of bis(ethylene acrylate) disulfide 
2,2’-dithiodiethanol (1.55 mL, 13 mmol) and triethylamine (5.4 mL, 3 eq) were 
dissolved in a 100-mL round-bottomed flask containing 40 mL of anhydrous 
dichloromethane under an argon blanket followed by submerging the flask in an ice-cold 
water bath. Acryloyl chloride (2.22 mL, 2.5 eq) was added dropwise to the reaction mixture 
and allowed to react for 2 h. The crude product mixture was washed with 1 M HCl three 
times and concentrated via rotary evaporation. The bis(acrylate) crosslinker was purified by 
silica gel column chromatography (4:1 hexanes:ethyl acetate), yielding 2.41 g of crosslinker 
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(71%), and structure was confirmed by 
1
H NMR (400 MHz, CDCl3) δ =  6.45 (dd, J = 17.2 
Hz, 2H), δ = 6.15 (dd, J = 10.3 Hz, 17.3 Hz, 2H), δ = 5.88 (dd, J = 10.6 Hz, 2H), δ = 4.44 (t, 
J = 7.0, 4H), δ = 2.99 (t, J = 7.0 Hz, 4H). 
2.2.1.3 Fabrication of PVP-based hydrogel nanoparticles 
A double nip laminator was used for filling molds against PET followed by 
immediate contact with a sheet of poly(ethylene terephthalate), to which the materials would 
be cured. Filled molds were minimally exposed to air to prevent evaporation of VP monomer 
due to its volatility. 20 µL of pre-particle solution was evenly distributed at the PET-mold 
nip for each foot of mold and laminated at 40 psi followed by a split and immediate 
lamination against corona-treated PET to prevent evaporation of VP. The filled mold-PET 
sandwich was cured in a UV oven ((λmax = 365 nm, 90 mW/cm
2
) for 10 min. The cured mold 
was delaminated from the PET sheet to reveal an array of particles, which were mechanically 
collected using DEPC-treated water and a cell scraper. PVP particles were isolated and 
washed via centrifugation (14 krpm, 4 ºC, 10 min).  
2.2.1.4 Characterization of hydrogels 
ζ-potentials and diameters of particles were determined by light scattering 
(Brookhaven Instruments Inc., 90Plus Particle Size Analyzer and ZetaPlus Zeta Potential 
Analyzer) on 20 µg/mL particle dispersions in 1 mM KCl. Particle concentrations were 
determined via thermogravimetric analysis (Pyris 1, PerkinElmer). For scanning electron 
microscopy, a small volume (5 µL) of particle suspension (1 mg/mL in H2O) was dispensed 
on a glass slide, coated with 2 nm of Au/Pd, and imaged (Hitachi model S-4700). 
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2.2.1.5 Cell culture and assays  
Luciferase-expressing HeLa cell line (HeLa/luc) was from Xenogen. HeLa/luc cells 
were maintained in DMEM high glucose supplemented with 10% FBS, 2 mM L-glutamine, 
50 units/mL penicillin and 50 µg/mL streptomycin, 1 mM sodium pyruvate, and non-
essential amino acids.  All media and supplements were from GIBCO except for FBS which 
was from Mediatech, Inc. Transfection with Lipofectamine
TM
 2000 was carried out according 
to manufacturer instructions. 
In vitro cell uptake analysis. HeLa/luc cells were plated in a 96-well plate at 
10,000/well and incubated overnight at 37°C.  Cells were dosed with particles in OPTI-MEM 
at 37 °C (5 % CO2) for 4 h or indicated time for cell uptake studies.  After incubation, cells 
were washed and detached by trypsinization. After centrifugation, cells were re-suspended in 
a 0.4 % trypan blue (TB) solution in Dulbecco’s Phosphate Buffers Saline solution (DPBS) 
to quench the fluorescein fluorescence from particles associated to the cell surface.  Cells 
were then washed and re-suspended in DPBS or fixed in 1% paraformaldehyde/DPBS, and 
analyzed by CyAn ADP flowcytometer (Dako). Cell uptake was represented as the 
percentage of cells that were positive in fluorescein fluorescence.  
In vitro cytotoxicity and luciferase expression assays. HeLa/luc cells were plated in a 
96-well plate at 10,000/well and incubated overnight at 37°C.  Cells were dosed with 
particles or Lipofectamine
TM
 2000/siRNA mix in OPTI-MEM at 37 °C (5 % CO2) for 4 h, 
then particles were removed, and complete grow medium was added for another 72 h 
incubation at 37°C.  Cell viability was evaluated with Promega CellTiter 96
®
 AQueous One 
Solution Cell Proliferation Assay, and luciferase expression level was evaluated with 
Promega Bright-Glo™ Luciferase Assay according to manufacturer’s instructions.  Light 
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absorption or bioluminescence was measured by a SpectraMax M5 plate reader (Molecular 
Devices).  The viability or luciferase expression of the cells exposed to PRINT particles was 
expressed as a percentage of that for cells grown in the absence of particles.  
2.2.2 Activity of siRNA after exposure to UV light with photoinitiator: compatibility 
with particle fabrication conditions 
Since wavelength-dependent, UV-induced damage (oxidation, dimer formation) has 
been noted for nucleic acids exposed to irradiation,
18–21
 the activity of siRNA was tested 
before and after exposure to UV light. To ensure that siRNA would retain activity when 
incorporated into hydrogels prepared via UV photocuring, a solution of siRNA and 
photoinitiator (HCPK) was treated with UV light for 5 min. The activity of siRNA was 
evaluated through transfection of HeLa cells stably expressing firefly luciferin gene with 
luciferase-targeting siRNA using Lipofectamine
TM
 2000 (Figure 2.1). The activity of UV-
treated siRNA was retained when compared to an untreated solution of siRNA. Viability of 
HeLa cells was maintained across all dosing concentrations. 
 
Figure 2.1 (a) Viability and (b) luciferase expression of HeLa cells dosed with 
Lipofectamine-siRNA complexes for 4 h followed by 72 h incubation. 
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2.2.3 Physicochemical characteristics of PVP-based hydrogels 
Structures of the monomers implemented into the pre-particle solution are illustrated 
in Figure 2.2a. The morphology of PVP-based hydrogels appeared cylindrical and rigid from 
the SEM micrographs in Figure 2.2b since these particles have a relatively high crosslink 
density. The cationic, amine-containing monomer (AETMAC) instilled a highly positive ζ-
potential for these particles (+68.2 ± 1.2 mV), which exhibited a diameter of 440.7 ± 9.2 nm.  
 
Figure 2.2 (a) Chemical structures of monomers implemented in PVP-based cationic 
hydrogel nanoparticles. (b) SEM micrographs of PVP-based particles containing siRNA 
illustrate cylindrical morphology and 200 x 200 nm dimensions. 
 
(a)
(b)
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2.2.4 Dosing PVP hydrogels on HeLa cells for cell uptake, cytocompatibility, and gene 
silencing 
PVP particles containing luciferase siRNA were tested for their ability to silence 
expression of the firefly luciferase gene in human cervical carcinoma (HeLa) cells. 
Internalization of particles proceeded rapidly, reaching saturation at low dosing 
concentrations (Figure 2.3a). Cell viability was maintained above 75% up to 34 µg/mL 
particle dosing concentration (Figure 2.3b). Silencing of luciferase expression was observed 
at 34 µg/mL particle dose (25 nM siRNA for 1 wt% loading); however, at higher particle 
dosing concentrations, cell viability was completely compromised (Figure 2.3b). Although a 
window of gene silencing and tolerable cytotoxicity was observed, a particle composition 
that would be tolerated at high particle doses was desired to allow for complete 
biocompatibility. 
 
Figure 2.3 (a) Uptake of PVP-based particles by HeLa cells and (b) viability and luciferase 
expression of HeLa cells dosed with PVP particles for 4 h followed by 72 h incubation at  
37 ºC. 
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approach to particle fabrication that would enable more flexible mold filling conditions (e.g. 
a composition that would not be sensitive to evaporation of volatile monomers) was pursued 
for faster particle production.  
2.3 Poly(ethylene glycol)-based cationic hydrogel nanoparticles for delivery of siRNA 
Seeking a more flexible particle fabrication procedure and biocompatible 
composition, PEG was investigated as a primary constituent of the particle matrix since 
evaporation should be negligible and the FDA has approved the use of PEG for several 
applications. PEG hydrogels offer attractive features for the encapsulation of biologics and 
therapeutics for biomedical applications.
22,23
 Crosslinked PEG hydrogels offer robust 
mechanical properties while providing the ability to tune modulus and release rate (diffusion) 
of cargos through the crosslinking density. Plasmid DNA has been encapsulated in 
photocrosslinked PEG-based hydrogels with controlled degradation and release 
properties.
24,25
 PEI-siRNA nano- and micro-particle polyplexes have been incorporated into 
photopolymerized PEG hydrogels for transfection of fibrosarcoma epithelial cells
26
 and 
dendritic cells.
27
 
In addition to serving as a hydrophilic, biocompatible network for encapsulation and 
release of biologics, PEG-grafted surfaces may enhance dispersibility (prevent aggregation) 
and cytocompatibility (minimize cellular toxicity) of nanoparticles while prolonging 
circulation time for delivery of siRNA.
28
 For example, combinatorial synthesis of core-shell 
nanoparticles containing monomethoxy oligo(ethylene oxide), to provide a hydrophilic shell, 
enabled encapsulation of siRNA, cellular internalization, and gene silencing in vitro and in 
vivo.
29
 PEG acts as a major component of self-assembled cyclodextrin-based polymer 
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nanoparticles (CALAA-01) containing siRNA in the first targeted delivery of siRNA to 
humans for therapeutic purposes.
30
 Adamantane-PEG and transferrin-modified adamantane-
PEG interact with hydrophobic domains of cyclodextrin through a strong non-covalent 
inclusion complex to provide ligand- and PEG-grafted nanoparticle surfaces for tumor 
delivery.  
To obtain a PRINT hydrogel matrix that would also enable conjugation of ligands 
through efficient reactions, a primary amine-containing monomer (2-aminoethyl 
methacrylate hydrochloride, AEM) was included as a major component of the composition. 
AEM also provides a positive charge to promote electrostatic attraction of siRNA to the 
particle while enabling cell uptake and transfection. The approach to particle fabrication 
involves a film-split procedure where the pre-particle solution is cast onto a sheet of PET to 
produce a thin film of appropriate thickness to fill mold cavities. PEG1K dimethacrylate was 
explored as the crosslinker while monomethoxy PEG5K acrylate served as the hydrophile to 
yield a porous, crosslinked network through which siRNA may diffuse and exit the particle 
as well as creating PEG-grafted surfaces. To minimize cytotoxicity and further promote 
dispersion in aqueous media, particles were PEGylated and tested for their in vitro behavior 
toward cell uptake and tolerance as well as gene knockdown. 
2.3.1 Experimental  
2.3.1.1 Materials 
N,N-dimethylformamide (DMF) (Acros Organics – DNase, RNase, and protease free, 
99.8%), DEPC-treated water (Ambion, Inc.), and potassium chloride solution (0.0100N 
±0.0001N, EMD Chemicals) were obtained from Fisher Scientific. PEG1K dimethacrylate 
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was purchased from Polysciences, Inc. and monomethoxy PEG5K acrylate was obtained from 
Creative PEGWorks. Anti-luciferase and control siRNA genome #3 were obtained from 
Dharmacon, Inc.: control siRNA sense: 5’-AUGUAUUGGCCUGUAUUAGUU-3’; anti-
sense: 5’-P-CUAAUACAGGCCAAUACAUU-3’. 2 mil wire wound rod was purchased 
from R.D. Specialties. Remaining reagents were purchased from Sigma Aldrich or mentioned 
in 2.2.1.1.  
2.3.1.2 Fabrication of PEG-based hydrogels containing siRNA 
2-aminoethyl methacrylate hydrochloride (50 wt%), PEG1K dimethacrylate (23 wt%), 
mPEG5K acrylate (20 wt%), 1-hydroxycyclohexyl phenyl ketone (1 wt%), and fluorescein o-
acrylate (1 wt%) were dissolved in DMF to which a 50 mg/mL solution of siRNA (5 wt%) in 
DEPC-treated water was added to yield a 4.5 wt% solution of solids. With a RNaseZAP-
treated 2 mil wire wound rod, 150 µL of solution was cast at 6 ft/min on a sheet of 
poly(ethylene terephthalate) (PET) while evaporating solvent with a heat gun to yield a 
transparent film. 200 x 200 nm cylindrical PFPE molds (4 x 12”, Liquidia Technologies) 
were laminated against the film at 45 psi and 6 ft/min. The mold was delaminated from the 
film followed by lamination against a corona-treated PET sheet and curing for 5 min in a UV 
chamber (λmax = 365 nm, 90 mW/cm
2
). The mold was delaminated from the PET sheet, 
revealing an array of particles on the PET sheet that were collected mechanically with 
DEPC-treated water using a cell scraper (1 mL/48 in
2
 of mold). The particle dispersion was 
centrifuged at 4 °C and 14 krpm for 15 min, followed by removal of the supernatant and re-
suspension in an appropriate volume of water for thermogravimetric analysis to determine 
particle yield. 
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2.3.1.3 Functionalization of PEG particles 
PEGylation through imine formation: particles were dispersed in pH 6.6 buffer at 1 
mg/mL to which monomethoxy PEG5K monoaldehyde (2 wt eq) was added and the reaction 
was allowed to proceed for 6 h followed by washing particles with buffer. 
PEGylation through amide formation: particles were dispersed in DMF at 2 mg/mL to 
which monosuccinimidyl succinate monomethoxy PEG2K (2 wt eq) and pyridine (4 wt eq) 
were added and reacted for 6 h followed by washing particles and re-suspending them in 
water. 
2.3.1.4 Characterization of hydrogel nanoparticles 
ζ-potential, diameters, yield, and morphology of particles was determined as 
previously described in 2.2.1.4. The release of siRNA from particles was evaluated by 
agarose gel electrophoresis: siRNA-loaded particles were incubated in PBS at 37°C for 
indicated times followed by centrifugation at 14 krpm for 15 min at 4°C.  The supernatants 
were collected and saved at -80 °C. 12 µL of sample (supernatants from particle dispersions, 
siRNA solutions, or particle dispersions) was mixed with 3 µL of 6x loading buffer (60% 
glycerol, 0.12 M EDTA in DEPC-treated water) and loaded into the gel. 70 V/cm was 
applied for 25 min and the gel was then imaged with ImageQuant LAS 4000 (GE). Analysis 
of siRNA band intensity was conducted with Image J software for quantification. siRNA 
loading was calculated by comparing the maximum amount of siRNA released to the particle 
mass.  Encapsulation efficiency of siRNA was calculated by comparing the wt% of final 
siRNA loading to the siRNA charged into the pre-particle composition (5 wt% of particle).  
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2.3.1.5 Cell culture and confocal laser scanning microscopy 
Cell culture and assays were conducted in a similar manner as reported in 2.2.1.5. For 
confocal microscopy, HeLa/luc cells were plated in 8-well chamber slides (BD) at 
10,000/well and incubated overnight at 37°C.  Cells were dosed with green fluorescent 
particles (fluorescein or DyLight 488 labeled) in OPTI-MEM at 37 °C (5 % CO2) for 4 h.  
Cells were then washed three times with PBS, fixed with 4% paraformaldehyde for 10 min, 
and permeabilized with 0.5% saponin for 30 min at room temperature. Cells were stained 
with 100 nM phalloidin-AlexaFluor 555 for actin for 1 h at room temperature, and then 
counterstained with 30 µM DAPI for 15 min. Images were collected with LSM710 confocal 
laser scanning microscope (Carl Zeiss).  
2.3.2 Fabrication and characterization of PEG-based nanoparticles  
The structures of new components in PRINT particles are illustrated in Figure 2.4a. 
As a preliminary evaluation of the behavior of PEG-based particles with cells, they were 
tested for cell internalization and toxicity. siRNA was not included in the composition; to 
compensate for its loss, the crosslinker content was increased to 23 wt% and the hydrophile 
to 25 wt%. Also, THF and DMF were both initially tested for preparing particles as the 
solvent of the pre-particle solution. To minimize toxicity from positively charged particles 
and to provide a stealth layer for future application, particles were PEGylated. Primary 
amines from AEM in the particle matrix were reacted with an aldehyde-terminated 
monomethoxy PEG5K to yield imine-linked PEGs (Figure 2.4b).  Before PEGylation, ζ-
potential of particles was +33.9 ± 4.1 mV with Z-average diameter of 289.0 ± 23.1 nm. The 
ζ-potential of particles was reduced to +24.0 ± 1.0 mV after PEGylation. The morphology of 
particles appears cylindrical with correct dimensions, yielding a notably “soft” appearance, 
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most likely attributable to the rubbery, porous PEG matrix (Figure 2.4c). PEGylated particles 
prepared in THF or DMF were readily internalized by HeLa cells (Figure 2.5a) and did not 
elicit any cytotoxicity. Cell viability was maintained greater than 90% across all doses 
(Figure 2.5b).  
 
 
Figure 2.4 (a) Chemical structures of monomers and macromonomers implemented in 
cationic PRINT particles. (b) Reaction scheme for PEGylation of primary amine-containing 
hydrogels with aldehyde-terminated mPEG5K through imine formation. (c) SEM micrographs 
of cationic PEG-based hydrogels illustrate cylindrical dimensions and soft qualities. 
  
 
Figure 2.5 (a) HeLa cell uptake of PEG-based particles prepared from THF and DMF pre-
particle solutions. (b) Viability of HeLa cells dosed with PEG-based particles prepared from 
THF and DMF pre-particle solutions. 
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2.3.3 Delivery of siRNA via hydrogels PEGylated with imines 
DMF was chosen as the solvent for the pre-particle solution albeit a heat gun is 
required to produce a dry film quickly while THF is sufficiently volatile. Small precipitates 
were noticed when THF was used as the solvent after anti-luciferase or control siRNAs were 
added to the pre-particle solution. DMF has a higher dielectric constant than THF, 
minimizing potential interactions between siRNA and pre-particle solution components as 
well as allowing for dissolution of salts. PEG-based particles were prepared containing 
luciferase and control siRNA. SEM micrographs of particles reveal their cylindrical nature 
(Figure 2.6) while light scattering demonstrates their size is roughly 250 nm with a ζ-
potential of ca. + 35  mV prior to PEGylation (Figure 2.6). ζ-potentials of particles decreased 
by approximately 10 mV after PEGylation (Table 1.1).  
 
Figure 2.6 SEM micrographs of PEG-based hydrogel nanoparticles confirms cylindrical 
dimensions. 
 
Table 2.1 ζ-potential and dynamic light scattering analysis of siRNA-charged, PEG-based 
particles before and after PEGylation. 
 Luc siRNA Control siRNA 
 
Before 
PEGylation 
After 
PEGylation 
Before 
PEGylation 
After 
PEGylation 
ζ-potential 
(mV) 
+36.5 ± 0.8 +24.0 ± 1.0 +32.2 ± 0.6 +22.4 ± 2.0 
Dz (nm) 240.8 ± 6.1 277.7 ± 11.8 
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Uptake of particles by HeLa cells occurred at low doses while cell viability was 
maintained across all dosing concentrations (Figure 2.7a). Luciferase expression persisted in 
HeLa cells dosed with particles containing control siRNA (2.7b). However, dose-dependent 
knockdown of luciferase gene was observed in HeLa cells dosed with particles containing 
luciferase siRNA. The half maximal effective concentration (EC50) for reducing luciferase 
expression was 68 µg/mL particle dosing concentration (2.7c). 
 
Figure 2.7 (a) HeLa cell uptake of PEG-based hydrogel nanoparticles after 4 h dosing time. 
Viability and luciferase expression of HeLa cells dosed with (b) control and (c) luciferase 
siRNA-containing nanoparticles for 4 h followed by 72 h incubation at 37 ºC. 
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hydrogels through amidation provides stable bonds that will persist in an aqueous 
environment, whether in vivo or when stored in buffer.  
 
 
Figure 2.8 (a) Reaction scheme for the PEGylation of hydrogels with succinimidyl succinate 
monomethoxy PEG2K through amidation. (b) SEM micrographs of PEG-based hydrogel 
nanoparticles demonstrates cylindrical features, monodispersity, and 200 x 200 nm 
dimensions. (c) Gel electrophoresis analysis of the time-dependent release of siRNA from 
hydrogels incubated in PBS at 2 mg/mL and 37 ºC. 
 
Primary amines from AEM were reacted with a succinimidyl succinate ester-
activated, monomethoxy PEG in organic solvent using the weak base catalyst pyridine 
(Figure 2.8a). Particle integrity was maintained as the morphology of the particles appeared 
appropriate: cylindrical in shape with height and diameter of 200 nm (Figure 2.8b). Time-
dependent release of siRNA from particles was investigated by incubating particles in PBS at 
(a)
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37 ºC and taking aliquots over 96 h. Release of siRNA appeared to reach a maximum 
concentration around 48 h, indicating an ion-triggered diffusion of cargo through the 
crosslinked network (2.8c). Based on the siRNA standard and through semi-quantitative 
analysis using ImageJ, loading of siRNA was calculated to be 1.4 wt% (28% encapsulation 
efficiency).  
Table 2.2 Zetasizer analysis of siRNA-charged hydrogels before and after PEGylation. 
Particle (siRNA) ζ-potential  (mV) Dz (nm) 
NP-NH2 (luciferase) +16.6 ± 0.38 438.8 ± 8.9 
NP-NH2 (control)
 
+17.6 ± 0.55 445.0 ± 10.4 
NP-mPEG2K (luciferase)
 
+10.2 ± 0.42 390.9 ± 5.0 
NP-mPEG2K (control) +9.72 ± 0.29 391.9 ± 8.5 
  
Dynamic Light Scattering (DLS) showed that particles had diameters around 400 nm 
and ζ-potentials of ca. +17 mV prior to PEGylation (and after exposure to PBS) while ζ-
potential decreased to +10 mV after PEGylation (Table 2.2). When PEGylated particles were 
dosed on HeLa cells, rapid and complete internalization occurred at low doses for samples 
containing luciferase and control siRNA (Figure 2.9a). Cytotoxicity was not elicited by 
PEGylated particles as seen by the high cell viability out to high dosing concentrations 
(Figure 2.9b). Luciferase expression was maintained in HeLa cells treated with particles 
containing control siRNA while dose-dependent knockdown of luciferase expression was 
noted for cells dosed with particles charged with luciferase siRNA (Figure 2.9c). The EC50 
for reducing luciferase expression was determined to be 5.8 µg/mL particle concentration (6 
nM siRNA). Confocal microscopy of HeLa cells dosed with PRINT particles (Figure 2.10) 
shows uptake of particles and their distribution throughout the cellular cytoplasm as well as 
the perinuclear region. 
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Figure 2.9 (a) HeLa cell uptake of PEGylated, siRNA-containing hydrogel nanoparticles 
after 4 h dosing at 37 ºC in cell media. (b) Luciferase expression of HeLa cells dosed with 
luciferase and control siRNA-containing particles for 4 h followed by 72 h incubation at  
37 ºC. (c) Viability of HeLa cell dosed with PEGylated, siRNA-containing hydrogels. Cells 
were dosed with particles for 4 h and incubated for 72 h in media. 
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Figure 2.10. Confocal micrographs of HeLa/luc cells dosed with 50 µg/mL of particles 
containing (a) luciferase or (b) control siRNA cargos for 4 h. Cellular actin cytoskeleton was 
stained with phalloidin (red) and nuclei with DAPI (blue), while particles (green) were 
labeled with the fluorescent monomer fluorescein o-acrylate during particle fabrication. 
 
2.3.5 Conclusions 
 
siRNA was physically encapsulated in cationic hydrogels, which were subsequently 
PEGylated prior to dosing on HeLa cells. PEGylated particles slowly released siRNA in 
neutral buffer under physiological conditions. With rapid cell internalization, efficient gene 
knockdown was attained by PEGylated hydrogels where cell viability was maintained across 
all dosing concentrations. Subsequent efforts to silence gene expression in target cells via 
PRINT nanoparticles entail covalent functionalization of particles with targeting ligands such 
that cell-specific gene silencing may be realized.  
2.4 Targeting cancer cells with ligand-conjugated hydrogels for gene silencing 
Numerous receptors are over-expressed as markers of diseased cells and may be 
harnessed for internalization of nanoparticles through specific ligand-receptor associations. 
The transferrin receptor is highly expressed by several cancer cell lines due its involvement 
20 µm 20 µm
(a) (b)
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in iron intake and cell proliferation. Ligands for the transferrin receptor used in tumor cells 
include anti-transferrin receptor antibodies (e.g. OKT9 for mice, human transferrin for 
human cell lines) with control proteins like Immunoglobulin G1 (IgG1) and holotransferrin. 
Reaction of amines from particles with activated, biotinylated PEG linkers allows for 
conjugation of antibodies through avidin-biotin strategies as has been previously 
demonstrated by Jin Wang et al.
31
. Furthermore, transferrin proteins were covalently reacted 
to maleimide-grafted PRINT nanoparticles to demonstrate the complex role of multivalency 
for nanoparticles targeting the transferrin receptor in cancer therapies. Specifically, drug-free 
targeted nanoparticles elicited death in Ramos cells through an apoptotic pathway as 
indicated by increased caspase 3/7 activity when presented with PRINT particles conjugated 
with human transferrin at high surface density.  
Self-assembled polymer nanoparticles have been explored for targeted delivery of 
siRNA.
32,33
 For example, after receptor-mediated endocytosis of cyclodextrin-based 
polymeric nanoparticles targeting the transferrin receptor, particles may become highly 
protonated and disrupted by harnessing the “proton sponge effect” to escape the endosome 
and deliver siRNA cargo effectively to the cytoplasm to knockdown gene expression.
34–36
  
For particles covalently functionalized with stealthing and targeting ligands, inclusion 
of endosomal escape agents or reversibly masking lytic behavior of delivery vehicles has 
been pursued. GALA, a 30 amino acid pore-forming peptide that becomes membrane-lytic 
after exposure to an endosomal pH environment, was incorporated into small unilamellar 
vesicles targeting the transferrin receptor to enhance gene delivery.
37
 To pursue effective 
delivery of siRNA from nanoparticles covalently functionalized with ligands, reversible 
functionalization of particle surfaces through labile bonds to ligands may enable escape from 
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the endosome after receptor-mediated endocytosis of targeted particles by cancer cells. 
Furthermore, masking the endosomolytic activity of carriers is required for targeting cells 
specifically and avoiding non-specific cell uptake. Functional maleic anhydride derivatives 
were pursued for masking primary amines on endosomolytic poly(vinyl ether)s, composed of 
alkyl and amino groups, to form stable maleamates under physiological conditions.
38
 
Maleamates exhibit sensitivity to slightly acidic conditions, hydrolyzing to yield the starting 
primary amine and maleic anhydride. Subsequent application of maleamate-masked, 
hepatocyte-targeted siRNA-conjugated poly(vinyl ether)s enabled effective in vivo gene 
silencing.
39
 Functional maleic anhydride derivatives may be applied to cationic, amine-
containing PRINT hydrogels to reversibly mask endosomolytic features while enabling 
stealthing and targeting properties. 
2.4.1 Experimental 
2.4.1.1 Materials 
Monosuccinimidyl succinate ester (SCM)-PEG2K-biotin, amine-PEG2K-biotin, and 
monomethoxy PEG5K monoacrylate was purchased from Creative PEGWorks. Anti-human 
CD71 (transferrin receptor) biotinylated OKT9 monoclonal antibody and biotinylated mouse 
IgG1 isotype control were purchased from eBioscience. UltraAvidin was obtained from 
Leinco Technologies. Remaining reagents were purchased from Sigma Aldrich. 
2.4.1.2 Synthesis of carboxylic acid-functionalized 2,3-dimethyl maleic anhydride 
(CDM) 
Triethyl-2-phosphonopropionate (5 g, 21 mmol) was added to a solution of sodium 
hydride (0.41 g, 18 mmol) in 36 mL anhydrous tetrahydrofuran (THF). After the bubbling 
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ceased, a solution of dimethyl-2-oxoglutarate (2.5 g, 14 mmol) in 7 mL anhydrous THF was 
added and stirred for an hour. Then 7 mL of water was added and the THF was removed by 
rotary evaporation. The resulting aqueous suspension was extracted with 3 × 50 mL ethyl 
ether. The ether extractions were combined, dried over sodium sulfate, filtered and 
concentrated to a dark orange oil. The oil was purified by silica gel chromatography using a 
2:1 ether:hexane eluent to obtain 2.1 g of triesters (geometric isomers of E- and Z-olefins) as 
a yellow oil. The mixture of triesters was dissolved in a 35 mL solution of 3.2 g of potassium 
hydroxide in a 1:1 mixture of water and ethanol. The resulting solution of triesters was 
heated to reflux for 1.5 h. The ethanol was then removed by rotary evaporation and the 
resulting aqueous solution was acidified to pH 0 with 2 M hydrochloric acid (HCl) and 
stirred for 10 min. This aqueous solution was then extracted with 2 x 250 mL ethyl acetate. 
The ethyl acetate extractions were combined, dried over sodium sulfate, filtered, and 
concentrated in vacuo to provide a yellow oil. CDM was recrystallized from the oil by 
mixing in a minimal amount of diethyl ether and maintaining the oil:ether (1:2) mixture 
under an atmosphere saturated with pentane vapors overnight. The resulting, obese-looking 
crystals were filtered, washed with cold diethyl ether, and ground up using a mortar and 
pestle to afford 1.3 g of pure CDM as a fine, white powder (overall yield 50%). 
1
H-NMR 
(400 MHz, CDCl3) δ = 10.8 (br, 1H, OH), δ = 2.77 (t, J = 7.2 Hz, 2H), δ = 2.68 (t, J = 7.2 
Hz, 2H), δ = 2.11 (s, 3H). Melting point: 97 – 98°C. 
2.4.1.3 Synthesis of CDM-PEG-biotin 
CDM (20 mg, 0.11 mmol) and EDC (21 mg, 0.11 mmol) were dissolved in 2.5 mL of 
dry dichloromethane (DCM). To this solution was added biotin-PEG45-NH2 (240 mg, 0.11 
mmol) and then DMAP (16 mg, 0.13 mmol). The reaction was stirred for 8 hrs. Five drops of 
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TFA was added to the mixture and stirred for 5 min. The reaction mixture was washed with 1 
M HCl and then a saturated solution of NaHCO3, dried over sodium sulfate, filtered, and 
concentrated in vacuo to afford CDM-PEG-biotin as a viscous oil (200 mg, 72% yield). 
1
H-
NMR (400 MHz, CDCl3) δ = 7.91 (br, 1H, NH), δ = 6.84 (br, 1H, NH), δ = 6.80 (br, 1H, 
NH), δ = 6.04 (br, 1H, NH), δ = 4.48 (s, 1H), δ = 4.30 (s, 1H), δ = 3.78 (t, J = 4 Hz, 2H), δ = 
3.48-3.61 (m, 200H), δ = 3.36-3.44 (m, 6H), δ = 3.07-3.20 (m, 2H), δ = 2.66-2.90 (m, 9H), δ 
= 2.50-2.54 (m, 3H), δ = 2.15-2.23 (m, 2H), δ = 2.08 (s, 3H), δ = 1.55-1.79 (m, 4H), δ = 
1.35-1.49 (m, 2H). 
2.4.1.4 Synthesis of carboxylic acid-functionalized tetrahydrophthalic anhydride (CTA) 
precursor 
Synthesis of methyl 2-tributylstannylacrylate. Methyl propiolate (10 g, 119 mmol) was added 
to 450 mL of dry THF and the solution was cooled to 0°C. Bis(triphenylphosphine)-
palladium(II)chloride (417 mg, 0.76 mmol) was added to the cooled solution. After 
tributyltin hydride (38.1 g, 131 mmol) was added dropwise to the stirring solution at 0°C, the 
solution was stirred for an additional 10 min at room temperature. The solution was 
concentrated in vacuo and the resulting thick syrup was purified by silica gel 
chromatography using hexanes as the eluent to obtain a clear viscous oil (36 g, 81% yield). 
1
H-NMR (400 MHz, CDCl3) δ = 6.89 (d, J = 2 Hz, 1H), δ = 5.92 (d, J = 2 Hz, 1H), δ = 3.73 
(s, 3H), δ = 1.49 (m, 6H), δ = 1.31 (m, 6H), δ = 0.97 (m, 6H), δ = 0.88 (t, J  = 7.2 Hz, 9H). 
Synthesis of 2,3-dicarbomethoxy-1,3-butadiene. A solution of Cu(NO3)2·3H2O (5 g, 21 
mmol) in 20 mL of THF was added to methyl 2-tributylstannylacrylate (8 g, 21 mmol). The 
reaction mixture was stirred for 10 min at room temperature until it turned brown. It was then 
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diluted with 300 mL of ethyl acetate and washed successively with 250 mL of 5% aqueous 
ammonia, 250 mL of water, and 250 mL of brine. The organic layer was dried over sodium 
sulfate, filtered and concentrated in vacuo. The resulting crude product was purified by silica 
chromatography using a EtOAc:hexanes (1:1) eluent to obtain a yellow liquid (2 g, 55% 
yield). Next, a solution containing 2,3-dicarbomethoxy-1,3-butadiene (1 g, 5.9 mmol) and 
methyl acrylate (4.0g, 47 mmol) in 210 mL dry toluene was heated to reflux at 115°C for 2 
days. The solution was then concentrated in vacuo and the resulting crude mixture was 
purified by silica chromatography using a EtOAc: hexanes (1:1) eluent to obtain a viscous oil 
(470 mg, 31% yield). 
1
H-NMR (400 MHz, CDCl3) δ = 3.76 (s, 6H), δ = 3.71 (s, 3H), δ = 
2.50-2.70 (m, 4H), δ = 2.32-2.41 (m, 1H), δ = 2.08-2.12 (m, 1H), δ = 1.66-1.76 (m, 1H). 
2.4.1.5 Synthesis of carboxylated tetrahydrophthalic anhydride-derivatized mPEG12 
1,2,4-tricarbomethoxy-1-cyclohexene (0.5 g, 2 mmol) was dissolved in a 20 mL 
solution of 1.8 g of potassium hydroxide in a 1:1 mixture of water and ethanol. The resulting 
solution of triesters was heated to reflux for 1.5 h. The ethanol was then removed by rotary 
evaporation and the resulting aqueous solution was acidified to pH 0 with 2 M hydrochloric 
acid (HCl) and stirred for 10 min. This aqueous solution was then extracted with 2 x 250 mL 
ethyl acetate. The ethyl acetate extractions were combined, dried over sodium sulfate, 
filtered, and concentrated in vacuo to obtain CTA as a white solid. Without further 
purification, CTA (20 mg, 0.11 mmol) and EDC (42 mg, 0.22 mmol) were dissolved in 2.5 
mL of dry dichloromethane (DCM). To this solution was added mPEG12-NH2 (123 mg, 0.22 
mmol) and then DMAP (32 mg, 0.26 mmol). The reaction was stirred for 8 hrs. Five drops of 
TFA was added to the mixture and stirred for 5 min. The reaction mixture was washed with 1 
M HCl and then a saturated solution of NaHCO3, dried over sodium sulfate, filtered, and 
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concentrated in vacuo to afford the title compound as a viscous oil (17 mg, 21% yield). 
1
H-
NMR (400 MHz, CDCl3) δ = 3.49-3.69 (m, 48H), δ = 3.38 (s, 3H), δ = 0.73-2.78 (m, 7H). 
2.4.1.6 Fabrication and functionalization of hydrogel nanoparticles 
PEG-based, cationic particles were prepared as previously described in 2.3.2. For 
biotinylation, particles were reacted with SCM- or CDM-PEG2K-biotin in DMF at 2 mg/mL 
for 2 h using pyridine (4 wt eq). Non-biotinylated amines were quenched with various 
anhydrides (2 wt eq unless noted otherwise) in DMF at 2 mg/mL with pyridine (4 wt eq) for 
30 min. Fluorescence of particles was compromised with most anhydrides due to acylation of 
fluorescein o-acrylate; therefore, particles quenched with small molecule anhydrides were 
treated with a 10% (v/v) of piperidine in DMF to restore fluorescence. Particles were washed 
with PBS and then incubated at 2 mg/mL with avidin (0.25 wt eq) for 30 min. Afterward, 
particles were isolated via centrifugation and washed with PBS to remove any free avidin. 
Biotinylated antibodies were then incubated with avidin-conjugated particles at 2 mg/mL for 
20 min in PBS at various stoichiometric ratios followed by washing particles to remove 
unbound antibody. 
2.4.1.7 Characterization of hydrogel nanoparticles  
ζ-potential measurements were conducted on 20 µg/mL particle dispersions in 1 mM 
KCl using a Zetasizer Nano ZS Particle Analyzer (Malvern Instruments Inc.). Studying ζ-
potential of functionalized particles as a function of pH was carried out using the MPT-2 
Autotitrator. DLS measurements were conducted on particle dispersions using 90Plus 
Particle Size Analyzer (Brookhaven Instruments Inc.). Gel electrophoresis studies were 
carried out in a similar manner as covered in 2.3.1.4. 
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2.4.2 Functionalization of hydrogels for targeting the transferrin receptor 
Biotinylated anti-transferrin CD71 receptor monoclonal antibody OKT9 and isotype 
control monoclonal antibody Immunoglobulin G1 (IgG1) were non-covalently conjugated to 
particles through avidin-biotin binding strategies. As an initial demonstration of the potential 
for the PEG-based, siRNA-containing particles to target the transferrin receptor, a protocol 
similar to that established by Wang et al.
31
 was carried out (Figure 2.11). First, particles were 
biotinylated with SCM-PEG2K-biotin followed by quenching unreacted amines with acetic 
anhydride. Particles were conjugated with avidin for subsequent addition of biotinylated 
antibodies. Resulting ζ-potentials of targeted particles were negative with diameters around 
350 nm (Table 2.3). To determine the minimal amount of antibody required for receptor-
mediated endocytosis, the concentration of biotinylated antibodies was screened in the 
conjugation reaction. A dose- and ligand density-dependent increase in cell uptake was 
observed for OKT9-conjugated particles (2.12a). Conversely, uptake of IgG1-conjugated 
particles was not observed across all dosing concentrations and antibody:particle ratios 
(2.12b). A minimal antibody:particle ratio of 10 was then established for subsequent efforts 
in the targeted delivery of siRNA.  
 
Figure 2.11 Reaction scheme for multi-step preparation of targeted particles through 
conjugation of biotinylated proteins to amine-quenched, avidinated particles. 
 
 
= avidin
= biotin-OKT9
= biotin
= biotin-IgG1
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Table 2.3 ζ-potential and DLS of protein-functionalized nanoparticles. 
 Antibody-conjugated particles 
 OKT9 IgG1 
ζ-potential (mV) -15.0 ± 0.8 -9.7 ± 0.4 
Dz (nm) 381.0 ± 14.0 334.0 ± 21.0 
 
Figure 2.12 HeLa cell uptake of (a) OKT9- and (b) IgG-conjugated hydrogel nanoparticles at 
multiple antibody:particle ratios and particle dosing concentrations. HeLa cells were dosed 
with particles for 4 h at 37 ºC in media. Antibody:particle ratio symbolizes milliequivalents 
of protein per mg of particle (wt/wt). 
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2.4.3 Targeted delivery of siRNA to cancer cells via hydrogels conjugated with targeting 
and stealthing ligands through labile bonds 
To ensure delivery of siRNA from the carrier to the cytoplasm of the target cell, 
endosomal escape is required after receptor-mediated endocytosis. Endosomolysis was 
enabled by the cationic amine-containing monomer; however, if all amines are irreversibly 
reacted, endosomal escape may be hindered. Therefore, reversible covalent modification of 
amines with maleic anhydride derivatives was pursued. Maleic anhydride derivatives (with 
substituents located at the 2 or 3 position) can react with amines to form acid-labile 
maleamates (Figure 2.13). The degree of acid lability for the maleamate depends on the steric 
constraints of the substituents. Generally, pH sensitivity increases with the number of 
substituents and resistance to ring opening. Maleic anhydride derivatives have been applied 
to polycations in gene therapy and drug delivery endeavors to reversibly mask their 
charge.
40,41
  
To investigate the behavior of maleamates on PRINT particles, a series of maleic 
anhydride derivatives were evaluated for their ability to enable cell-specific uptake of 
antibody-conjugated particles. Select anhydrides were further tested for their ability to cleave 
under endosomal conditions and yield positively charged particles that should be able to 
achieve endosomal escape. A maleic anhydride-activated, biotin-terminated PEG was 
synthesized for reversible conjugation of ligands (Figure 2.13). Targeted particles were 
prepared in the manner previously described with a couple adjustments to the protocol: 
particles were biotinylated with CDM-PEG2K-biotin and instead of quenching non-
biotinylated amines with acetic anhydride, maleic anhydride derivatives were implemented. 
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ζ-potential of particles reacted with maleic anhydride indicated that they had been 
functionalized as denoted by their negative values (Table 2.4).  
 
Figure 2.13 Reaction scheme for reversibly quenching amines with maleic anhydride 
derivatives, whose chemical structures are illustrated. Chemical structure of CDM-activated, 
biotin-terminated PEG2K is shown for the preparation of particles functionalized with acid-
labile ligands. 
    
HeLa cell uptake of OKT9-conjugated particles quenched with all anhydrides reached 
saturation at relatively low doses while non-specific uptake of IgG1-conjugated particles 
increased with acid lability of the maleamate (Figure 2.14). Particularly, DMA-quenched 
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particles exhibited high background uptake (60% at 100 µg/mL) while the next most acid 
labile maleamate (CDM) reached greater than 15% uptake at 200 µg/mL. The remaining 
anhydride-quenched particles displayed markedly low background uptake of IgG1-
conjugated particles.  
Table 2.4 ζ-potential of antibody-conjugated particles quenched with different maleic 
anhydrides. 
Anhydride 
ζ-potential of targeted particles 
(mV) 
OKT9 IgG1 
DMA -15.1 -16.3 
CDM -7.2 -7.7 
TPA -27.9 -28.4 
CA -24.7 -21.1 
CAA -30.3 -22.4 
Ac2O -11.2 -11.3 
 
 
Figure 2.14 HeLa cell uptake of OKT9- and IgG1-conjugated particles quenched with 
different maleic anhydrides. 
 
The ζ-potential behavior of particles quenched with anhydrides that demonstrated 
targeting selectivity and were known to cleave under mildly acidic conditions were evaluated 
after incubation in different buffers. Specifically, particles were incubated in PBS and pH 5.5 
(citrate) buffer at 37 ºC for 25 min to observe maleamate lability under physiological and 
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endosomal conditions (lifetime of endosome), respectively. CDM-quenched particles became 
slightly positive after incubation in neutral buffer, most likely due to a burst hydrolysis, 
which may account for some non-specific uptake. When CDM-quenched particles were 
incubated in buffer of endosomal pH for 25 min, they became more highly charged with a ζ-
potential around that of bare hydrogels (Table 2.5).  
With pH sensitivity intermediate between CDM and mono-substituted maleic 
anhydrides, TPA was investigated for its ability to form maleamates that maintain a negative 
ζ-potential under physiological conditions and respond to an acidic environmental trigger for 
hydrolysis. Indeed, TPA-quenched particles resumed a negative ζ-potential after incubation 
in PBS while they become positively charged after incubation in acidic buffer. The mono-
substituted maleic anhydride, cis-aconitic anhydride, was tested for ζ-potential behavior: a 
negative charge was maintained under physiological conditions and after exposure to an 
acidic environment. Therefore, CDM and TPA were selected for their ability to yield siRNA-
containing, targeted particles. 
Table 2.5 ζ-potential analysis of functionalized particles after exposure to physiological and 
endosomal conditions. 
 
Progression of the endosomal environment was mimicked to study the ζ-potential of 
CDM- and Ac2O-quenched particles by incubating particles in buffer that decreased from pH 
Quenching group 
ζ-potential after 25 min in buffer at 37 ºC 
pH 7.4 (mV) pH 5.5 (mV) 
CDM +4.09 ± 3.51 +11.3 ± 3.36 
TPA -32.5 ± 4.68 +9.06 ± 3.23 
CAA -30.3 ± 5.71 -26.5 ± 3.64 
None +12.0 ± 4.56 +11.8 ± 3.48 
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7.4 to 5.4 over 25 min (Figure 2.15). Acetic anhydride-quenched particles resumed a slightly 
negative ζ-potential while CDM-functionalized particles gradually became positively 
charged after exposure to endosomal conditions.  
 
Figure 2.15 ζ-potential of CDM- and Ac2O-quenched particles as a function of pH over 25 
min. 
 
When luciferase siRNA-charged, TPA- and CDM-quenched targeted particles were 
dosed on HeLa cells, gene knockdown was not observed (Figure 2.16a,b) although selective 
cell uptake of OKT9-conjugated particles was noted. To investigate the lack of gene 
silencing, the siRNA remaining in functionalized particles was evaluated through gel 
electrophoresis. Significant loss of siRNA was encountered in the reactions carried out on 
particles for functionalization with stealthing and targeting ligands (Figure 2.16c). The effect 
of each reaction condition in the multi-step preparation of targeted particles required 
analysis.  
After establishing that siRNA was lost, the effect of acetylating particles on the 
integrity of siRNA was compared to PEGylated nanoparticles. siRNA was retained in 
particles exposed to conjugation conditions while five minutes of acetylation rendered 
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may damage siRNA through acylation and destroy the electrostatic attraction of siRNA to 
amines. 
 
 
Figure 2.16 Viability and luciferase expression of HeLa cells dosed with (a) TPA- and (b) 
CDM-quenched, antibody-conjugated particles. (c) Gel electrophoresis of siRNA released 
from (A) PEGylated nanoparticles and (B) transferrin receptor-targeted nanoparticles. 
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The effect of salt concentration on extracting siRNA was also investigated by 
incubating particles in increasingly concentrated KCl salt solutions. After 17 h incubation in 
different buffers, the amount of siRNA remaining in the particle decreased with increasing 
salt concentration of the buffer (Figure 2.17b). Therefore, siRNA may diffuse from hydrogels 
under an ionic environment in a time- and salt concentration-dependent manner. To 
overcome the significant loss of siRNA with small molecule anhydrides, maleic anhydride 
derivatives of monomethoxy ethylene glycol oligomers were pursued such that penetration of 
quenching groups throughout the particle matrix and resulting loss of siRNA would be 
minimized, i.e. particle surfaces were targeted for PEGylation through use of larger 
anhydride derivatives. 
 
Figure 2.17 (a) Gel electrophoresis of siRNA released from particles exposed to different 
reaction conditions after incubation in PBS at 37 ºC for 22 h. (b) Gel electrophoresis of 
siRNA remaining from particles loaded into wells after incubation in water or KCl solutions 
of different ionic strength. 
Samples:
A) NP-mPEG, 5min acetylation
B) NP-mPEG, 20min acetylation
C) NP-mPEG
Std siRNA (ng)
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2.4.4 Conjugation of PEGylated ligands and stealthing groups to nanoparticles for 
targeted delivery of siRNA 
CDM-activated ethylene glycol oligomers of eight and twelve repeat units were tested 
for their impact on the integrity of siRNA associated with particles. After incubating 
functionalized particles in buffer to release siRNA, loss of siRNA appeared minimal, 
especially with CDM-mPEG12 (Figure 2.18). The ζ-potentials of CDM-mPEG12-
functionalized particles were found to be negative, indicating masking of cationic primary 
amines. Therefore, it seemed appropriate to test the cell uptake selectivity, cell viability, and 
gene silencing capability of CDM-masked, targeted particles containing luciferase siRNA.  
 
Figure 2.18 Gel electrophoresis of siRNA released from particles functionalized with 
different ligands after incubation in PBS at 2 mg/mL and 37 ºC. 
   
Cell uptake of CDM-mPEG12-masked particles differed from particles quenched with 
the small molecule CDM in that non-specific uptake of IgG1-conjugated particles was 
notably high (70 % at 200 µg/mL) (Figure 2.19a). The acid sensitivity of particles quenched 
with CDM-mPEG12 most likely is higher than that of CDM-quenched particles due to a lower 
density of maleamates from steric crowding of mPEGs and limited diffusion into the interior 
1       2       3      4        5           6                   
1: CDM-PEG-biotin     2: CDM-PEG-biotin + CDM-mPEG8
3: CDM-PEG-OKT9     4: CDM-PEG-OKT9  + CDM-mPEG8
5. SCM-mPEG45 6. CDM-PEG-biotin + CDM-mPEG12
siRNA standard (ng) Particle samples
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of particles. Acid lability of CDM-mPEG-masked particles was significantly high such that 
complete cell death was induced at the highest particle dosing concentration (200 µg/mL) 
(Figure 2.19b). Cell death may have been encountered potentially from excessive exposure of 
particle amines prior to endocytosis such that cell lysis occurred from the highly positively 
charged particle. Significant luciferase knockdown was not elicited by CDM-mPEG-masked, 
targeted particles. Due to the high toxicity encountered with targeted particles, a maleamate-
derivatized mPEG12 with moderate acid lability was desired.  
 
Figure 2.19 (a) HeLa cell uptake of OKT9- and IgG-conjugated particles quenched with 
CDM-mPEG12 after 4 h dosing time. (b) Viability and luciferase expression of HeLa cells 
dosed with CDM-masked, OKT9-conjugated particles for 4 h followed by 48 h incubation in 
media at 37 ºC. 
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Carboxy-installed, tetrahydrophthalic anhydride (CTA)-derivatized mPEG12 was 
synthesized and tested for its effect on siRNA integrity in particles. Roughly 75% of siRNA 
remained in particles functionalized with CTA-mPEG12 relative to PEGylated nanoparticles 
while particles quenched with TPA do not reveal the presence of any remaining siRNA 
(Figure 2.20b). Next, siRNA-containing, CTA-mPEG12-quenched targeted particles were 
prepared for luciferase knockdown studies using SCM-PEG2K-biotin and SCM-mPEG12 as 
the non-endosomolytic, control system. Functionalization of particles to create a wholly acid-
labile, transferrin receptor-targeted particle system is illustrated in Figure 2.20a. Like TPA-
masked particles, the ζ-potential of ligand-functionalized, CTA-mPEG12-masked particles 
remained negative (-3.24 ± 3.23 mV) under cell dosing conditions (PBS, pH 7.4 at 37˚C) for 
at least 4 h while it turned positive (+4.53 ± 3.07 mV) under endosome-like conditions (pH 
5.5 at 37˚C) in only 25 min. These ζ-potential values projected minimal non-specific cell 
uptake of targeted particles while providing endosomal escape of the cargo before lysosomal 
degradation of the siRNA cargo. 
Transferrin receptor-targeted, CTA-mPEG12-masked particles were tested for 
luciferase siRNA delivery on HeLa/luc cells. Three types of particles were fabricated: 
OKT9-labeled particles carrying 1) luciferase siRNA or 2) control siRNA, and IgG1-labeled 
particles carrying 3) luciferase siRNA. As a negative control for these acid-labile particles, 
another set of particles conjugated with NHS-PEG2K-biotin and NHS-mPEG12 were prepared, 
generating particles with non-labile amides on the surface. Zetasizer characterization of 
antibody-conjugated hydrogels with different cargos and ligands demonstrates similar 
diameters among particles and negative ζ-potentials (Table 2.6). When HeLa/luc cells were 
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treated with CDM-mPEG12- and NHS-mPEG12-quenched particles, higher uptake of OKT9-
labeled particles compared to the IgG1-labeled analogs (Figure 2.21) was observed.  
 
 
Figure 2.20 (a) Establishment of wholly acid-labile system: functionalization of hydrogel 
nanoparticles with a biotinylated targeting ligand and different amine masking agents. (b) 
Gel electrophoresis comparison of siRNA released after 48 h incubation from (A) cationic 
NP-mPEG2K, (B) CTA-mPEG12- and (C) TPA-quenched targeted particles confirm that 
siRNA damage or loss occurred during the acylation reaction with TPA while a reasonable 
amount of cargo still remained for the targeted, CTA-mPEG12-quenched particles relative to 
that of cationic particles. 
 
 
 
(a)
(b)
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Table 2.6 Characterization of antibody-conjugated, CTA/NHS-mPEG12-quenched hydrogels.
 
mPEG12, antibody, siRNA ζ-potential / mV Dz / nm PDI 
CTA, OKT9, luc -17.3 ± 0.40 414.4 ± 7.0 0.126 
CTA, IgG, luc -14.4 ± 0.29 420.7 ± 5.4 0.166 
CTA, OKT9, crtl -18.1 ± 0.68 404.4 ± 4.5 0.174 
CTA, IgG, crtl -18.3 ± 0.42 409.1 ± 13.5 0.124 
NHS, OKT9, crtl -6.29 ± 0.27 454.3 ± 6.2 0.142 
NHS, OKT9, luc -7.56 ± 0.31 426.1 ± 12.3 0.155 
NHS, IgG1, luc -5.72 ± 0.15 434.3 ± 11.7 0.124 
  
 
Figure 2.21 HeLa cell uptake of CTA-mPEG12-quenched particles after 4 h dosing expressed 
as (a) % control and (b) mean fluorescence intensity. (c) HeLa cell uptake of NHS-mPEG12-
quenched particles after 4 h dosing. 
 
50% reduction in luciferase expression was seen for HeLa cells dosed with CTA-
mPEG12-masked, luciferase siRNA-containing particles at 200 µg/mL (ca. 100 nM siRNA) 
in Figure 2.22c, whereas particles carrying control siRNA or IgG1-labeled particles carrying 
luciferase siRNA did not reduce luciferase expression (Figure 2.22a,b). Also, the CTA-
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mPEG12-masked particles did not display any detectable cytotoxicity by the MTS assay. 
Thus, enhanced uptake of negatively charged particles afforded by transferrin receptor-
mediated endocytosis allowed enough particles to enter cells to cause observable knockdown 
of the target gene.  Although non-acid labile groups (NHS-) provided targeting specificity 
(Figure 2.23), knockdown of luciferase expression was not achieved, which indicates that the 
unmasking of the surface amines is the underlying mechanism for endosomal escape. CTA-
mPEG12-masked targeted particles showed lower knockdown efficiency compared to the 
cationic NP-mPEG2K, which may be attributed to the lower siRNA encapsulation level of 
targeted particles (0.7 wt%) which is about half that of cationic NP-mPEG2K (1.4 wt%) 
(Figure 2.24). Although gene silencing was achieved with targeted particles, a composition 
that transfects more efficiently while enabling access to other organs such as the liver was 
desired. 
 
 
Figure 2.22 Viability and luciferase expression of HeLa cells dosed with CTA-mPEG12-
quenched particles containing control or luciferase siRNA conjugated with OKT9 or IgG 
antibodies for 4 h followed by 48 h incubation in media. 
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Figure 2.23 Viability and luciferase expression of HeLa cells dosed with NHS-mPEG12-
quenched particles containing luciferase or control siRNA conjugated with OKT9 or IgG1 
antibodies when dosed at 200 µg/mL for 4 h followed by 48 h incubation in media. 
  
 
Figure 2.24 Time-dependent release of siRNA from hydrogels after post-fabrication 
functionalization with targeting ligands when incubated at 2 mg/mL and 37 °C in PBS 
demonstrates loss of physically entrapped cargo (0.7 wt% encapsulated compared to 1.4 wt% 
originally encapsulated). Post-fabrication functionalization involved step-wise biotinylation, 
PEGylation, avidination, and conjugation of biotinylated protein to particles accompanied by 
multiple washes of particles. 
 
2.5 Optimization of rice-shaped hydrogel nanoparticle composition for gene silencing in 
hepatocytes  
PEGylated nanoparticles can passively target liver cells, namely hepatocytes and 
Kupffer cells. Hepatic parenchyma composes the main connective tissue of the liver and 
serves important regulatory roles, which are also implicated in several diseases. Kupffer cells 
are the liver’s immune cells (macrophages) located in sinusoidal walls as part of the 
mononuclear phagocytic system. Since the liver contributes to major vascular, metabolic, and 
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secretory functions, diseases developed in hepatocytes are of interest and may be addressed 
with RNAi. Infectious and metabolic disorders in hepatocytes may be treated with siRNA 
delivery vectors after systemic administration. Size, shape, and surface characteristics of 
nanoparticles influence their biodistribution; yet, common organs of nanoparticle 
accumulation are the spleen and liver due to diffusion, filtration, or clearance.  
To prepare nanoparticles that would have potential for delivery to hepatocytes with 
~150 nm fenestrations, a smaller particle dimension was adopted (80x320 nm) in which one 
dimension is less than the size of liver fenestrations. To optimize gene knockdown and 
maximize cytocompatibility, the structure of amine-containing monomers and their content 
were screened in addition to varying the siRNA loading. Amine monomers have been 
screened in the development of combinatorial libraries of poly(β-amino ester)s42,43 and lipid-
like materials
44,45
 for transfection of cells with pDNA and siRNA. Monomers with pH-
dependent degree of amine protonation and permanent charges potentially present different 
degrees of internalization, endosomolytic activity, and siRNA binding/release properties. 
Combinations of primary amine and quaternary ammonium-containing monomers with 
(meth)acrylamide and (meth)acrylate polymerizable groups were tested for their capacity to 
enable transfection via hydrogel nanoparticles. To provide a crosslinked, hydrophilic 
network, PEG700 diacrylate and tetraethylene glycol monoacrylate were implemented as the 
crosslinker and hydrophile.  
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2.5.1 Experimental 
2.5.1.1 Materials 
Poly(vinyl alcohol), 75% hydrolyzed with MW ≈ 2 kDa, was obtained from Acros 
Organics. PEG700 diacrylate, Irgacure 2959, 2-(acryloylamino)-N,N,N-
trimethylethanaminium iodide, and tetraethylene glycol were purchased from Sigma. 
Tetraethylene glycol monoacrylate (HP4A) was synthesized in-house and kindly provided by 
Dr. Matthew C. Parrott, Dr. Ashish Pandya, and Mathew Finniss. 2-aminoethyl methacrylate 
hydrochloride was purchased from Polysciences, Inc. 5 mil wire wound rod was purchased 
from R. D. Specialties. 80 x 320 nm PRINT molds were graciously supplied by Liquidia 
Technologies. Remaining reagents and materials were obtained as included in previous 
experimental sections. 
2.5.1.2 Fabrication of cationic rice-shaped nanoparticles 
Primary and quaternary amine-containing, (meth)acrylate- and (meth)acrylamide-
based monomers were implemented in particle matrices (Figure 2.24a). The composition of 
the pre-particle solution for preparation of hydrogel nanoparticles is listed in Table 2.7 where 
the amine content was tested at 30 and 50 wt% while charging each with 5 or 10 wt% 
siRNA. The pre-particle solution was prepared at 2.5 wt% in DEPC-treated water. To enable 
wetting of pre-particle solution contents on PET from a water solution and to increase 
porosity, poly(vinyl alcohol) was implemented. Furthermore, a water-soluble photoinitiator 
(Irgacure 2959) was used in the pre-particle solution. With a #5 Mayer Rod, a film was cast 
on a sheet of PET, which was subsequently laminated to Liquidia molds (80x320 nm 
dimensions) at 40 psi. Next, the mold was delaminated from the PET sheet and laminated to 
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a sheet of corona-treated PET at 40 psi. The mold-PET sandwich was then cured for 5 min in 
a UV oven. Particles were collected mechanically using a cell scraper and water (ca. 1 mL 
per foot).  
Table 2.7 Compositions of pre-particle solutions for screening siRNA delivery efficiency. 
 
 
 
 
 
2.5.1.3 Particle characterization, cell culture, and cell assay 
Particles were characterized and cell culture/assays were conducted in a manner 
similar to those reported in previous experimental sections. 
2.5.2 Characterization and in vitro behavior of cationic rice hydrogel nanoparticles 
Rice-shaped hydrogel nanoparticles prepared with different amine-containing 
monomers (Figure 2.25a) demonstrated that ζ-potential increased with amine content (except 
for with AETMAC), exhibiting values from +28 to +40 mV (Table 2.8). In general, the ζ-
potential of particles was higher for 50 wt% AEM relative to 30 wt% AEM. The chemical 
structures of new monomers implemented in the particle matrix illustrate the use of an 
oligomeric ethylene glycol acrylate, PEG diacrylate crosslinker, water-soluble benzoin 
photoinitiator, and poly(vinyl alcohol) as a porogen and PET-wetter (Figure 2.25b). SEM 
micrographs of select rice-shaped nanoparticles confirmed their 80x320 nm dimensions, 
monodispersity, and soft features (Figure 2.25c). 
Component wt % 
siRNA 5 10 
Amine 30, 50 30, 50 
HP4A 49, 29 44, 24 
Poly(vinyl alcohol) 10 10 
Irgacure 2959 1 1 
PEG16-DA 5 5 
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Luciferase siRNA-charged hydrogel nanoparticles fabricated from different amine 
monomers were screened for transfection efficiency on luciferase-expressing HeLa cells. For 
AEM-based hydrogels, luciferase expression and viability decreased with increasing amine 
content and particle dosing concentration (Figure 2.26). Gene silencing efficiency increased 
with siRNA loading for both amine contents. The EC50 for silencing luciferase expression 
was plotted for each particle composition using Lipofectamine
TM
 2000 as the common 
transfection benchmark (Figure 2.27). Acrylamide monomers were found to be more potent 
materials for gene silencing than their acrylate analogs. Combining primary and quaternary 
amine functionalities did not enhance transfection relative to primary amines. Higher amine 
contents elicited luciferase knockdown more effectively. In general, cell viability decreased 
at higher particle dosing concentrations and amine contents. The most effective composition 
for silencing luciferase expression was based on 50 wt% AEMAm and 10 wt% siRNA 
charged into the pre-particle solution.  
 
 
Figure 2.25 Chemical structures of (a) primary amine and quaternary ammonium 
(meth)acrylate and (meth)acrylamide monomers and (b) new monomers implemented in 
cationic hydrogel matrices. (c) SEM micrographs of select rice-shaped hydrogel 
nanoparticles (30% AEM, 5 wt% siRNA). 
 
(a)
(b)
(c)
90 
 
 
 
 
Table 2.8 ζ-potentials of cationic hydrogel nanoparticles prepared with different amine-
containing monomers. 
Amine Monomer 
ζ-potential (mV) 
Amine, siRNA (wt%) 
50,5 50,10 30,10 30,5 
AEMAm +35.9 ± 1.3 +35.4 ± 0.6 +31.8 ± 0.7 +31.1 ± 1.1 
AEM +39.8 ± 0.6 +38.8 ± 1.1 +34.6 ± 0.6 +34.8 ± 0.6 
AETAm +30.3 ± 1.1 +31.1 ± 0.5 +26.3 ± 0.1 +26.0 ± 1.1 
AET +27.7 ± 2.4 +37.6 ± 0.4 +31.1 ± 0.4 +33.5 ± 0.8 
AEM-AET (50-50) +37.1 ± 4.9 +34.2 ± 4.9 +30.4 ± 0.7 +31.7 ± 1.7 
 
 
 
 
 
 
 
Figure 2.26 Viability and luciferase expression of HeLa cells dosed with AEM-based 
cationic hydrogel nanoparticles containing siRNA. Half-maximal effective concentration 
(EC50) of siRNA (nM) required for gene knockdown is based on 5 wt% siRNA charged into 
the pre-particle solution. 
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Figure 2.27 Half maximal effective concentration (EC50) of siRNA (nM) required to reduce 
gene expression by 50%. For each particle sample, EC50s were based on 5 or 10 wt% siRNA 
loading into hydrogel nanoparticles. 
 
2.6 Reversibly coating rice-shaped particles with terpolymer ligands through 
polyelectrolyte attraction for targeting hepatocytes 
 Hepatocytes express asialoglycoprotein receptors, which recognize and internalize 
galactose, lactose, and N-acetylgalactosamine ligands. Nanoparticles and gene delivery 
vectors have been functionalized with these sugar ligands for targeted gene therapy. For 
example, a lactosylated PEG-siRNA conjugate was linked via an acid-labile β-thiopropionate 
to poly(L-lysine) to form polyion complex micelles that demonstrated in vitro gene 
knockdown.
46
 Additionally, galactose-terminated PEG-functionalized PEI was pursued for 
delivery of DNA to human hepatocarcinoma (HepG2) cells, which enhanced transfection 
efficiency relative to PEI.
47
 N-acetylgalactosamine-grafted dynamic polyconjugates 
demonstrated effective in vivo delivery of siRNA to hepatocytes.
39
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conjugated to galactose- and mannose-terminated PEGs via a disulfide linkage for in vitro 
gene silencing.
48
 The delivery of pDNA-galactosylated poly(L-lysine) complexes was 
investigated for targeted delivery to HepG2 cells while exploring the influence of fusogenic 
peptides.
49
 HepG2 cell internalization of magnetic nanoparticles surface-modified with 
galactose, glucose, and sialic acid was studied, focusing on spatial orientation of ligands.
50
 
The attachment of hepatocytes was enhanced by poly(acrylic acid)-grafted PET films 
functionalized with galactose.
51
  
Recently, cationic nanoparticles have been coated electrostatically with polyanion-
based ligands to alter surface properties and enable targeting capabilities. Coating 
nanoparticles electrostatically avoids modification of the biophysical properties of 
nanoparticles encountered through covalent functionalization. Increasing covalent ligand 
substitution of cationic polymers can decrease gene delivery efficiency (condensation and 
endosomal escape) by modifying the polymer’s original functionality.52,53  Poly(glutamic 
acid)-based RGD ligands (which target integrin receptors on endothelial cells) were coated 
on cationic poly(β-amino ester) nanoparticles to enable ligand-specific gene delivery to 
human primary cells
54
 while also demonstrating serum stability. Peptide ligands without 
receptor specificity but rather varying in charge density were tethered to poly(glutamic acid) 
to observe the effect on biodistribution and gene delivery when coated on cationic poly(β-
amino ester) nanoparticles.
55
 A low coating density of PGA ligands without a cationic insert 
promoted accumulation in liver and gene delivery.  
After screening PRINT particle compositions to establish effective transfection, the 
ideal composition was tested in nanoparticles for targeting hepatocytes with electrostatic 
coatings. Poly(acrylic acid)-based terpolymers were synthesized with galactose and glucose 
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(control) ligands, PEG spacers, and mPEG stealth layers. Ligand density was tested for 
selective receptor-mediated endocytosis in mouse-derived hepatocytes in vitro. Gene 
silencing properties and in vivo biodistribution of coated nanoparticles was also evaluated. 
2.6.1 Experimental 
2.6.1.1 Materials 
DyLight 488 maleimide, Float-a-lyzer dialysis units, methanol, dichloromethane, and 
silica gel were purchased from Fisher Scientific. Poly(ethylene glycol) derivatives were 
obtained from Laysan Bio, Inc. (SCM-PEG2K-NHBoc) and Creative PEGWorks (mPEG5K-
NH2). AlexaFluor 555 maleimide was purchased from Invitrogen. Polyacrylic acid 
(molecular weight ≈ 1,800 g/mol), 4-aminophenyl galactopyranoside, 4-aminophenyl 
glucopyranoside, and remaining chemicals were purchased from Sigma Aldrich or obtained 
elsewhere as previously reported. FVII siRNA was purchased from Dharmacon, Inc. with 
sense sequence 5’-GGAucAucucAAGucuuAcT*T-3’ and antisense sequence 5’-
GuAAGAcuuGAGAuGAuccT*T-3’ where 2’-OMe modified nucleotides are in lower case 
and phosphorothioate linkages are represented by asterisks. Amine-modified ELAV1 and 
FVII siRNAs were provided by Novartis. 
2.6.1.2 Synthesis of ligands for stealthing particles and targeting hepatocytes 
Synthesis of PAA-mPEG5K. PAA (MW ≈ 1,800 g/mol, 180 mg, 2.5 mmol) was reacted with 
mPEG-NH2 (4.5 g, MW ≈ 4,500 g/mol, 0.4 eq) in a 250-mL round-bottomed flask containing 
0.1 M MES buffer (170 mL, pH 5) along with EDC (1.16 g, 3 eq) and sulfo-NHS (0.54 g, 1 
eq) for 4 h followed by raising the pH to 7.4 and allowing the reaction to proceed for 96 h. 
Crude product was concentrated by lyophilization and subsequently dialyzed (Slide-a-lyzer) 
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repeatedly with a 20 kDa MWCO membrane in DI water for 48 h followed by freeze-drying 
to yield PAA-mPEG. The yield of product was 3.30 g (64% yield). Degree of mPEG 
substitution on PAA was determined to be 25 mol% via 
1
H NMR. 
Synthesis of galactose/glucose-PEG-NHBoc and -NH2. SCM-PEG-NHBoc (MW ≈ 2,000 
g/mol, 0.6 g, 0.3 mmol) was dissolved in anhydrous DMF (10 mL). Separately, 4-
aminophenyl galacto/glucopyranoside (1.0 g, 10 eq) was dissolved in anhydrous DMF (15 
mL) and combined with the PEG solution in an oven-dried, N2-purged 50 mL round-
bottomed flask. The reaction was left to proceed for 16 h at room temperature. Solvent was 
removed via rotary evaporation followed by purification via silica gel column 
chromatography (85:15 DCM:MeOH) to provide 0.43 g of galactose/glucose-PEG-NHBoc 
(72%). Subsequently, 
t
Boc groups were removed by dissolving the product in 50:50 
DCM:TFA (12 mL) and stirring for 1 h. Solvents were removed via rotary evaporation and 
the product was dissolved in minimal volume of PBS and dialyzed (Slide-a-lyzer) with a 2 
kDa MWCO membrane against PBS and then DI water repeatedly followed by lyophilization 
and filtration to yield galactose/glucose-PEG-NH2. Sugar-functionalized PEGs were 
analyzed by 
1
H NMR and MALDI-MS.  
The observed molecular weight distribution of Boc-deprotected, sugar-functionalized 
PEG (Figure 2.28a) matched the predicted molecular weight, differing less than 0.5 
mass/charge ratio over relevant molecular masses as noted in the MALDI-MS spectrum 
(Figure 2.28b) and Table 2.9.  
Synthesis of PAA-gal/glu. PAA-mPEG (60 mg, 2 umol) and galactose (gal)/glucose (glu)-
PEG-NH2 (0.5, 2, or 8 eq) were reacted in PBS (12 mL) along with EDC (6 eq) and sulfo-
NHS (6 eq) after first activating in 0.1 M MES buffer. The reaction was allowed to proceed 
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for 48 h after which the crude product was purified via repeated dialysis (20 kDa MWCO) 
over 48 h, followed by lyophilization, providing PAA-gal/glu terpolymers with ca. 10, 20, 
and 30 mol% substitution of sugars when 0.5, 2, and 8 eq were implemented in reactions. 
2.6.1.3 Characterization of ligands, cell assays, and coating cationic hydrogels with 
poly(acrylic acid)-based ligands  
Characterization of polymers was carried out by 
1
H NMR (400 MHz) and MALDI-
MS (IonSpec-FTMS, 9.4T). Cell culture, assays, and microscopy were conducted as 
previously described using human hepatocarcinoma (HepG2) and mouse-derived hepatocyte 
(AML12) cell lines. 
PAA-mPEG: 
1
H NMR (400 MHz, D2O) δ = 3.49-3.69 (m, 100H), δ = 2.40-1.01 (m, 
3H). Galactose-PEG-NHBoc: 
1
H NMR (400 MHz, CDCl3) δ = 2.85 (s, 9H), 7.05 (d, 2H), 
7.55 (d, 2H). PAA-gal10: 
1
H NMR (400 MHz, D2O) δ = 3.49-3.69 (m, 4755H), 7.05 (d, 2H), 
7.55 (d, 2H). PAA-gal20: 
1
H NMR (400 MHz, D2O) δ = 3.49-3.69 (m, 3433H), 7.05 (d, 2H), 
7.55 (d, 2H). PAA-gal30: 
1
H NMR (400 MHz, D2O) δ = 3.49-3.69 (m, 2699H), 7.05 (d, 2H), 
7.55 (d, 2H). 
 1
H NMR and mass spectra analysis was similar for glucose-derived ligands. 
For screening the effect of ligand density on ζ-potential, particles were incubated with 
various weight ratios of ligands in PBS for at least 30 min prior to analysis. Coated hydrogels 
were prepared by mixing a 2 mg/mL dispersion of hydrogels in water with an equal volume 
of ligand solutions (at different concentrations) in 2x PBS. A 30 µL aliquot was then taken 
for dilution into 1 mL of 1 mM KCl to obtain ζ-potential measurements.  The optimal ligand 
density was then implemented in subsequent studies directly when harvesting particles or 
after fabrication. To study the pH-responsiveness of coated hydrogels, which had been 
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washed with buffer, they were re-suspended in buffers of different pH; afterward, a 30 µL 
aliquot was taken for dilution in 1 mM KCl and ζ-potential analysis. 
 
Figure 2.28 (a) Structural breakdown of galactose-PEG-NH2 for predicting molecular weight 
as would be observed by MALDI-MS in Table 2.9. (b) MALDI-MS spectrum of galactose-
PEG-NH2. 
  
Table 2.9 Molecular weight (MW) analysis by MALDI-MS of galactose-PEG-NH2 with 
predicted and observed mass based on repeat units (n) of PEG. 
 
(a)
(b)
n Predicted MW + Na
+ 
Observed MW + Na
+ 
34 1892.38 1892.60 
35 1936.41 1936.59 
36 1980.44 1980.59 
37 2024.47 2024.59 
38 2068.50 2068.59 
39 2112.53 2112.58 
40 2156.56 2156.57 
41 2200.59 2200.57 
42 2244.62 2244.56 
43 2288.65 2288.56 
44 2332.68 2332.55 
45 2376.71 2376.54 
46 2420.74 2420.53 
47 2464.77 2464.52 
48 2508.80 2508.51 
49 2552.83 2552.50 
50 2596.86 2596.49 
51 2640.89 2640.48 
52 2684.92 2684.47 
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2.6.1.4 Intravenous injection of nanoparticles and analysis of tissues 
 
 
Particles were administered intravenously into C57BL/6 mice (6-10 weeks old) at 0.5 
mg/mouse in 150 µL water or PBS. 48 h after dosing, mice were bled submandibularly for 
blood samples, then euthanized with CO2 followed by cervical dislocation, and major organs 
were collected for further analysis, including liver, lung, spleen, kidney, and heart.  
To track particle distribution in vivo, the isolated organs were imaged with IVIS 
Luminar (Calipar Life Sciences) for particle-associated fluorescence (DyLight 680 or 
DyLight 488 maleimide) and analyzed with Living Image software.   
For histology analysis, liver tissues were frozen in O.C.T. compound, and 5 µm 
sections were made with Cryostat (Leica).  Sections were fixed in acetone for 5 min at 4°C, 
rehydrated in PBS, and blocked with 10% BSA for 30 min at room temperature. Sections 
were then stained with rat anti-mouse MARCO  (Santa Cruz Biotechnology) for 1 h at room 
temperature, followed by AlexaFluor 647-labeled goat anti-rat antibody (Invitrogen) plus 100 
nM phalloidin AlexaFluor 555 (Invitrogen) and 30 µM DAPI (Fisher Scientific) for 30 min 
at room temperature. After washes, sections were mounted in FluorSave reagent 
(CalBiochem) and observed with Zeiss 710 confocal scanning microscope.  
For quantitative RT-PCR analysis of target gene expression, small pieces of liver 
tissues were preserved in 1 mL RNALater (Qiagen) at room temperature overnight. RT-PCR 
amplification and quantification of gene expression were conducted as previously reported
56
.  
Primers and probes: Human β-actin, Forward: GGT CAT CAC CAT TGG CAA TG; 
Reverse:  TAG TTT CGT GGA TGC CAC AG; Probe: FCA GCC TTC CTT CCT GGG 
CAT GGA Q; Mouse Factor VII, Forward: ACA AGT CTT ACG TCT GCT TCT; Reverse: 
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CAC AGA TCA GCT GCT CAT TCT; Probe: FTC TCA CAG TTC CGA CCC TCA AAG 
TCQ. Mouse β-Actin, Forward: CTG CCT GAC GGC CAG GTC; Reverse: CAA GAA 
GGA AGG CTG GAA AAG A, Probe: FCA CTA TTG GCA ACG AGC GGT TCC GQ. F 
represents 5’-Fluorescein (FAM) and Q represents Quencher (TAMRA). 
2.6.2 Behavior of cationic nanoparticles coated with terpolymer ligands 
Figure 2.29 Two-step reaction scheme for preparation of PAA-based terpolymers with 
graphical illustrations. 
 
PAA-based ligands were synthesized according to the reaction scheme illustrated in 
Figure 2.29. Cationic rice-shaped hydrogel nanoparticles were coated with PAA-based 
terpolymer ligands to negate the positive surface charge, provide a stealth PEG layer, and 
present saccharide ligands to target hepatocytes. After internalization by cells, the 
carboxylates from PAA should protonate in the endosome since the pH of the endosome 
approaches the pKa of PAA (pKa ~ 5). Protonation of carboxylates should result in 
dissociation of the ligand coating from particles due to loss of electrostatic attraction, 
revealing endosomolytic particles capable of siRNA delivery (Figure 2.30).  
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Figure 2.30 Illustration of coating cationic nanoparticles with PAA-based terpolymer ligands 
under physiological conditions followed by dissociation of the coating under endosomal 
conditions. 
 
ζ-potential of bare cationic hydrogels decreased as a function of ligand concentration 
(Figure 2.31a) until a maximum around 30 wt eq of ligand to particle. At higher ligand ratios, 
charge screening most likely neutralizes the ζ-potential, approaching neutrality. Flocculation 
(aggregation or settling) of coated particles was not observed over 5 days when incubated in 
PBS at 4 ºC. The response of ligand coating stability on cationic hydrogels was assessed in a 
pH-dependent fashion (Figure 2.31b). Buffers (100 mM) with pH values ranging from 5.0 to 
7.0 were prepared with citric acid and dibasic sodium phosphate. ζ-potential was determined 
as a function of pH for hydrogels coated with 20 wt eq ligand. From physiological pH (7.4) 
to endosomal conditions (pH 5.5), ζ-potential increases linearly (r2 = 0.98), proceeding from 
negative values to positive ones due to protonation of carboxylates and dissociation of the 
coating. It is notable that ζ-potential magnitudes are not as great in these studies as compared 
to previous ones, probably because these hydrogels were not incubated in buffer, isolated, 
and re-suspended in 1 mM KCl.  
Endosomal pH 
PBS, pH  7.4
100 
 
 
Figure 2.31 (a) ζ-potential of cationic nanoparticles as a function of ligand concentration, 
demonstrating ligand density-dependent surface properties. (b) ζ-potential of coated 
nanoparticles subjected to buffers of decreasing pH, mimicking the progression of the 
endosome. 
 
2.6.3 Evaluation of in vitro targeting hepatocytes with coated nanoparticles 
The most effective gene silencing composition (50% AEMAm cationic monomer) 
was implemented in targeting experiments. Coated hydrogels were prepared for in vitro 
dosing on mouse-derived hepatocyte cell line AML12 with 10 wt eq mPEG-PAA as well as 
mPEG-PAA functionalized with PEG-galactose and -glucose (Table 2.10) for evaluating 
time-dependent internalization (Figure 2.32a). The coating apparently minimized aggregation 
of hydrogels (smaller Dz with lower standard deviations) where coated hydrogels exhibited 
negative ζ-potentials. Minimal ligand was implemented such that asialoglycoprotein 
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receptors (ASGPRs) would not be overloaded or blocked by free galactose ligands that may 
potentially dissociate from particles during incubation. Cell uptake was pretty similar among 
the coated hydrogels. Specifically, time-dependent AML12 cell uptake studies demonstrated 
that coatings slowed the rate of internalization; yet, coatings did not provide receptor-
mediated endocytosis. Nonetheless, AML12 cells tolerated coated hydrogels as noted by 
maintenance of cell viability out to high dosing concentrations while a slight decrease in 
viability was noted for cells dosed with cationic particles (Figure 2.32b).  
 
Figure 2.32 (a) Time-dependent AML12 cell uptake of bare 80x320 nm particles and ligand-
coated particles at 100 µg/mL dosing concentration. (b) Viability of AML12 cells dosed with 
cationic and ligand-coated particles after 48 h incubation at 37 ºC. 
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Table 2.10 Zetasizer analysis of hydrogels dosed on hepatocytes. 
Coating ζ-potential / mV Dz / nm 
None +37.6 ± 1.4 448.6 ± 18.7 
mPEG -8.3 ± 0.5 339.9 ± 2.4 
Galactose -9.9 ± 0.3 340.5 ± 6.0 
Glucose -11.2 ± 0.4 380.7 ± 8.9 
 
 The mol% substitution of sugar moieties on terpolymers was then screened at 10, 20, 
and 30 % to observe the effect on cell uptake specificity since ligand density has been 
demonstrated to influence receptor-mediated endocytosis. Zetasizer analysis of particles 
demonstrated that cationic particles exhibited positive ζ-potentials while coated particles 
exhibited negative values (Table 2.11). Cationic hydrogels were readily internalized by 
AML12 cells, reaching 100% cell uptake after 30 min of dosing cells with particles (Figure 
2.33). As previously noted, the rate of internalization was slower for coated nanoparticles 
although differential uptake was not observed between galactose- and glucose-functionalized 
terpolymers.  
Internalization of coated particles was then evaluated on human hepatocarcinoma 
(HepG2) cells to observe whether uptake behavior would be different in another liver cell 
line. After 1 h dosing of particles on HepG2 cells, cationic particles were mostly internalized 
and notable uptake of coated particles occurred at moderate particle doses (Figure 2.34a). 
Coated particles exhibited reduced uptake relative to cationic particles at short time points. 
Selective uptake of galactose-coated particles was not signficantly apparent after 1 h relative 
to glucose-coated particles. After 24 h, complete uptake of all particles was observed across 
all particle dosing concentrations (Figure 2.34b). Therefore, the electrostatic coatings appear 
to stealth particles, minimize the rate of internalization, and decrease toxicity; however, 
selective targeting of hepatocytes was not observed for galactose-coated particles relative to 
glucose-coated particles by human and mouse hepatocytes in vitro. 
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Table 2.11 ζ-potential of bare and ligand-coated cationic hydrogels. 
Ligand (mol%) ζ-potential (mV) 
None (cationic) +9.9 ± 0.7 
PAA-gal 10 -4.6 ± 0.3 
PAA-gal 20 -6.0 ± 0.5 
PAA-gal 30 -5.0 ± 0.3 
PAA-glu 10 -6.9 ± 0.0 
PAA-glu 20 -4.8 ± 0.6 
PAA-glu 30 -8.5 ± 1.8 
 
Figure 2.33 Time-dependent AML12 cell uptake of cationic particles coated with terpolymer 
ligands bearing different degrees of ligand substitution when dosed at 100 µg/mL. 
     
 
Figure 2.34 HepG2 cell uptake of bare 80x320 nm hydrogel nanoparticles and ligand-coated 
hydrogels bearing different mol% of ligand after (a) 1 h and (b) 24 h dosing times. 
  
The absence of selective uptake for galactose- and glucose-coated nanoparticles may 
be attributed to size restrictions and strict spacing requirements among sugar moieties 
imposed by asialoglycoprotein receptors. Glycolipid-laden liposomes were prepared with 
sizes ranging from 30 to 90 nm in diameter and evaluated for specific uptake by 
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asialoglycoprotein receptors.
57
 Particles with a diameter greater than 70 nm could not be 
recognized and processed by asialoglycoprotein receptors. Galactosylated poly(β-amino 
ester)s did not enhance delivery to hepatocytes or increase specificity.
58
 The spatial 
orientation of ligands was seen to influence the receptor-mediated uptake of magnetic 
nanoparticles where tri-antennary ligands provided effective internalization.
50
 The mol% 
incorporation of a tri-antennary N-acetylgalactosamine PEG-lipid conjugate was incorporated 
into ionizable lipid nanoparticles with diameters ranging from 40-70 nm.
59
 Clearly many 
factors influence the uptake specificity of galactose ligand-coated nanoparticles. Therefore, 
future endeavors to obtain asialoglycoprotein receptor-mediated endocytosis of galactose-
decorated PRINT nanoparticles may require diameters less than 70 nm with a high density of 
ligands presented in a triantennary fashion. 
2.6.4 Factor VII gene knockdown in vitro by rice-shaped hydrogel nanoparticles 
Although selective uptake of nanoparticles was not observed, evaluation of gene 
silencing properties and in vivo behavior was pursued since the coatings enabled attractive 
features such as stealth-like properties, minimization of toxicity, and maintenance of particle 
dispersion stability. Circulating in serum as an inactive precursor protease, Factor VII (FVII) 
allows for quick determination of potential for efficacy in delivering siRNA via hydrogels to 
liver hepatocytes by measuring serum protein levels through robust chromogenic assays. The 
composition of hydrogels (Table 2.12) selected for delivery of Factor VII was based on the 
experiments screening amine-containing monomers as well as siRNA and amine content for 
the lowest EC50. Zetasizer analysis (Table 2.13) of all hydrogels dosed on cells illustrates that 
coated hydrogels had negative ζ-potentials where the magnitude was greater for washed 
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particles than unwashed ones. siRNA was released from hydrogels by washing with 10x  
PBS and the encapsulation efficiency was determined to be 79.8 ± 4.2 % (Figure 2.35). 
Table 2.12 Composition of cationic hydrogels for delivery of Factor VII. 
 
 
 
 
 
 
 
 
 
Table 2.13. Zetasizer analysis of hydrogels dosed on AML12 cells. 
Coating ζ-potential / mV Dz / nm 
None (cationic) +27.9 ± 0.8 299.8 ± 5.9 
PAA-mPEG
*
 -16.7 ± 0.3 307.5 ± 5.7 
PAA-mPEG -8.5 ± 0.3 323.6 ± 5.7 
PAA-gal
*
 -18.9 ± 1.0 335.7 ± 0.5 
PAA-gal -11.7 ± 0.4 354.2 ± 5.2 
*
Denotes that particles had been washed in buffer prior to dosing cells. 
 
 
Figure 2.35 Gel electrophoresis analysis of siRNA released from particles incubated in 10x 
PBS. 
All particles were tolerated pretty well by AML12 cells: no change in cell viability 
was noted for coated hydrogels while cationic ones elicited a slight decrease at the highest 
dosing concentration. Cationic hydrogels were internalized to a greater degree than all coated 
rice particles; yet, AML12 cells internalized all particles (cell uptake ~ 100%) after 48 h 
dosing and incubation time even at low particle concentrations (Figure 2.36a). Based on 
Component wt% 
AEMAm 50 
HP4A 23 
Poly(vinyl alcohol) 10 
Irgacure 2959 1 
DyLight 488 maleimide 1 
PEG16-DA 5 
Factor VII siRNA 10 
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confocal microscopy images (Figure 2.37), a significant number of all rice hydrogels were 
internalized by AML12 cells, distributing throughout the cytoplasm and perinuclear region. 
 
 
 
 
 
Figure 2.36 (a) AML12 cell uptake of bare and ligand-coated hydrogel nanoparticles.  
(b) Viability of AML12 cells dosed with bare and ligand-coated, siRNA-containing 
nanoparticles. 
*
Denotes that particles were washed in buffer prior to dosing on cells. 
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Figure 2.37 Confocal microscopy overlay images of AML12 cells incubated with cationic 
and coated hydrogels (tagged green with DyLight 488 maleimide). Nucleus was stained with 
DAPI (blue) and actin was stained with Phalloidin (red). 
  
 
Figure 2.38 qRT-PCR for relative FVII mRNA level in AML12 cells dosed with hydrogels 
containing FVII siRNA and Lipofectamine
TM
 2000 mixed with either ApoB or FVII siRNA. 
Cationic rice particles or hydrogels coated with PAA-mPEG or -gal were dosed on cells and 
incubated for 48 h.
 *
Denotes that particles were washed in buffer prior to dosing on cells. 
   
qRT-PCR was conducted for analysis of relative FVII levels in AML 12 cells dosed 
with hydrogels and Lipofectamine-siRNA complexes (Figure 2.38). Significant suppression 
of FVII mRNA levels was observed for cells dosed with hydrogels containing FVII siRNA 
while Lipofectamine
TM
 2000 did not elicit as efficient gene knockdown. Control siRNA (Apo 
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B) mixed with Lipofectamine
TM
 2000 did not decrease FVII mRNA levels. Selective mRNA 
knockdown by targeted hydrogels was not observed since AML12 cells internalize PAA-
mPEG-coated particles after ca. 48 h dosing and incubation time. Furthermore, coated 
particles that were dosed on cells directly or washed with PBS both provided efficient gene 
knockdown. 
 
2.6.5 Injection of rice-shaped hydrogel nanoparticles into mice 
80x320 nm cationic, PAA-gal-, and PAA-glu-coated hydrogel nanoparticles were 
injected into the tail vain of B6 mice (n=3, 150 µL of 2 mg/mL dispersion). Livers were 
harvested 48 h post-injection and 5 µm cryosections were stained. Actin was stained red with 
Phalloidin and macrophages were tagged magenta with anti-macrophage antibody 
(MAC387). Particles were tagged green through incorporation of DyLight 488 maleimide. 
Rice hydrogels were shown to be partially localized with Kupffer cells. Cationic particles 
were found lining hepatocytes while hydrogel nanoparticles coated with PAA-based ligands 
were notably internalized by hepatocytes and distributed throughout the cell (Figure 2.39). 
Gene silencing was not observed by RT-PCR, most likely due to inefficient delivery of 
siRNA to hepatocytes. To enable systemic delivery of siRNA entrapped in rice-shaped 
hydrogels, a covalent incorporation approach with triggered cargo release was desired to 
maximize delivery of siRNA to hepatocytes in vivo. 
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Figure 2.39 Confocal microscopy of tissues from mice injected with different nanoparticles: 
(a) PAA-glu and (b) PAA-gal with 30 mol% substitution of saccharides, (c) cationic 
nanoparticles, and (d) no nanoparticles (PBS). 
   
2.7 Future directions for delivery of physically-entrapped siRNA in PRINT particles 
Given the potential for plug-and-play approaches to the fabrication of PRINT 
particles, a wide range of chemical compositions and functionalities may be accessed for 
delivery of siRNA. Chemical compositions may include use of degradable matrices, 
(a) (b)
(c) (d)
110 
 
endosomolytic moieties, and reactive handles for controlled release of siRNA, high 
transfection efficiency, and functionalization with ligands. 
2.7.1 Range of particle matrices for encapsulation of siRNA and delivery to cells 
Polysaccharides, biopolymers, and polyesters are attractive matrices for PRINT 
particles to carry siRNA since they are biodegradable and should not pose toxic or 
immunogenic responses. Alginate, a carboxylic acid-containing polysaccharide, may be 
mixed with siRNA followed by the addition of calcium for ionic crosslinking toward the 
transfection of cells. Use of calcium phosphate in particular could enhance endosomal escape 
as demonstrated by efficient systemic siRNA transfection using biodegradable calcium 
phosphate nanoparticles with lipid coatings.
60
 Collagen, atelocollagen, and agar may serve as 
gel-like networks for encapsulation and transfection with siRNA. Solution or thermal 
processing could be conducted to produce PRINT particles.
61
  
Atelocollagen consists of three polypeptide chains (mainly GXY) in a helical 
structure and acts as a rod-like polymer (MW ~ 300 kDa, length ~ 300 nm, diameter 1.5 nm). 
With low antigenicity (due to removal of telopeptides from collagen), atelocollagen is 
biocompatible and biodegradable. Exhibiting water solubility at lower temperatures and 
solidifying to refibrillation over 30 ºC, the sol-gel transition of atelocollagen may be 
controlled with pH, salt concentration, temperature, and chemical modifications. 
Atelocollagen has been demonstrated to enhance accumulation of particles in tumor sites and 
enable effective in vitro and systemic in vivo delivery of siRNA.
62–67
 Protein matrices that are 
rendered transiently insoluble may be used for delivery of siRNA as has been demonstrated 
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by Jing Xu et al.
68
 Avidin could be an interesting matrix to which biotinylated targeting 
ligands (e.g. proteins) and/or PEG linkers could be non-covalently conjugated. 
Water-soluble polysaccharides like dextran, sugars like galactose, and polyols like 
poly(vinyl alcohol) could be mixed with siRNA to produce PRINT particles through solution 
of thermal filling techniques. Chlorosilanes may be harnessed to crosslink particles and 
produce a degradable matrix.
69
 Alternatively, particles may be lipidized with lipid-
chlorosilanes to produce hydrophobic surfaces onto which functional lipids may be 
physisorbed (Figure 2.40). For example, as has been demonstrated by W. Hasan et al., 
hydrophobic PRINT particles may be coated with transfecting lipids (DOTAP and DOPE) 
for effective delivery of siRNA. Additionally, PEG-lipids could be adsorbed to particles to 
provide a stealth layer in addition to ligands for targeting cell receptors. 
Distearoylphosphoethanolamine (DSPE)-PEG-maleimide could be functionalized with 
proteins, peptides, or small molecules to serve as a targeting ligand. 
 
Figure 2.40 Structures of lipidated chlorosilanes, hydrophobic bischlorosilanes, and 
dichlorosilanes where R may consist of different alkyl substituents. 
 
Degradable hydrogel matrices may be implemented for the delivery of siRNA using 
crosslinkers with degradable linkages. Acid-sensitive linkages include hydrazones, acetals, 
ketals, and silyl ethers for which photopolymerizable crosslinkers may be synthesized 
(Figure 2.41) to produce degradable PRINT particles as has been previously demonstrated 
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with the controlled degradation rate of a family of alkyl-substituted bifunctional silyl ether 
crosslinkers.
70
 Enzymatically degradable crosslinkers with peptide sequences that may be 
cleaved by endosomal and lysosomal proteinases such as Cathepsin B, which plays a role in 
cancer progression, could be useful for controlled intracellular delivery of cargos.
71,72
 
A disulfide-containing crosslinker with greater water solubility (Figure 2.41) may be 
synthesized through step-growth polymerization of triethylene glycol diamine with 
bis(ethylene acrylate) disulfide. Acid- and reductively-labile crosslinkers could be 
synthesized to provide two mechanisms for degradation by reacting dichlorosilanes with 
2,2’-dithiodiethanol.    
 
 
Figure 2.41 Structures of degradable crosslinkers for hydrogel particles. 
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2.7.2 Cationic hydrogels 
Amine monomers such as amine-containing acrylates and thiols may be pursued for 
incorporation into cationic hydrogel particles to modulate the charge density, electrostatic 
attraction with siRNA, availability of functional handles, cell internalization profiles, 
endosomal escape, and toxicity of the delivery vector (Figure 2.42). Amines with different 
degrees of substitution may be pursued to further harness the proton-sponge effect. (Meth) 
acrylate and (meth) acrylamide, amine-containing monomers could provide different degrees 
of hydrogen bonding with siRNA to influence release properties. Amine-containing 
monomers that are not commercially available may be synthesized according to Fig 2.43 by 
reacting primary amine-terminated, amine-containing molecules with acid chloride- or N-
hydroxysuccinimide-activated acrylates.  
A library of amine-containing acrylates may be synthesized by reacting amine-
containing small molecules (Figure 2.44) with the appropriate activated acrylate. 
Additionally, amines may be reacted with thiirane (ethylene sulfide) to yield free thiols that 
may polymerize into the particle matrix through photoinitiated thiol-ene addition. Cysteine-
containing endosomolytic peptides may also be used for covalent incorporation into particles 
where thiol groups may serve as chain transfer agents. The cysteine-containing peptides may 
be endosomolytic peptide derivatives like KALA and GALA. Additionally, peptides full of 
arginine, histidine, and lysine residues may be designed to harness guanidino, imidazole, and 
primary amine functional groups for enhanced endosomolysis.  
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Figure 2.42 Structures of amine-containing acrylic monomers that may be purchased 
commercially or specially synthesized. 
 
 
 
 
 
 
 Figure 2.43 Reaction schemes for the synthesis of amine-containing monomers.  
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Figure 2.44 Structures of amine-containing small molecules that may be used to synthesize 
acrylamide-based or thiol-presenting cationic monomers using acryloyl chloride or thiirane. 
R = H or CH3. 
   
2.7.3 Ligands for reversible covalent conjugation 
To create a wholly acid-labile, ligand-decorated particle surface, CDM-activated, 
maleimide-terminated PEG may be synthesized by reacting amine-PEG-maleimide with 
CDM. Subsequently, non-PEGylated amines may be quenched using CTA-mPEG as 
previously demonstrated. Amine- and thiol-containing peptides, proteins, or small molecules 
may be conjugated to the maleimide group through Michael addition. Unreacted maleimide 
groups may be quenched with small molecules like ethanolamine or oligomers like 
monomethoxy-PEG-amine. For targeting tumor endothelial cells, thiol-containing RGD 
(RAD control) peptides may be conjugated to the maleimide group. To reach liver 
hepatocytes, N-acetyl-D-galactosamine (glucosamine control) could be conjugated as well. A 
wide range of protein and antibody ligands should be accessible to target nanoparticles to cell 
receptors since the proteins have a reasonable number of lysine and cysteine residues that 
may be harnessed for nucleophilic addition to maleimide groups. 
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2.7.4 Ligands for electrostatic complexation to nanoparticles 
Polyelectrolyte attraction of polyanionic ligands to cationic nanoparticles was 
previously covered in section 2.6. Further development of coated PRINT particles with 
polyacid-based ligands could potentially enable stealthing and selective uptake if designed 
appropriately. Instead of randomly grafting mPEG and PEG-ligand chains from the polyacid 
backbone with few repeat units, polyacid tethers may be more effective to instill 
polyelectrolyte attraction between particles and ligands. For example, similar to previously 
reported studies,
54,55
 poly(glutamic acid)- or poly(aspartic acid)-tethered peptide or small 
molecule ligands may enable stealthing properties, alter biodistribution, and yield receptor-
mediated endocytosis for gene delivery. Polyacids are particularly attractive for coating 
cationic nanoparticles since they should disassociate in the endosomal environment due to 
the pH sensitivity of ionizable carboxylic acid groups. Other polyanions including groups 
like phosphates and sulfates may enable electrostatic attraction to cationic nanoparticles; 
however, the interaction may be substantial such that disassembly and shedding of the 
coating does not readily occur under intracellular conditions when also considering that the 
phosphate and sulfate groups may not protonate under endosomal conditions. Another 
approach to polyanion-tethered ligands may entail controlled radical polymerization of an 
anionic monomer (e.g. acrylic acid) followed by end functionalization for conjugation of 
PEG or PEG-ligands. Side-by-side comparison of polyanion-tethered ligands compared to 
polyanions with randomly distributed ligands would uncover the effect of substituent 
placement on the stability of the coating and ability to target cells for receptor-mediated 
endocytosis. 
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CHAPTER 3 
REDUCTIVELY-RESPONSIVE SIRNA-CONJUGATED HYDROGEL 
NANOPARTICLES FOR GENE SILENCING IN LIVER HEPATOCYTES 
3.1 Introduction to siRNA conjugates for gene silencing  
 Systemic administration of siRNA to target tissues and cells requires particular design 
features to overcome in vivo barriers such as degradation by nucleases in serum, clearance by 
the reticuloendothelial system, and filtration by major organs. To overcome in vivo 
challenges, siRNA conjugates offer beneficial characteristics such as enhanced serum 
stability, modification of biodistribution profiles, improved transfection efficiency, and 
avoidance of macrophage uptake. Lipid, peptide, antibody, and polymer siRNA conjugates 
have been explored for systemic delivery alone or when formulated as nanoparticles.
1
 Lipids 
such as cholesterol have been conjugated to siRNA, e.g. via a pyrrolidone linkage, for 
enhanced transfection efficiency in vitro and silencing of apoB in mice after intravenous 
administration.
2
 Cholesterol-conjugated siRNA has also been incorporated into core-shell 
nanoparticles to improve FVII gene silencing in mice.
3
 Lipidated siRNA has been 
synthesized by attaching siRNA to dipalmitoyl phosphothioethanol via a disulfide linkage for 
enhanced nuclease stability, reductively-triggered release, and increased gene delivery 
efficiency in vitro when formulated as nanosized mixed polymeric micelles.
4
 
 Gene silencing in a rat model bearing an intracranially-transplanted brain tumor was 
elicited by siRNA-antibody conjugates. Specifically, biotinylated siRNA was conjugated to 
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blood brain barrier-targeted immunoliposomes through a streptavidin-functionalized 
antibody targeting the transferrin receptor.
5
 Polyvalent nucleic acid nanostructures have been 
developed as a platform for oligonucleotide delivery
6
 that does not require use of polymers, 
lipids, or ions for transfection. Propargyl ether-modified oligonucleotides can be absorbed to 
gold nanoparticle surfaces and crosslinked followed by dissolving away the gold core. High 
density of oligonucleotides in the correct orientation minimized nuclease degradation and 
afforded cell uptake for gene silencing. Quantum dots have been conjugated with siRNA via 
reductively-labile disulfide bonds to enable gene knockdown in vitro while control siRNA- 
conjugated quantum dots (with a non-degradable linkage) did not induce gene knockdown.
7
  
Phage display allowed for the identification of a skin penetrating and cell entering 
(SPACE) peptide, which was conjugated to siRNA for skin delivery to knockdown target 
proteins (interleukin-10 and GADPH).
8
 siRNA has been conjugated to polymers for 
enhanced transfection and delivery, e.g. to lactosylated PEG through an acid-labile linkage in 
the formulation of polyion complex micelles for enhanced intracellular delivery.
9
 
Additionally, siRNA has been covalently conjugated through disulfide linkages to 
hepatocyte-targeted poly(vinyl ether)s to elicit in vivo gene knockdown in mice livers after 
systemic administration.
10
  
3.2 Preparation of polymerizable siRNA macromers for covalent incorporation into 
hydrogel nanoparticles 
Reproduced with permission from Dunn, S. S.; Tian, S.; Blake, S.; Wang, J.; 
Galloway, A. L.; Murphy, A.; Pohlhaus, P. D.; Rolland, J. P.; Napier, M. E.; DeSimone, J. 
M. J. Am. Chem. Soc. 2012, 134, 7423-7430. Copyright 2012 American Chemical Society. 
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Acrydite DNA oligonucleotides have been incorporated into hydrogels for nucleic 
acid hybridization assays
11,12
 while a CpG oligonucleotide methacrylamide has been 
copolymerized into acid-degradable microparticles to invoke immune responses.
13,14
  For the 
triggered release of therapeutic conjugates from particles or delivery vectors under 
biologically relevant conditions, acid-labile,
15–17
 enzymatically degradable,
18,19
 and redox-
sensitive linkages
20
 have been examined. Glutathione and reducing enzymes are present at 
high concentrations inside cells relative to the extracellular space in normal and cancer cell 
lines.
21
  Considering the serum stability of disulfide conjugates,
20,22
 cleavage of disulfide 
linkages in therapeutic conjugates may selectively occur in the intracellular reducing 
environment. Disulfide-siRNA conjugates to polymers and lipids have been previously 
reported
4,10,23–25
 as reductively-labile systems. In this work, siRNA was derivatized with a 
photopolymerizable acrylate bearing a degradable disulfide linkage for reversible covalent 
incorporation into the PRINT hydrogel nanoparticles.  
3.2.1 Experimental 
3.2.1.1 Materials  
2,2’-dithiodiethanol, acryloyl chloride, PEG700 diacrylate, disuccinimidyl carbonate 
(DSC), 2-aminoethyl methacrylate hydrochloride (AEM), 1-hydroxycyclohexyl phenyl 
ketone (HCPK), fluorescein O-acrylate, tetraethylene glycol, and Irgacure 2959 were 
purchased from Sigma Aldrich. Poly(vinyl alcohol), 75% hydrolyzed with MW ≈ 2 kDa, was 
obtained from Acros Organics. Tetraethylene glycol monoacrylate (HP4A) was synthesized 
in-house and kindly provided by Dr. Matthew C. Parrott, Dr. Ashish Pandya, and Mathew 
Finniss. PRINT molds were graciously supplied by Liquidia Technologies. siRNAs were 
purchased as duplexes from Dharmacon, Inc. Sense sequence of amine-modified and native 
125 
 
anti-luciferase siRNA: 5’-N6-GAUUAUGUCCGGUUAUGUAUU-3’; anti-sense: 5’-P-
UACAUAACCGGACAUAAUCUU-3’. Sense sequence of amine-modified and native 
control siRNA: 5’-N6-AUGUAUUGGCCUGUAUUAGUU-3’; anti-sense: 5’-P-
CUAAUACAGGCCAAUACAUU-3’. All other reagents were obtained from Thermo Fisher 
Scientific, Inc. in molecular biology grade or RNase-free when available. 
3.2.1.2 Synthesis of siRNA macromers 
Degradable disulfide macromer precursor: 2,2’-dithiodiethanol (15 mL, 0.12 mol) was 
dissolved in anhydrous DMF (250 mL) in a 500-mL round-bottomed flask containing NEt3 
(20.5 mL, 1.2 eq) under a N2 blanket to which acryloyl chloride (11.0 mL, 1.1 eq) was added 
dropwise and allowed to react for 8 h. Crude product was extracted into dichloromethane 
against 5% LiCl and purified via silica gel chromatography (EtOAc:hexanes) to provide 
monoacrylate-substituted 2,2’-dithiodiethanol (63% yield). 2-((2-
hydroxyethyl)disulfanyl)ethyl acrylate (10 g, 48 mmol) was dissolved in anhydrous 
acetonitrile (100 mL) in a N2-purged 250-mL round-bottomed flask, followed by addition of 
disuccinimidyl carbonate (14.8 g, 1.2 eq). The reaction proceeded for 8 h and the product 
was purified by silica gel chromatography (EtOAc:hexanes 4:1) to afford 2-N-
hydroxysuccinimide, 2’-acryloyl-dithiodiethanol as a clear, viscous liquid (82% yield). 1H 
NMR (600 MHz, CDCl3) δ = 6.46 (dd, J = 17.4 Hz, 1H), δ = 6.2 (dd, J = 10.7 Hz, 6.8 Hz, 
1H), δ = 5.90 (dd, J = 10.7 Hz, 1H), δ = 4.59 (t, J = 6.5 Hz, 2H), δ = 4.45 (t, J = 6.5 Hz, 2H), 
δ = 3.05–3.00 (m, J = 6.8 Hz, 4H), δ = 2.87 (s, 4H).  
Non-degradable siRNA conjugate precursor: N-hydroxyethyl acrylamide (15 mL, 0.14 mol) 
was dissolved with DSC (51.9 g, 1.4 eq) in ACN:DMF 4:1 (250 mL) and reacted for 16 h. 
Afterward, ACN was removed via rotary evaporation and product was extracted into EtOAc 
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against 5% LiCl. Product was concentrated and purified by silica gel column 
chromatography (EtOAc:hexanes 4:1) to provide 2-(succinimidyl carbonate)ethyl acrylamide 
(80% yield) as a fine white solid. 
1
H NMR (600 MHz, CDCl3) δ = 6.50 (br, 1H, NH), δ =  
6.34 (dd, J = 17.1 Hz, 1H), δ = 6.19 (dd, J = 10.3 Hz, 6.4 Hz, 1H), δ = 5.71 (dd, J = 10.3 Hz, 
1H), δ = 4.46 (t, J = 5.0, 2H), δ = 3.71 (m, J = 5.5 Hz, 2H), δ = 2.87 (s, 4H). 
siRNA macromers: siRNA-NH2 (2 mg, 148 nmol, anti-luciferase siRNA or control sequence) 
was dissolved in DEPC-treated PBS (200 µL) in a 1.5-mL RNase-free Eppendorf tube. 
Separately, 2-N-hydroxysuccinimide, 2’-acryloyl-dithiodiethanol (5.2 mg, 100 eq)  or 2-
(succinimidyl carbonate)ethyl acrylamide (3.8 mg, 100 eq) was dissolved in RNase-free 
DMF (150 µL) and added to the solution of siRNA. The reaction was allowed to proceed for 
36 h where additional 100 eq of the acrylate or acrylamide were added to the reaction 
mixture every 12 h. 5 M NH4OAc (50 µL) and EtOH (1.1 mL) were added to the reaction 
mixture, which was vortexed for 15 s. The sample was incubated in a -80 °C freezer for 4 h 
followed by centrifugation (14 krpm, 4 °C, 20 min) to pellet the siRNA. The supernatant was 
decanted and the pellet was washed twice with 70% EtOH (ice-cold) to provide siRNA 
prodrug (79% yield). HR-ESI-MS: m/z found for siRNA sense strand [M-H]
-
 = 6832.366; 
m/z calc. for disulfide macromer [M-H]
-
 = 7067.676; found [M-H]
-
 = 7067.855; m/z calc. for 
siRNA acrylamide macromer [M-H]
-
 = 6974.506; found [M-H]
-
 = 6974.871.  
3.2.1.3 Characterization of siRNA macromers and analysis of bioactivity 
Characterization of siRNA prodrug precursors was carried out on a 600 MHz Bruker 
NMR Spectrometer equipped with a Cryoprobe and siRNA macromonomers were analyzed 
by an IonSpec Fourier Transform Mass Spectrometer FTMS (20503 Crescent Bay Drive, 
Lake Forest, CA 92630) with a nano electrospray ionization source in combination with a 
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NanoMate (Advion 19 Brown Road, Ithaca, NY 14850) chip based electrospray sample 
introduction system and nozzle operated in the negative ion mode as well as reversed phase 
high-performance liquid chromatography.  
Analysis of siRNA macromonomers by reversed phase HPLC demonstrates that 
modifications of siRNA-NH2 with acrylamide and disulfide precursors yield a single peak 
and increase retention time relative to unmodified siRNA-NH2 (Figure 3.1). Oligonucleotides 
were analyzed using 0.1 M triethylammonium acetate buffer (pH 7.0) and a gradient of 0 to 
35% acetonitrile over 20 min followed by a gradient to 100% acetonitrile over the next 15 
min. HPLC runs were conducted at a flow rate of 0.2 mL/min using Zorbax Eclipse XDB-
C18 column (4.6 x 150 mm, 5 µm, Agilent) and Agilent 1200 Series Multiple Wavelength 
Detector SL. 
 
 Figure 3.1 Analysis of native siRNA and siRNA macromers by reversed phase HPLC.  
 
 The activity of luciferase and control siRNA before and after derivatization with the 
disulfide precursor was tested in vitro using a HeLa cell line stably transfected with firefly 
luciferase reporter gene. The amine-terminated (native) and pro-drug siRNA were dosed on 
HeLa cells after complexation with Lipofectamine
TM
 2000 transfection reagent. The siRNA 
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complexes were allowed to remain on the cells for 4 h followed by further incubation for 2 
days at 37 ºC in cell media. Knockdown of luciferase expression was evaluated by measuring 
bioluminescence. Native and pro-drug siRNA elicited comparable knockdown (Figure 3.2) 
while gene silencing was absent when dosing control (inactive) siRNA. Maintenance of 
siRNA activity after modification indicates compatibility of the oligonucleotide with reaction 
and purification conditions involved in pro-drug synthesis.  
 
Figure 3.2 (a) Luciferase expression and (b) viability of HeLa/luc cells dosed with luciferase 
and control sequences of native (siRNA-NH2) and degradable siRNA prodrug (PD) 
complexed to Lipofectamine 2000TM and incubated for 48 h. Retention of siRNA activity 
after macromonomer synthesis was confirmed by evaluating transfection efficiency before 
and after siRNA derivatization. 
 
 
 
 
Luciferase expression
0 200 400 600
0
20
40
60
80
100
120
luc siRNA-NH2
crtl siRNA-NH2
luc siRNA PD
crtl siRNA PD
siRNA identity
siRNA (nM)
%
 o
f 
c
o
n
tr
o
l
(a)
Cell viability
0 200 400 600
0
20
40
60
80
100
120
luc siRNA-NH2
crtl siRNA-NH2
luc siRNA PD
crtl siRNA PD
siRNA identity
siRNA (nM)
%
 o
f 
c
o
n
tr
o
l
(b)
129 
 
3.2.1.4 Particle characterization, analysis of siRNA by gel electrophoresis, and cell 
studies 
Particle characterization and cell studies were conducted in a similar manner as 
reported in 2.3.1.  
3.2.2 Fabrication of hydrogels via PRINT process for covalent incorporation of siRNA 
For reversible covalent incorporation of siRNA into hydrogel nanoparticles, native 
siRNA-NH2 was modified with a disulfide-containing acrylate precursor while implementing 
a non-degradable control acrylamide (Figure 3.3a). In the designed ‘pro-siRNA hydrogels’, it 
was envisioned that the siRNA cargo would be retained in the particle until entry of the 
particle into the cytoplasm of a cell, where the disulfide linkage would be cleaved in the 
reducing  environment, allowing for release and delivery of the siRNA (Figure 3.3b). A 
water-based pre-particle composition containing the disulfide siRNA pro-drug and 
hygroscopic, liquid monomers was applied to fabricate cylindrical (d = 200 nm; h = 200 nm) 
loosely-crosslinked cationic PRINT hydrogel particles using a film-split technique.  SEM 
micrographs confirmed the dimensions and shape of cylindrical siRNA-containing particles 
(Figure 3.3c).  
 
Figure 3.3 (a) Structures of degradable and non-degradable siRNA macromers as well as 
native siRNA, (b) Illustration of pro-siRNA hydrogel behavior under physiological and 
intracellular conditions, and (c) SEM micrograph of pro-siRNA, 200 x 200 nm cylindrical 
nanoparticles (scale bar = 2 µm). 
(a)
(b)
Reducing 
environment
Hydrogels with siRNA incorporated
Extracellular, physiological conditions
Hydrogels and released siRNA
Intracellular conditions
(c)
130 
 
 
The time-dependent release of the siRNA from the pro-drug PRINT hydrogel 
particles was evaluated under physiological and reducing conditions (Figure 3.4). The siRNA 
was retained in the hydrogel particles over 48 h at 37 °C in PBS while the siRNA was 
quickly released from hydrogels when incubated in a reducing environment (5 mM 
glutathione), reaching maximum concentration around 4 h (Figure 3.4a). 
 
Figure 3.4 Release profiles and stability of siRNA in 30% AEM-based hydrogels. All 
hydrogels were washed with 10x PBS buffer to remove the sol fraction containing 
unconjugated siRNA before release studies were performed. (a) Time-dependent incubation 
of pro-siRNA hydrogels (1 mg/mL) in PBS and under reducing conditions (glutathione, 5 
mM) at 37 °C. (b) Selective release of the disulfide-coupled siRNA prodrug (PD) from 
hydrogels under reducing conditions compared to the acrylamide (AA) macromer and native 
siRNA (NH2). Hydrogels were incubated in 10x PBS with or without 5 mM glutathione for 4 
h at 1 mg/mL and 37 °C. (c) Retention of siRNA integrity when conjugated to hydrogels 
after exposure to 10% fetal bovine serum (FBS) over time. Naked siRNA PD macromer was 
incubated at 36 µg/mL in 10% FBS for given times, proceeded by storage of solution. pro-
siRNA hydrogels were incubated at 1.2 mg/mL in 10% FBS at 37 °C for given times 
followed by incubation in 10x PBS (5 mM glutathione) for 4 h at 1.2 mg/mL and 37 °C to 
release siRNA. Differences in siRNA migration observed in gels among the standards and 
samples which were released from hydrogels incubated in PBS and 10x PBS may arise from 
the differences in salt concentrations of sample solutions. 
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3.2.3 pro-siRNA hydrogels for gene silencing 
3.2.3.1 Screening the amine content of hydrogel nanoparticles 
The PRINT particles were designed to have a positive zeta potential to facilitate cell 
internalization and endosomal escape by including an amine monomer (AEM, 2-
aminoethylmethacrylate hydrochloride). It is known that excessive amine content in 
hydrogels may disrupt and destroy the plasma membrane, eliciting cell death. Conversely, an 
insufficient amine content may not enable efficient cell uptake and endosomal escape for 
transfection. To optimize cytocompatibility and gene silencing efficiency of pro-siRNA 
hydrogels, the AEM content was varied from 5 to 50 wt% (Table 3.1). Pro-siRNA hydrogels 
were not PEGylated as were siRNA-complexed hydrogels whereby the cytocompatibility of 
bare particles would be determined. For systemic delivery of particles in vivo, sheddable 
coatings that reveal bare particles are attractive to enable targeting and endosomal escape for 
effective gene delivery.
26,27
 
ζ-potentials of cationic hydrogels increased with amine content and the Z-average 
diameters (Dz) of the resultant particles ranged from 250 to 350 nm (Table 3.2). 
Encapsulation of the siRNA in the hydrogel PRINT particles reached a roughly constant 
value once the amine content was greater than or equal to 20 wt% (Figure 3.5). The 
encapsulation efficiency was determined to be ca. 35% for AEM contents ≥ 20 wt% while 
when only using 5% AEM, the encapsulation was lower (ca. 15%). When the pro-drug, 
disulfide-containing siRNA hydrogel PRINT particles were dosed onto luciferase-transfected  
cells (HeLa/luc) for 5 h followed by 48 h incubation at 37 °C, dose-dependent knockdown of 
the luciferase expression was observed (Figure 3.6a) for hydrogels with amine contents 
greater than 5 wt% AEM. Cytocompatibility was maintained at the lower amine contents and 
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dosing concentrations (Figure 3.6b). It appeared that the 30% AEM-containing PRINT 
hydrogel particles provided the ideal combination of gene silencing efficiency (EC50 ~ 20 nM 
siRNA) and cytocompatibility (even at high dosing concentrations).  
Table 3.1 Composition of pre-particle solution for fabrication of pro-siRNA hydrogels. 
Component Function wt % 
PEG700 diacrylate crosslinker 5 
Tetraethyleneglycol monoacrylate hydrophile 73–28 
2-aminoethyl methacrylate HCl cationic handle 5–50 
Poly(vinyl alcohol) 2 kDa porogen and PET-wetter 10 
Irgacure 2959 photoinitiator 1 
DyLight 488 maleimide fluorescent dye 1 
siRNA cargo 5 
  
 
Table 3.2 Zetasizer analysis of pro-siRNA hydrogels with variable amine content. 
Amine content (wt%) ζ-potential  (mV) Dz (nm) 
5% AEM +18.2 ± 0.5 350.2 ± 5.4 
20% AEM +22.6 ± 0.1 281.6 ± 1.9 
25% AEM +27.1 ± 0.3 307.4 ± 6.6 
30% AEM +27.9 ± 1.5 324.3 ± 5.6 
40% AEM +30.6 ± 1.0 281.3 ± 6.0 
50% AEM +34.1 ± 0.4 253.7 ± 3.4 
 
 
Figure 3.5 Gel electrophoresis of siRNA released from hydrogels prepared with different 
amine monomer contents. Hydrogels were incubated in 10x PBS containing 5 mM 
glutathione at 1.7 mg/mL for 4 h at 37 °C. 
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Figure 3.6 (a) Luciferase expression and (b) viability of HeLa/luc cells dosed with cationic 
pro-siRNA hydrogels fabricated with different amine (AEM) contents. Cells were dosed with 
particles for 5 h followed by removal of particles and 48 h incubation in media. Data are 
representative of two independent experiments. The error bars represent standard deviation 
from triplicate wells in the same experiment. Half maximal effective concentrations (EC50s) 
of siRNA (nM) for luciferase gene knockdown are listed in the legend. EC50 was not 
available (NA) for hydrogels prepared with 5 wt% AEM due to the absence of dose-
dependent luciferase knockdown. 
 
3.2.3.2 Implementing additional siRNA cargos into hydrogel nanoparticles to 
investigate gene silencing specificity 
To study the response of pro-siRNA hydrogels to a reducing environment, non-
disulfide acrylamide siRNA-based hydrogel particles and native siRNA-complexed particles 
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were prepared as controls. Release of native siRNA-NH2 occurred rapidly from these porous, 
loosely-crosslinked hydrogels (Figure 3.7). Figure 3.8 showed that different siRNAs were 
loaded into hydrogel particles and remained associated with particles directly after 
harvesting. Unconjugated siRNA was found in hydrogels charged with native siRNA or 
siRNA macromers due to incomplete conversion; therefore, in the following experiments all 
particles were extensively washed with 10x PBS to remove the sol fraction containing free 
siRNA.  
 
Figure 3.7 Gel electrophoresis of native siRNA-NH2 released from 30 wt% AEM-based 
hydrogels over time in PBS at 1 mg/mL and 37 ºC shows rapid release of cargo. 
 
To further investigate the in vitro gene knockdown efficacy of the PRINT hydrogel 
particles, the 30% AEM-based hydrogel composition was utilized with four different cargos: 
(1) native luc siRNA, (2) degradable disulfide luc siRNA, (3) non-degradable, acrylamide luc 
siRNA, and (4) degradable disulfide control siRNA. Zetasizer analysis of the hydrogel 
PRINT particles indicated that their size and charge were similar (Table 3.3) and gel 
electrophoresis (Figs. 3.9) allowed for confirmation of the release of the various cargos. After 
dosing the particles on cells and incubating for 48 h, cell viability was maintained above 80% 
for all of the samples across all dosing concentrations, except for the particles charged with 
the free siRNA (Figure 3.10). Uptake of all of the hydrogel particles approached saturation at 
around 50 µg/mL particle concentration (Figure 3.11a). Dose-dependent silencing of 
luciferase expression was elicited notably for the pro-drug, disulfide-based siRNA-containing 
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hydrogel particles while the control particles did not elicit significant gene knockdown 
(Figure 3.11b).  
 
Figure 3.8 Characterization of particle work-up and behavior after harvesting by gel 
electrophoresis. Particles prepared from 30 wt% AEM-based composition without dye were 
charged with native siRNA (NH2), disulfide pro-drug macromer (PD), and acrylamide 
macromer (AA) in addition to blank particles without siRNA (B). Particles were loaded into 
the wells of the gel (left) at 1 mg/mL to observe the presence of siRNA in hydrogels directly 
after harvesting particles, after washing unconjugated siRNA, and after incubation in 
glutathione-containing buffer. Corresponding unconjugated siRNA was washed from 
hydrogels with 10x PBS, isolated from the supernatant of particle dispersions, and run on the 
gel (right) as well as supernatants from particles incubated in 5 mM glutathione-containing 
buffer (10x PBS) for 4 h at 37 ºC to illustrate the removal of unconjugated siRNA and 
triggered release of the disulfide-conjugated siRNA. 
 
Figure 3.9 Gel electrophoresis analysis of siRNAs (abbreviation below) released from 
hydrogels incubated at 2.5 mg/mL for control knockdown studies under reducing conditions 
(5 mM glutathione, GSH) in 10x PBS for 4 h at 37 °C. lucAA
1
: acrylamide non-degradable 
luciferase siRNA; NH2
2
: native amine luciferase siRNA; lucPD
3
: degradable luciferase 
siRNA prodrug; crtlPD
4
: degradable control siRNA prodrug. 
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Table 3.3 Zetasizer analysis of cationic hydrogels charged with different siRNAs. 
siRNA cargo ζ-potential (mV) Dz (nm) 
Luc prodrug +17.3 ± 0.2 340.0 ± 7.0 
Luc AA prodrug +16.7 ± 0.2 292.6 ± 6.4 
Luc NH2 +20.8 ± 0.8 304.2 ± 6.7 
Crtl prodrug +17.4 ± 1.0 325.6 ± 1.2 
 
 
Figure 3.10 Viability of HeLa/luc cells dosed with cationic hydrogels charged with different 
siRNA cargos. Cells were dosed with particles for 4 h followed by removal of particles and 
48 h incubation in media. 
 
The transfection efficiency between siRNA-complexed, PEGylated particles and pro-
siRNA hydrogels is comparable, which can be explained by differences in release 
characteristics. PEGylated particles release siRNA slowly in PBS while pro-siRNA 
hydrogels rapidly release siRNA under intracellular conditions. Confocal microscopy images 
of HeLa cells dosed with particles (Figs. 3.11c-f) illustrates uptake of the particles, which 
accumulated largely in the cytoplasm and perinuclear region. Given the internalization of 
cationic particles by HeLa cells and distribution throughout the cytoplasm and perinuclear 
area, potential exists for the encapsulation of other therapeutic nucleic acids in hydrogel 
nanoparticles to transfect diseased cells. 
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Figure 3.11 30% AEM-based hydrogel particles charged with different siRNA cargos for 
transfection of HeLa cells. (a) Cellular uptake. HeLa/luc cells were dosed with particles for 4 
h followed by trypan blue treatment and flow cytometry analysis. (b) Luciferase expression.  
HeLa/luc cells were dosed with particles for 4 h followed by removal of particles and 48 h 
incubation in media. Data in (a) and (b) represent one of two independent experiments. The 
error bars represent standard deviation from triplicate wells in the same experiment. Note that 
all hydrogels were thoroughly washed after fabrication to remove non-conjugated siRNA in 
the sol fraction. (c)-(f) Confocal micrographs. HeLa/luc cells were dosed with 50 µg/mL 
hydrogels containing (c) luc PD (d) luc siRNA-NH2, (e) luc acrylamide, and (f) control PD 
siRNA cargos for 4 h. Cellular actin cytoskeleton was stained with phalloidin (red) and 
nuclei with DAPI (blue) while particles (green) were labeled with the fluorescent monomer, 
DyLight 488 maleimide. 
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3.3 Targeting hepatocytes with PRINT particles 
Since selective uptake of galactose-functionalized terpolymer ligand-coated PRINT 
hydrogel nanoparticles was not observed by hepatocytes in vitro and asialoglycoprotein 
receptors have requirements for uptake, e.g. specific restrictions on upper particle size limit 
(70 nm) for endocytosis and distinct spatial orientation of ligands presented at specific 
densities on nanoparticle surfaces, alterative receptors were sought. Hepatic receptors with 
additional flexibility in nanoparticle size and presentation of ligands may involve low density 
lipoprotein (LDL) receptors. LDL receptor-related protein 1 (LRP1), a transmembrane 
glycoprotein, plays many biological roles from endocytosis of numerous ligands to 
modulation of blood brain barrier function.
28,29
 Hepatic functions of LRP1 involve clearance 
of plasma proteins like FVII. Most importantly, LRP1 and LRP2 can be targeted for 
endocytosis by lactoferrin-conjugated nanoparticles. Lactoferrin, a large, multifunctional 
glycoprotein related to transferrin, was conjugated to nanoparticles for systemic 
administration to enhance delivery to hepatocytes.
30
 
LRP was identified to play a crucial role in the uptake of a peptide sequence from the 
tail fiber protein (p17) of a T7 phage in liver parenchymal cells in vitro and in vivo.
31
 The 
p17-derived peptide was functionalized with streptavidin for conjugation to biotinylated 
liposomes. Targeted delivery of p17-conjugated liposomes to hepatocytes was demonstrated 
after tail vein injection into mice relative to control peptide-conjugated liposomes.
32
 
Adapting the lactoferrin protein and p17-derived peptides to PRINT particles, targeted 
delivery of particles to hepatocytes was investigated in vitro and in vivo. 
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3.3.1 Experimental  
3.3.1.1 Materials 
 Previously obtained materials listed in 3.3 were used for these studies. SCM-PEG5K-
maleimide was from Laysan Bio, Inc. Succinic anhydride and lactoferrins (human and 
bovine) were purchased from Sigma Aldrich. The T7 phage p17 peptide was obtained from 
Genscript with a cysteine residue added to the N-terminus. BCA Protein Assay Kit was 
obtained from Pierce, Thermo Fisher Scientific.  
3.3.1.2 Particle fabrication and characterization as well as cell studies 
Particle fabrication was carried out in a similar manner as for 30 wt% AEM pro-
siRNA hydrogels: for compositions without siRNA, the wt% of HP4A was correspondingly 
increased. 80x180, 80x320, and 200x200 nm PRINT molds were graciously provided by 
Liquidia Technologies. Cell culture and analysis was conducted as described previously, 
using AML12, HepG2, and RAW cells in these experiments. Particle characterization by 
SEM, TGA, and Zetasizer analysis was conducted as previously described.   
The bicinchoninic acid assay (BCA) was used to quantify protein or peptide 
conjugated to nanoparticles. Instructions were followed from the manufacturer for protein 
quantification in creating standards of protein using serial dilutions and particles were 
directly analyzed. 200 µL of reagent mixture was added to each well in 96-well plates to 
which 20 µL of sample (protein standard or particle dispersion) was added for absorbance 
reading on a Spectrophotometer at 562 nm. 
3.3.1.3 Functionalization of particles with lactoferrin and p17-derived peptide  
Particles were functionalized with biological ligands by first PEGylating particles at 
0.5 mg/mL in anhydrous DMF for 6 h using pyridine base and SCM-PEG5K-maleimide at 
140 
 
given weight equivalents. Optionally, non-PEGylated amines were quenched with succinic 
anhydride (2 wt eq) in anhydrous DMF at 1 mg/mL particle concentration for 2 h. Particles 
were washed with PBS and re-suspended in sodium borate buffer (pH 9.5) or other buffers at 
0.5 mg/mL for conjugation of lactoferrin (or ethanolamine control ligand at given wt eq) for 
4 h at given wt ratios, followed by washing with PBS. For conjugation of p17 peptide, 
particles were incubated with the peptide overnight in PBS at listed stoichiometric ratios. 
Lastly, particles were washed to remove any free ligand.  
3.3.2 Lactoferrin conjugation strategies for enabling receptor-mediated endocytosis of 
200 nm cylindrical hydrogels 
Bovine lactoferrin was first pursued for conjugation to nanoparticles to enable 
receptor mediated endocytosis. The reaction scheme for preparing 200 nm targeted particles 
is outline in Figure 3.12. Particles were PEGylated with SCM-PEG5K-maleimide followed by 
quenching half of the particles with succinic anhydride. Subsequently, particles were reacted 
with either lactoferrin or ethanolamine (EtOHNH2, control ligand, 2 wt eq) in basic buffer. 
Zetasizer analysis of particles (Table 3.4) indicated that they all exhibited negative ζ-
potentials. Unquenched particles embraced negative ζ-potentials most likely due to the 
intramolecular rearrangement that polymerized AEM readily undergoes to form an alcohol. 
Quenched particles showed ζ-potentials of greater magnitude, most likely due to the 
carboxylates contributing more anionic character.  
Internalization of lactoferrin- and ethanolamine (control)-conjugated particles (Figure 
3.13), which were not quenched with succinic anhydride, by AML12 cells reached ca. 100% 
at low dosing concentration. Mean fluorescence intensity (MFI) of AML12 cells dosed with 
unquenched particles shows high values, increasing with concentration. For quenched 
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particles, differential uptake was observed between lactoferrin- and ethanolamine-conjugated 
particles: lactoferrin reached maximum cell uptake around 50 µg/mL while control particles 
demonstrated low background uptake (ca. 20%) at this dose. MFI of AML12 cells illustrates 
a large difference in uptake between lactoferrin-conjugated particles and ethanolamine- 
quenched particles. 
 
Figure 3.12 Reaction scheme for preparation of ligand-conjugated hydrogels. 
Table 3.4 Zetasizer analysis of ligand-conjugated nanoparticles. 
Particle (ligand) ζ-potential (mV) Dz (nm) 
Lactoferrin, no quench  -2.5 ± 0.4 365.1 ± 2.4 
Lactoferrin, quench   -6.5 ± 0.1 386.0 ± 4.4 
EtOHNH2, no quench   -2.2 ± 0.2 379.5 ± 23.7 
EtOHNH2, quench -9.6 ± 0.1 384.9 ± 4.8 
 
The effect of media (complete medium or OPTI-MEM) was explored on cell uptake 
selectivity of nanoparticles in vitro. Uptake of targeted, quenched 200 nm particles by 
AML12 cells was similar to previous studies where high internalization occurred at low 
doses for LTF-conjugated particles while uptake of LTF-free (ethanolamine-reacted, control) 
particles was notably lower when incubated in complete medium or OPTI-MEM (Figure 
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3.14a). MFI of AML12 cells incubated with particles illustrates a significant difference in 
uptake between LTF- and ethanolamine-conjugated particles (Figure 3.14b). 
 
 
Figure 3.13 AML12 cell uptake of ligand-conjugated particles expressed as (a) % of control 
cells and (b) mean fluorescence intensity. 
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Figure 3.14. AML12 cell uptake after dosing with 200 nm ligand-conjugated particles 
expressed as (a) % of control cells and (b) mean fluorescence intensity. 
 
3.3.3 Screening lactoferrin density on 80x180 nm hydrogels for targeting hepatocytes 
To test the targeting capabilities of another particle dimension and to screen bovine 
lactoferrin ligand density, 80x180 nm hydrogel nanoparticles were prepared for 
functionalization with ligands at different reaction stoichiometries. Previously, 200 nm 
particles were prepared with 1 wt eq lactoferrin; for 80x180 nm particles, the stoichiometry 
was titrated to low concentrations and amines were quenched with succinic anhydride post-
PEGylation. Zetaszier analysis (Table 3.5) illustrates that all functionalized particles 
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exhibited negative ζ-potentials around -10 to -15 mV with diameters of ca. 250 nm. These 
particles were dosed on AML12 cells along with previously-prepared 200 nm ligand-
conjugated, quenched particles.  
Uptake of targeted, quenched 200 nm particles by AML12 cells was similar to 
previous studies where high internalization occurred at low doses for LTF-conjugated 
particles while uptake of LTF-free (ethanolamine-reacted, control) particles was notably 
lower when incubated in complete medium or OPTI-MEM (Figure 3.15). MFI of AML12 
cells incubated with particles illustrates a significant difference in uptake between LTF- and 
ethanolamine-conjugated particles (Figure 3.15b).  
Table 3.5 Zetasizer analysis of functionalized 80x180 nm hydrogel nanoparticles. 
Particle (ligand, wt eq) ζ-potential (mV) Dz (nm) 
EtOHNH2, 4 -14.5 ± 3.2 252.7 ± 15.4 
Lactoferrin, 1 -9.8 ± 0.3 246.5 ± 4.7 
Lactoferrin, 1/5 -10.0 ± 0.8 237.2 ± 3.5 
Lactoferrin, 1/50 -11.7 ± 0.4 261.8 ± 3.0 
Lactoferrin, 1/500 -12.5 ± 0.6 260.1 ± 11.6 
 
Internalization of ligand-conjugated 80x180 nm hydrogel nanoparticles by AML12 
cells shows similar trends to the 200 nm particles. Uptake of ligand-conjugated particles (at 
higher ligand density) reached saturation in a dose-dependent manner while the control 
(ethanolamine)-conjugated particles and low density LTF-conjugated particles were not 
readily internalized (Figure 3.15). Incubation of targeted particles in OPTI-MEM or complete 
medium (Figure 3.16) resulted in the same differential uptake between particles conjugated 
with sufficient protein and control particles. 
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Figure 3.15 AML12 cell uptake of targeted particles incubated in (a) OPTI-MEM or (b) 
complete medium. 
 
3.3.4 Evaluating human lactoferrin-conjugated nanoparticles targeted to mouse 
hepatocytes in vitro 
80x180 nm hydrogel nanoparticles conjugated with human lactoferrin (LTF) were 
selectively internalized by AML12 mouse hepatocytes relative to control particles. Bovine 
lactoferrin was previously tested and demonstrated the same selective internalization, 
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suggesting that ligand recognition is conserved among species. 80x180 nm hydrogels were 
reacted with SCM-PEG5K-maleimide followed by quenching non-PEGylated amines with 
succinic anhydride. PEGylated particles were then either reacted with human lactoferrin 
(hLTF) or ethanolamine (no LTF). Selective uptake of hLTF-conjugated hydrogels occurred 
across all dosing concentrations (Figure 3.16). Zetasizer analysis of particles (Table 3.6) 
showed that ζ-potentials were negative with diameters around 250 nm.  
 
 
Figure 3.16 (a) AML12 cell uptake (%) of hydrogel nanoparticles functionalized with hLTF 
or EtOHNH2. (b) Mean fluorescence intensity of AML12 cells dosed with functionalized 
particles. 
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Table 3.6 Zetasizer analysis of functionalized hydrogels. 
Sample ζ-potential (mV) Dz (nm) 
EtOHNH2 -12.9 ± 1.1 270.0 ± 10.8 
hLTF -12.2 ± 1.1 231.4 ± 1.0 
 
3.3.5 Targeting human and mouse hepatocytes with lactoferrin- and peptide-conjugated 
nanoparticles  
Human lactoferrin- and T7 phage peptide-conjugated 80x180 nm hydrogel 
nanoparticles were tested for their selective uptake by HepG2 (human) and AML12 (mouse) 
hepatocytes relative to control particles and macrophages. Selective uptake of lactoferrin-
conjugated particles was observed in HepG2 and AML12 hepatocytes while all particles 
were equally internalized by macrophages. 
 
Figure 3.17 SEM micrograph of 80x180 nm hydrogel nanoparticles. 
 
The morphology and dimensions of 80x180 nm hydrogel nanoparticles were assessed 
via SEM to provide visualization of the rod-shaped nanoparticles (Figure 3.17). Ligand-
conjugated particles were prepared by reacting 80x180 nm particles with SCM-PEG5K-
maleimide followed by quenching non-PEGylated amines with succinic anhydride. Control 
particles were prepared by reacting maleimide-grafted particles with ethanolamine 
(EtOHNH2) in basic buffer, peptide-conjugated particles were prepared by reacting a thiol-
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terminated peptide with a maleimide-grafted particle in PBS, and lactoferrin-conjugated 
particles were obtained by incubating lactoferrin with particles in basic buffer.  
 
Figure 3.18 Cell uptake of ligand-conjugated particles. (a) AML12, (b) HepG2, and  
(c) RAW 264.7 cells were dosed with particles to investigate internalization of particles 
conjugated with different ligands. 
 
Selective uptake of lactoferrin-conjugated particles by HepG2 and AML12 
hepatocytes was observed (Figure 3.18a,b) relative to control particles. Peptide-conjugated 
particles were not readily internalized by hepatocytes, potentially due to insufficient ligand 
density. RAW macrophages internalized lactoferrin- and peptide-conjugated particles 
similarly at the highest particle dosing concentration. Confocal microscopy was conducted on 
AML12 and RAW cells dosed with all three types of particles (Figure 3.19 and 3.20). A 
confocal microscopy image was also obtained for HepG2 cells dosed with lactoferrin-
conjugated particles (Figure 3.20d). Notable uptake of particles by AML12 cells was only 
observed for cells dosed with ligand-conjugated particles (Figure 3.19c) relative to control 
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(Figure 3.19b) and peptide-conjugated (Figure 3.19d) particles. Internalization of all three 
particle samples by RAW cells can be noted in the confocal micrographs shown in Figure 
3.20a-c. Uptake of lactoferrin-conjugated particles by HepG2 cells can be inferred from the 
confocal micrograph of Figure 3.20d although actin is not apparent.  
 
Figure 3.19 (a)-(d) Confocal micrographs of AML12 cells dosed with ligand-conjugated 
particles. (a) Cells were not dosed with particles. (b)-(d) AML12 cells were dosed with (b) 
control particles, (c) human lactoferrin-conjugated particles, (d) peptide-conjugated particles. 
Actin was stained with Phalloidin (Alexa Fluor 555, red), nuclei were stained with DAPI 
(blue), and particles were labeled green with DyLight 488 maleimide. 
 
(a) (b)
(c) (d)
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Figure 3.20 Confocal micrographs of (a)-(c) RAW cells and (d) HepG2 cells dosed with 
ligand-conjugated particles. (a)-(c) RAW cells were dosed with (a) control particles, (b) 
human lactoferrin-conjugated particles, and (c) peptide-conjugated particles. (d) HepG2 cells 
were dosed with lactoferrin-conjugated particles. Actin was stained with Phalloidin (Alexa 
Fluor 555, red), nuclei were stained with DAPI (blue), and particles were labeled green with 
DyLight 488 maleimide. 
  
3.3.6 Screening peptide density on hydrogel nanoparticles for targeting hepatocytes in 
vitro 
A cysteine-terminated T7 phage p17 peptide was tested as a ligand on nanoparticles 
to target hepatocytes. 200 nm cylindrical particles were functionalized with the peptide at 
(a) (b)
(c) (d)
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various ratios and a control ligand (ethanolamine). Particles functionalized with the peptide 
at the highest stoichiometric ratio enabled selective uptake. 
200 x 200 nm cylindrical cationic hydrogel nanoparticles were prepared using the 30 
wt% AEM-based composition. Particles were reacted with SCM-PEG5K-maleimide followed 
by quenching non-PEGylated amines with succinic anhydride. The cysteine-terminated 
peptide was conjugated to particles through thiol-maleimide addition at 0.25, 0.5, and 1.0 wt 
equivalent. The BCA assay was utilized for quantifying the number of peptides conjugated to 
nanoparticles (Table 3.7). The amount of peptide conjugated to particles was detectable at the 
highest peptide:particle stoichiometric ratio. Zetasizer analysis of targeted particles 
demonstrated that their diameters were around 300 nm while ζ-potential values were around  
-10 mV (Table 3.7). Particles were dosed on hepatocytes for in vitro analysis of targeting 
capabilities of the peptide.   
Table 3.7 Zetasizer analysis of peptide- and control ligand-conjugated particles. 
Ligand, equiv Dz (nm) ζ-potential (mV) Peptides/particle 
EtOHNH2, 1.0 307.7 ± 2.8 -15.0 ± 3.2 NA 
Peptide, 0.25 304.4 ± 3.9 -8.9 ± 0.2 NA 
Peptide, 0.5 306.3 ± 3.7 -8.0 ± 0.1 NA 
Peptide, 1.0 325.6 ± 3.4 -8.1 ± 0.3 8.31 x 10
4 
NA denotes that the signal was below the lower limit of detection.  
AML12 cell uptake of functionalized particles occurred most notably for particles 
reacted with the phage peptide at the highest stoichiometric ratio (Figs. 3.21a,b) while 
remaining particle samples were not readily internalized. Lower peptide ratios during the 
conjugation reaction may not have enabled sufficient functionalization of particles to be 
recognized by hepatocyte receptors.  
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Figure 3.21 (a) AML12 cell uptake of peptide-functionalized cylindrical nanoparticles.  
(b) Mean fluorescence intensity of AML12 cells dosed with functionalized nanoparticles. 
 
3.4 Targeted PRINT particles for in vivo delivery to hepatocytes 
After establishing promising targeted delivery of lactoferrin- and p17 peptide-
conjugated hydrogel nanoparticles to hepatocytes in vitro, the in vivo biodistribution and 
accumulation in hepatocytes was examined for functionalized hydrogels. Nanoparticle 
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hydrogels with different surface properties were investigated through conjugation of different 
ligands and quenching through covalent and electrostatic strategies. 
3.4.1 Experimental 
3.4.1.1 Materials 
 Materials used for preparing functionalized hydrogel nanoparticles were previously 
reported in sections 3.3.1. 
3.4.1.2 Fabrication, functionalization, and analysis of particles as well as in vitro cell 
studies 
 Previously reported protocols in 3.2.1 and 3.3.1 were implemented for the fabrication, 
functionalization, and analysis of particles in addition to the in vitro cell uptake studies. 
3.4.1.3 In vivo studies 
 Particles were administered to mice and RT-PCR was conducted as described in 
section 2.6.1.4. 
3.4.2 Investigating the effect of covalent quenching on biodistribution of functionalized 
hydrogel nanoparticles 
 Four particle samples were prepared for administration to mice followed by liver 
histological analysis to determine whether particles accumulated in hepatocytes. Particles 
were either PEGylated or conjugated with human lactoferrin. Each particle type was divided 
into cationic and amine-quenched samples to determine if quenching would be necessary for 
targeting in vivo. Cationic 80x180 nm hydrogels were either reacted with SCM-mPEG5K or 
SCM-PEG5K-maleimide. 3/5 of PEGylated particles were quenched with succinic anhydride 
and 2/5 were left unquenched. Maleimide-functionalized particles were then conjugated with 
hLTF. Quenched particles exhibited negative ζ-potentials while unquenched particles were 
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still positive (Table 3.8). Four particle samples were prepared for administration to mice 
followed by liver histological analysis to determine whether particles accumulated in 
hepatocytes. Particles were either PEGylated or conjugated with human lactoferrin. Each 
particle type was divided into cationic and amine-quenched samples to determine if 
quenching would be necessary for targeting in vivo. 
Table 3.8 Zetasizer analysis of functionalized hydrogel nanoparticles. 
Sample ζ-potential (mV) Dz (nm) 
PEG, quenched -30.9 ± 0.7 260.4 ± 2.7 
PEG +13.0 ± 1.5 235.2 ± 4.9 
hLTF, quenched -13.8 ± 0.6 226.8 ± 7.0 
hLTF +4.3 ± 0.3 226.9 ± 2.7 
  
Significant accumulation of functionalized particles in hepatocytes was not observed. 
PEGylated and lactoferrin-conjugated particles that were quenched with succinic anhydride 
accumulated to some extent in the liver while unquenched particles were not observed 
notably in liver sections. Unquenched, PEGylated particles did not accumulate notably in 
liver tissue (Figure 3.22a,b) while quenched, PEGylated particles were observed in liver 
sections (Figure 3.22c,d). Unquenched, lactoferrin-conjugated particles did not accumulate 
notably in liver tissue (Figure 3.23a,b) while quenched, lactoferrin particles were observed in 
liver sections (Figure 3.23c,d). Both lactoferrin-conjugated and PEGylated, cationic particles 
that were not quenched were not observed notably in liver, most likely due to aggregation 
and clearance by the RES. Although quenched particles can be observed in liver tissue, they 
appear somewhat aggregated and do not seem well-dispersed and -distributed throughout 
hepatocytes as well as observed in previous studies with 80x320 nm, PAA-mPEG-coated 
nanoparticles (Figure 2.39). Therefore, PAA-based coatings may be promising for in vivo 
gene silencing. Furthermore, quenching the positive charge of functionalized particles with 
PAA avoids the use of small molecule anhydrides, which may damage siRNA cargo. 
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Figure 3.22 Images of liver sections from different mice dosed with 80x180 nm (a,b) 
unquenched, PEGylated particles, or (c,d) quenched, PEGylated particles. Nuclei were 
stained with DAPI (blue), actin was stained with phalloidin (Alexa Fluor 555, gray), 
macrophages were marked with MARCO (AlexaFluor 488, green), and particles were 
labeled with DyLight 680 (red). 
 
(a) (b)
(c) (d)
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Figure 3.23 Images of liver sections from different mice dosed with (a,b) unquenched, 
lactoferrin-conjugated particles, or (c,d) quenched, lactoferrin-conjugated particles. Nuclei 
were stained with DAPI (blue), actin was stained with phalloidin (Alexa Fluor 555, gray), 
macrophages were marked with MARCO (AlexaFluor 488, green), and particles were 
labeled with DyLight 680 (red). 
 
 
 
 
(a) (b)
(c) (d)
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3.4.3 Electrostatic quenching of ligand-functionalized hydrogel nanoparticles for 
targeting hepatocytes 
3.4.3.1 Evaluating noncovalent quenching of functionalized cationic hydrogels for 
targeting hepatocytes in vitro 
Human lactoferrin- and T7 phage peptide-conjugated 200 nm hydrogel nanoparticles 
were tested for selective uptake by AML12 (mouse) hepatocytes relative to ethanolamine 
when quenching the positive charge with PAA. Previously prepared targeted particles were 
quenched with succinic anhydride; however, a covalent quenching approach may not be 
applicable for delivery of siRNA, but rather electrostatic quenching seemed appropriate to 
minimize damage to siRNA. Ethanolamine was not observed to behave as a negative control, 
i.e. ethanolamine-conjugated particles were internalized to the same degree as ligand-
conjugated particles (Figure 3.24). Although PAA quenching did not yield selective uptake 
as seen with acylation of amines using succinic anhydride, sustained dispersion stability was 
noted with PAA-quenched particles.  
Particles were PEGylated with SCM-PEG5K-maleimide and half of the particles were 
incubated with PAA (30 wt eq) in PBS. Next, particles were reacted with either lactoferrin or 
ethanolamine (EtOHNH2) in sodium borate buffer while PBS was used to conjugate T7 
phage p17 peptide overnight. To the half of particles that were not previously mixed with 
PAA, they were subsequently mixed with PAA (30 wt eq) and washed a couple times with 
PBS. Zetasizer analysis of functionalized particles indicated that they all displayed a negative 
charge and had diameters around 300-400 nm (Table 3.9). Contrary to non-PAA coated 
particles previously explored, dispersion stability was noted by the absence of large 
158 
 
aggregate formation. After 24 h, particles quenched with PAA exhibited roughly the same 
diameters.  
Flow cytometry analysis of AML12 cells dosed with functionalized hydrogels 
showed that targeting selectivity was not observed. In particular, the negative control 
particles (ethanolamine-conjugated) were internalized to the same degree as protein- and 
peptide-conjugated hydrogels (Figure 3.24). Electrostatic absorption of PAA to hydrogels 
does not have the same quenching effect as a covalent approach (e.g. with succinic 
anhydride) to provide targeting selectivity in vitro. However, the ζ-potential of particles was 
rendered negative by quenching with PAA. Ideally particles will accumulate notably in liver 
hepatocytes although in vitro selective uptake was not observed. 
Table 3.9 Zetasizer analysis of functionalized 200 nm hydrogels. 
Particle (ligand, PAA
*
) ζ-potential (mV) Dz (nm) Dz (nm), 24 h 
EtOHNH2, A -18.6 ± 0.7 347.1 ± 5.1 337.5 ± 1.3 
Lactoferrin, A -18.2 ± 0.6 326.1 ± 4.6 321.9 ± 9.9 
Peptide, A -14.2 ± 0.2 405.0 ± 8.0 407.2 ± 7.6 
EtOHNH2, B -14.1 ± 0.8 412.6 ± 11.5  
Lactoferrin, B -15.2 ± 0.7 373.4 ± 9.3  
Peptide, B -14.2 ± 0.8 297.6 ± 6.5  
*
A: PAA before protein conjugation; B: PAA coat after protein conjugation 
 
 
Figure 3.24 AML12 cell uptake of functionalized hydrogels coated with PAA (a) before and 
(b) after ligand conjugation. 
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3.4.3.2 Administration of hydrogel nanoparticles with different surface properties to 
mice to observe bioaccumulation in organs 
80x320 nm hydrogels were prepared using the 30 wt% AEM-based composition with 
three different surface characteristics for intravenous injection in mice. The three particle 
samples were: (1) cationic, (2) PAA-mPEG-coated, and (3) lactoferrin-conjugated. Tissue 
analysis showed that all particles notably accumulated in livers while cationic particles also 
largely distributed to the lung. PAA-mPEG and lactoferrin-conjugated particles distributed 
well throughout liver tissue while cationic particles appeared more aggregated, possibly due 
to accumulation in Kupffer cells.  
80x320 nm particles were prepared with the 30% AEM-based composition as 
previously tested. Particles were harvested off PET with a solution of water or PAA-mPEG-
containing PBS at roughly 30 wt eq. Particles harvested in water were PEGylated with SCM-
PEG5K-maleimide. Next, particles were reacted with lactoferrin in sodium borate buffer. 
Lactoferrin-conjugated particles were then mixed with PAA (30 wt eq) and washed a couple 
times with PBS. All particles were ultimately re-suspended in PVA-containing PBS.  
Zetasizer analysis demonstrated that all particles exhibited negative ζ-potentials with 
diameters around 200-250 nm. BCA analysis of lactoferrin-conjugated particles indicated 
there were 2.2 x 10
3
 proteins per nanoparticle. 
Table 3.10 Zetasizer and BCA analysis of nanoparticles injected into mice. 
Particle ζ-potential (mV) Dz (nm) Ligand density 
PAA-mPEG -9.1 ± 0.4 197.5 ± 5.1  
Lactoferrin -13.4 ± 0.9 218.7 ± 3.4 2.2 x 10
3 
Cationic +14.7 ± 0.4 248.1 ± 3.7  
 
Compared to background fluorescence of untreated mice, livers of mice injected with 
all types of nanoparticles showed notable fluorescence intensity (Figure 3.25a). Also, lungs 
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of mice injected with cationic nanoparticles demonstrated high fluorescence intensity 
compared to untreated mice and those injected with PAA-coated particles. Significant 
differences in fluorescent intensity among untreated mice and those injected with 
nanoparticles were not observed in kidneys, spleen, heart, and intestine/stomach. 
Quantitation of fluorescence intensity (Figure 3.25b) confirms qualitative differences 
observed in organ imaging. 
  
Figure 3.25 (a) Organ imaging of untreated mice and those injected with nanoparticles for 
biodistribution analysis. (b) Fluorescence intensity of untreated mice and those injected with 
nanoparticles. 
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distribution of particles in liver tissue (Figure 3.26). 0.5 mg of particles was injected 
intravenously and livers were harvested 24 h post-injection and frozen. 5 µm sections were 
stained and imaged with confocal microscopy. Cationic particles appear aggregated to some 
degree in confocal images, most likely due to their charge and localization in Kupffer cells. 
The negative charge on functionalized and PAA-coated particles ideally enhanced their 
dispersion and minimized uptake by macrophages. PAA-mPEG-coated and lactoferrin-
conjugated, PAA-coated particles appear to be well-distributed throughout liver tissue. 
Distribution of particles throughout liver tissue ideally will enable transfection with siRNA-
conjugated, functionalized hydrogels.  
 
Figure 3.26 Liver histology from mice injected with cationic, PAA-mPEG-coated, and 
lactoferrin-conjugated, PAA-coated nanoparticles (two images per particle sample). Particles 
were labeled with DyLight 488 maleimide (green), cell nuclei were stained blue with DAPI, 
and actin was stained red with Phalloidin (AlexaFluor 555). 
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3.4.3.3 siRNA-conjugated hydrogel nanoparticles for in vivo gene silencing 
80x320 nm cationic hydrogel particles were prepared with the 30 wt% AEM-based 
composition, charged with either FVII or ELAV siRNA, and harvested off PET with a 
solution of water or PAA-mPEG-containing PBS at roughly 30 wt eq. Half of the particles 
harvested in water were PEGylated with SCM-PEG5K-maleimide. Next, particles were 
reacted with lactoferrin in sodium borate buffer. Lactoferrin-conjugated particles were then 
mixed with PAA (30 wt eq) and washed a couple times with PBS. All particles were 
ultimately re-suspended in PVA-containing PBS. Zetasizer analysis (Table 3.11) confirmed 
that cationic particles had a positive ζ-potential while PAA-mPEG-coated and lactoferrin-
conjugated, PAA-quenched particles had negative ζ-potentials. BCA assay allowed for 
quantitation of lactoferrin conjugated to particles. Diameters of particles ranged from ca. 300 
to 360 nm. Gel electrophoresis of siRNA released from particles (Figure 3.27) showed that 
particles had encapsulation efficiencies around 28-33%. 
Table 3.11 Zetasizer and BCA analysis of pro-siRNA nanoparticles for in vivo gene 
silencing. 
Particle, siRNA, sample 
label 
ζ-potential 
(mV) 
Dz (nm) 
Ligand density 
(protein/particle) 
PAA-mPEG, ELAV, A -15.4 ± 0.5 303.3 ± 6.6 NA 
Lactoferrin, ELAV, B -24.2 ± 0.8 372.2 ± 4.3 4.8 x 10
3
 
Cationic, ELAV, C +18.3 ± 3.2 292.8 ± 6.9 NA 
PAA-mPEG, FVII, D -11.3 ± 0.2 327.2 ± 11.3 NA 
Lactoferrin, FVII, E -19.4 ± 0.5 357.5 ± 3.1 6.7 x 10
3 
Cationic, FVII, F +23.7 ± 0.7 306.9 ± 4.7 NA 
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Figure 3.27 Gel electrophoresis analysis of siRNA-containing nanoparticles. Particles were 
incubated in 5 mM glutathione-containing 10x PBS (0.05% PVA) at 2 mg/mL for 4 h 
followed by isolation of supernatants for loading into the gel. Encapsulation efficiency was 
calculated to be 28-33% for the samples listed. Corresponding sample labels are provided in 
the Zetasizer table. 
 
 
Figure 3.28 Relative FVII gene expression of mice without treatment or after administration 
of different hydrogel nanoparticles. n.s. not significant; 
**
P < 0.01; t-test, double-tailed,  
 n = 3.  
   
0.5 mg of particles was dosed per mouse which corresponds to ca. 0.4 mg/kg siRNA 
doses. FVII siRNA-conjugated hydrogel nanoparticles coated with PAA-mPEG elicited a 
statistically significant decrease in target FVII levels (Figure 3.28, greater than 40% 
knockdown). Conversely, ELAV1 siRNA-conjugated particles coated with PAA-mPEG did 
not significantly alter expression of FVII. Cationic particles loaded with ELAV1 or FVII 
siRNA did not influence expression of FVII, most likely due to inefficient accumulation in 
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hepatocytes. LTF-functionalized, PAA-quenched particles did not cause significant 
knockdown of FVII gene expression. 
3.4.3.4 Targeting hepatocytes with ligand-functionalized hydrogel nanoparticles 
prepared with different reaction conditions 
Since a notable gene silencing effect was not observed with pro-siRNA, LTF-
functionalized nanoparticles in vivo, conjugation conditions were evaluated to maximize 
amine content while enabling selective cell uptake. 200 nm cationic hydrogels (30% AEM-
based composition) were harvested mechanically in water, followed by functionalization 
with SCM-PEG5K-maleimide (1 wt eq) using pyridine base in DMF overnight.  
Table 3.12 Zetasizer and BCA analysis of functionalized nanoparticles. 
Ligand, conditions ζ-potential (mV) Dz (nm) Proteins/particle 
LTF, PBS, 24 h -11.0 ± 1.0 371.3 ± 1.9 6.8 x 10
3 
EtOHNH2, PBS, 24 h -11.8 ± 0.6 370.2 ± 6.7 NA 
LTF, pH 8.5, 1 h -11.4 ± 0.6 385.7 ± 4.7 5.1 x 10
3
 
EtOHNH2, pH 8.5, 1 h -10.8 ± 0.7 397.6 ± 5.8 NA 
LTF, pH 8.5, 4 h -12.5 ± 0.6 324.4 ± 4.8 7.1 x 10
3
 
EtOHNH2, pH 8.5, 4 h -10.7 ± 0.2 326.5 ± 3.1 NA 
LTF, pH 9.5, 1 h -12.8 ± 1.4 334.2 ± 9.1 6.3 x 10
3
 
EtOHNH2, pH 9.5, 1 h -11.9 ± 0.8 318.8 ± 6.5 NA 
LTF, pH 9.5, 4 h -11.9 ± 0.5 316.6 ± 8.7 9.7 x 10
3
 
EtOHNH2, pH 9.5, 4 h -12.3 ± 1.2 320.2 ± 4.4 NA 
NA implies that signal was not detectable in BCA analysis  
  
Fewer equivalents of PEG were used to minimize the amount of amines reacted. Non-
PEGylated amines were quenched with succinic anhydride. Lactoferrin (LTF) or 
ethanolamine (control, EtOHNH2) were conjugated to PEGylated particles under different 
reaction conditions: (1) PBS for 24 h, (2) pH 8.5 buffer for 1 and 4 h, and (3) pH 9.5 buffer 
for 1 and 4 h. Increasingly basic conditions may result in rearrangement of AEM from amine 
into alcohol through intramolecular cyclization for unquenched particles; therefore, shorter 
reaction times and more neutral buffers were tested. Particles were washed and BCA analysis 
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was conducted on particle samples to determine the amount of protein conjugated to 
nanoparticles.  
 
 
Figure 3.29 Uptake of functionalized hydrogel nanoparticles by AML12 cells shown as (a) 
percentage of cells with particles and (b) MFI of cells. 
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Selective uptake of LTF-functionalized particles by AML12 cells was observed 
relative to control particles for all conjugation conditions (Figure 3.29). MFI of AML12 cells 
shows that conjugating protein to particles in pH 8.5 buffer yielded the highest uptake, 
followed by pH 7.4 and then pH 9.5. Unquenched, targeted particles were prepared for 
conjugation of ligands in PBS for 24 h and pH 8.5 for 1 h to evaluate ζ-potential relative to 
bare, cationic particles. The ζ-potential of targeted particles conjugated with ligands in PBS 
was +14.8 ± 1.2 mV and +15.7 ± 0.5 mV for particles conjugated with ligand in pH 8.5 
buffer. Unquenched, targeted particles prepared under the aforementioned conditions 
exhibited ζ-potentials similar to bare, cationic particles (+16.7 ± 0.5 mV). Application of 
these targeted particles toward in vivo studies at higher doses may enable complete gene 
silencing similar to PAA-mPEG-coated nanoparticles. 
3.5 Recovery of siRNA throughout particle fabrication and pursuing scalability 
To account for all of the siRNA implemented in preparing particles, excess material 
remaining on the delivery sheets, draw down table, and Mayer Rod was collected in addition 
to the sol fraction from particles for quantification. Recovered siRNA was then charged into 
the pre-particle solutions to prepare pro-siRNA hydrogel nanoparticles, exhibiting 
encapsulation efficiency similar to charging siRNA prodrug directly after synthesis.  
In addition to recovering precious siRNA implemented in particle fabrication, a more 
scalable protocol for fabrication of particles was pursued. Specifically, a procedure that 
would enable rapid particle curing (in less than a minute) and avoid mechanical harvesting 
was desired. A UV-LED curing system was developed for quick particle curing and a 
sacrificial harvesting layer was used to extract particles from the mold for “bead harvesting”. 
A bead harvester with controlled air flow was used to create a stable water bead at the nip 
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that may dissolve away the harvesting layer, liberating particles into solution as the particle 
array-covered film passes through the nip. 
3.5.1 Experimental  
3.5.1.1 Materials 
Materials were obtained as previously reported in previous sections. 2,4,6-
trimethylbenzoyl-diphenyl-phosphineoxide (TPO) was obtained from Sigma. An LED curing 
system was implemented for select studies, implementing TPO as the photoinitiator. 
Plasdone (64 kDa) was purchased from BASF. Bead harvesters were graciously provided by 
Liquidia Technologies. The UV-LED setup was prepared at UNC by Sarah Mueller using 
StarFire MAX (150 x 20 mm, 4 W/cm
2, λ = 380-420 nm) from Phoseon Technology. 
3.5.1.2 Particle fabrication and siRNA recovery methods  
The 30% AEM-based composition with 5 wt% siRNA was pursued for preparation of 
pro-siRNA hydrogel nanoparticles as conducted through previously reported procedures. The 
following measures were taken for recovering siRNA implemented in pro-siRNA hydrogel 
fabrication: (1) after laminating the delivery sheet against the mold, remaining material was 
collected from the delivery sheet with a cell scraper using DEPC-treated water, (2) excess 
pre-particle solution drawn past PET sheet, after casting a film, was collected from the draw 
down table with water and a cell scraper, and (3) the Mayer rod was placed vertically on the 
draw down table and a few milliliters of water were dispensed on the top, letting it drip down 
for collection. When pro-siRNA hydrogels were washed with 10x PBS, the sol fraction was 
stored. All samples were concentrated through lyophilization and dialyzed (MWCO 2kDa) to 
remove monomers. 
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3.5.1.3 Fabrication of particles through scalable protocols 
Compositions in Table 3.13 were used to prepare 2.5 wt% pre-particle solutions of 
monomers in DEPC-treated water (Hg cure) or methanol (for the LED cure). The film split 
technique was used to fill PRINT molds. Instead of laminating corona-treated PET to filled 
molds, UV curing chambers were purged with N2, followed by quickly inserting filled molds, 
briefly re-purging with N2, and curing for given times. Cured particles were then laminated 
against Plasdone harvesting layer at 240 ºF to adhere the sacrificial polymer to particles. 
After returning to room temperature, the Plasdone layer was removed, revealing an array of 
particles, which were then bead-harvested with water. Particles were subsequently washed 
with 10x PBS to remove the sol fraction. 
3.5.1.4 Particle characterization and cell studies   
Characterization of particles and cell studies were conducted as previously reported in 
in section 3.4.1.2. 
3.5.2 Recovery of siRNA in the PRINT process 
 
Figure 3.30 Gel electrophoresis of siRNA recovered from delivery sheet and washed from 
particles. (1-3) siRNA standard of 50, 100, and 200 ng; (4-5) delivery sheet contents after 
filling the mold; (6) sol fraction of siRNA macromer recovered in 10x PBS. 
 
In an attempt to recover siRNA throughout particle fabrication, delivery sheets were 
harvested after filling the mold and non-conjugated siRNA was washed from hydrogels. 300 
µL of pro-siRNA pre-particle solution containing 0.38 mg siRNA was used to prepare two 
delivery sheets for filling two feet of 200 nm cylindrical molds (1.7 mg particles). Collection 
1     2    3    4     5 6
Gel lane designations:
1, 2, 3 – siRNA standard: 50, 100, 200 ng
4 – delivery sheet contents after filling the mold
5 – delivery sheet contents after filling th  mold
6 – sol fraction of siRNA macromer recovered in 10x 
PBS washes
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of delivery sheet contents with water was performed after filling molds using a cell scraper. 
Collected delivery sheet contents were subjected to dialysis (2 kDa MWCO membrane) to 
remove monomers and crosslinker. Gel analysis (Figure 3.30) shows the integrity of siRNA 
recovered from delivery sheets (lanes 4 and 5). UV-Vis analysis of siRNA prodrug recovered 
from the delivery sheet totaled 0.21 mg of siRNA (56% of the starting siRNA in the pre-
particle solution). Since pro-siRNA hydrogels are subjected to washing after fabrication to 
remove non-conjugated siRNA, the 10x PBS washes were retained and concentrated for 
analysis. Lane 6 (Figure 3.27) shows siRNA washed from hydrogels (26 µg total by UV-Vis, 
7% of original pre-particle solution). When combined with siRNA prodrug released from 
hydrogels (31 µg), the siRNA recovered totaled 15% of the starting siRNA in the pre-particle 
solution. Approximately 71% of the siRNA originally charged was collected. 
When casting films, excess solution may be drawn past the edge of the PET sheet and 
could be collected for analysis. The remaining 25% may remain residually on the Mayer Rod 
and require addition of other solvents like EtOH to remove components efficiently while 
gently scraping the Mayer Rod.  
Recovered siRNA was then charged into the pre-particle solution for preparing 
cationic pro-siRNA hydrogels (30% AEM composition). Hydrogels were thoroughly washed 
and then incubated in glutathione-containing 10x PBS for release of prodrug (Figure 3.31). 
Conversion of pro-siRNA (ca. 30%) was similar to that for pro-siRNA hydrogels prepared 
with prodrug directly after synthesis. 
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Figure 3.31 siRNA released from hydrogels charged with recovered siRNA that were 
incubated in GSH-containing 10x PBS for examining cargo release. 
  
3.5.3 Scaling up pro-siRNA hydrogels of various dimensions for gene knockdown 
3.5.3.1 Exploring fabrication conditions for open face curing particles 
In pursuit of scalable methods to fabricate pro-siRNA hydrogels, 200 nm particles 
were prepared by curing molds open-face on the mercury bulb UV lamp as well as on the 
LED curing system. By gel electrophoresis, conversion of siRNA macromer was lower 
(Figure 3.32) than when curing molds closed face against PET.  
Table 3.13 Compositions of pre-particle solution for fabrication of pro-siRNA hydrogels. 
Component wt% (Hg cure) wt % (LED cure) 
PEG700 diacrylate 5 5 
HP4A 49 59 
AEM 30 30 
Poly(vinyl alcohol) 2 kDa 10 0 
Irgacure 2959 1 0 
TPO 0 1 
siRNA prodrug 5 5 
 
The conventional composition (Table 3.13, Hg cure) was implemented in curing 
filled molds on the Hg bulb lamps; however, the same water-based composition was not 
implemented for curing molds on the LED system. The photoinitiator for the LED 
composition (2,4,6-Trimethylbenzoyl-diphenyl-phosphineoxide) is water-insoluble; 
therefore, modifications were made to the composition, including solvent (MeOH), removal 
50     100     200               
siRNA standard (ng) 
Hydrogels 
with recovered 
siRNA
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of PVA, and change of photoinitiator (Table 3.13). Cured particles were thermally 
transferred to PVA-coated PET, bead-harvested with DEPC-treated water, and thoroughly 
washed with buffer to remove the sol fraction. From Figure 3.32, conversion of siRNA 
appears to be roughly 5% when molds were cured on the LED for 12 sec while conversion 
was not attained when curing for 3 sec. Curing molds with the Hg bulb lamp enabled 18% 
conversion of prodrug monomer. Closed face curing molds against PET yields 35% 
conversion of siRNA macromer (e.g. when charging 5 wt% siRNA, 1.75 wt% siRNA is 
conjugated to the matrix). Longer curing times may be required for increased conversion of 
siRNA pro-drug macromer.  
 
Figure 3.32 Release of siRNA from hydrogels cured under different conditions, which were 
incubated at 0.5 mg/mL in 10x PBS containing glutathione for 4 h at 37 °C. 
 
3.5.3.2 Varying siRNA loading in hydrogel nanoparticles and assessing gene knockdown 
siRNA pro-drug content was varied in hydrogel nanoparticles fabricated via a 
scalable protocol to optimize gene silencing efficiency. Gene silencing efficiency increased 
with siRNA loading. Effective gene knockdown was observed for 200 nm and 80x320 nm 
hydrogels charged with 5 wt% siRNA.  
200x200 nm cylindrical nanoparticles were prepared from the pre-particle solution 
compositions listed in Table 3.14 by open-face curing molds for 30 s using the LED curing 
chamber, transferred to Plasdone at 240 ºF, and bead-harvested with water. Particles were 
then repeatedly washed in 10x PBS containing 0.05% PVA and re-suspended in 1x PBS 
50        100     200        
siRNA standard (ng)
12          3          5   
LED cure (s)
Hg cure 
(min)
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containing 0.05% Plasdone (for particles containing 0.1-5.0 wt% siRNA). Particles charged 
with 5 wt% siRNA were washed and re-suspended in DEPC-treated water to promote uptake 
and endosomal escape. Particles were dosed on HeLa cells for in vitro studies. Zetasizer 
analysis demonstrated that particles had similar charges and diameters (Table 3.15). Gel 
analysis illustrated high encapsulation efficiency of siRNA prodrugs (Figure 3.33). 
Table 3.14 Compositions of LED-cured pro-siRNA hydrogels. 
Component Function wt % 
PEG700 diacrylate crosslinker 10 
Tetraethyleneglycol monoacrylate hydrophile 56.9-52.0 
2-aminoethyl methacrylate HCl cationic handle 30 
TPO photoinitiator 2 
DyLight 488 maleimide fluorescent dye 1 
siRNA PD cargo 0.1-5.0 
  
 
Table 3.15 Zetasizer analysis of LED-cured pro-siRNA hydrogels. 
siRNA wt% ζ-potential / mV Dz / nm 
0.1 +24.9 ± 0.9 312.5 ± 7.0 
0.5 +26.2 ± 0.5 317.5 ± 3.0 
1.0 +25.3 ± 3.2 307.5 ± 12.3 
2.5 +25.6 ± 2.9 305.2 ± 9.6 
5.0 +20.3 ± 1.4 307.5 ± 1.9 
 
 
Figure 3.33 Gel analysis of particles incubated in 10x PBS (5 mM) at 37 °C for 4 h 
illustrates that that encapsulation efficiency appeared to be high for all samples (ca. 75% or 
greater except ca. 55% for 5 wt% siRNA-charged particles). 
 
   
50        100       200        0.1        0.5        1.0        2.5          5.0
siRNA  standard (ng) Particles (wt% siRNA)
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Figure 3.34 (a) HeLa cell uptake, (b) viability, and (c) luciferase expression after dosing 
with particles containing different siRNA loadings. 
  
Cell uptake occurred rapidly at low doses and viability was maintained across all 
dosing concentrations (Figure 3.34a,b). Luciferase gene silencing efficiency increased with 
siRNA loading where gene knockdown was most effective for hydrogels charged with 5 wt% 
siRNA (Figure 3.34c).  
Next, 80x320 nm hydrogel nanoparticles were evaluated for scale-up fabrication and 
gene silencing activity. Characterization of hydrogels through Zetasizer analysis indicated a 
positive ζ-potential of ca. +23 mV and a diameter around 260 nm (Table 3.16). When 
particles were dosed on HeLa cells, viability was maintained across all dosing concentrations 
(Figure 3.35a). Gene silencing was achieved notably for cells dosed with 80x320 nm 
hydrogels. Gene silencing efficiency of hydrogels prepared through the scalable protocol 
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may not be as high as for pro-siRNA particles fabricated through closed-face curing and 
mechanical harvesting due to difference in particle morphology and siRNA release 
characteristics. Combining components from the closed-face curing protocol with water-
soluble LED photoinitiator may allow for equivalent transfection efficiency by particles 
prepared through a scalable protocol. 
Table 3.16 Zetasizer analysis of LED-cured 80x320 nm hydrogel nanoparticles. 
Particle dimensions (nm) ζ-potential / mV Dz / nm 
80x320 +23.2 ± 3.9 258.8 ± 5.5 
 
 
Figure 3.35 (a) Viability and (b) luciferase expression of HeLa cells dosed with rice-shaped, 
pro-siRNA hydrogel nanoparticles fabricated through LED curing. 
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3.6 Future work for siRNA-conjugated, functionalized hydrogels 
Delivery of RNAi therapies in vivo to treat various disease targets may be pursued 
with well-defined particulate vectors prepared via PRINT technology. Derivatives of siRNA 
macromers containing acid-labile or enzymatically-degradable linkages may be pursued to 
explore different release profiles under biologically relevant conditions. Additional matrices 
and coatings may be explored to further enhance biocompatibility, endosomal escape, 
biodistribution, and targeting particular cells. Instead of polymerizing siRNA into hydrogel 
matrices, particles may be conjugated with siRNA post-fabrication to control surface density 
of siRNA on particles. 
3.6.1 siRNA macromers with different degradable linkages 
 
 
Figure 3.36 Synthetic routes to siRNA pro-drug macromers containing degradable linkages. 
(a) 2’-hydroxyl groups of the backbone or the (b) 5’ terminal alcohol of the oligonucleotide 
may be reacted with acrylate-functionalized chlorosilanes. (c) Amine-terminated siRNA may 
be reacted with an NHS-activated chlorosilane to yield a pendant silyl ether prodrug.  
(d) siRNA may be end-functionalized with a NHS-activated, methacrylated Cathepsin B- 
cleavable peptide for use as a prodrug. 
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Photopolymerizable siRNA macromers bearing acid-labile or enzymatically 
degradable linkages may be prepared to explore the controlled release of cargo from particles 
under different environments. For example, native siRNA may be reacted with chlorosilane 
acrylates in different stoichiometric ratios to yield siRNA macromers containing silyl ether 
linkages from nucleobases off the backbone or at the terminal end of the oligonucleotide 
(Figure 3.36). Controlled terminal conjugation of siRNA with silyl ether linkages may be 
carried out by reacting an NHS-activated silyl ether acrylate with amine-terminated siRNA. 
Endosomal and lysosomal peptidases like Cathepsin B may be harnessed to cleave 
degradable peptide linkages installed in the siRNA macromer by linking a heterobifunctional 
peptide containing an NHS and methacrylate with amine-terminated siRNA. 
3.6.2 Additional matrices for siRNA-conjugated hydrogels 
For mucociliary transport of particles, chitosan has been demonstrated to exhibit 
enhanced mucociliary properties. One of the principal repeating units of chitosan is 
glucosamine, which may be acrylated to create a photopolymerizable monomer applicable to 
fabrication of hydrogels. α-alkyl acrylic acids (such as propylacrylic acid) may be used as 
major constituents of hydrogel matrices that are water-soluble and negatively charged at 
physiological pH; yet, under endosomal (acidic) conditions, poly(propyl acrylic acid) 
undergoes a conformational change upon protonation of carboxylates to behave 
endosomolytically. Amine-containing monomers such as those listed in 2.7.2 may also be 
used in hydrogel matrices.  
Controlled radical polymerizations may afford greater conversion of siRNA 
macromers into the particle matrix and a well-defined network structure. ATRP and RAFT 
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polymerizations have been conducted to produce nanogels and may potentially be applied to 
PRINT given the correct fabrication conditions. Preparing particles through solution 
polymerizations may also enable better incorporation of siRNA macromers and enhance 
uniformity of network structure. Larger mold feature sizes may facilitate retention of solvent 
when open-face curing without taking additional steps to prevent evaporation such as chill 
plates or covering the filled molds. To enable UV-LED curing of filled molds from water-
based solutions, a hydrophilic phosphine oxide photoinitiator may be pursued (Figure 3.37). 
 
Figure 3.37 Proposed structure of water-soluble phosphine oxide photoinitiator. 
 
3.6.3 Endosomolytic coatings on nanoparticles for gene delivery 
In addition to functionalized poly(acrylic acid) derivatives mentioned in the previous 
chapter, poly(alkyl acrylic acid)s could be functionalized with mPEG and ligands to enable 
stealthing, targeting, and endosomolytic features. Poly(alkyl acrylic acid)s have demonstrated 
promise for endosomolysis toward delivery of biologics to the cellular cytoplasm.
33
 
Functional poly(glutamic acid)s may be pursued as a biodegradable polyanionic coating. 
Hyaluron, a carboxylic acid-containing polysaccharide, may be coated to cationic particles to 
provide a negative charge and act as a targeting ligand to melanoma cells. 
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3.6.4 Conjugation of siRNA post-particle fabrication  
To avoid the need for collecting the siRNA remaining on the delivery sheet after 
filling molds, siRNA may be conjugated to the particle post fabrication. Conjugation 
strategies may be similar to nucleic acid nanostructures
6,34
 where a high density of siRNA 
may be packed onto the surface of nanoparticles. High density of oligonucleotides 
conjugated to the particle surface, obtained through use of high salt concentration during 
conjugation reactions to minimize electrostatic repulsion, has potential to minimize nuclease 
degradation, provide diffusion through tissue, and enable cell uptake without posing toxicity 
from amine-containing species. Non-degradable conjugation strategies for siRNA to particles 
may entail implementing carboxylic acid-containing monomers like 2-carboxyethyl acrylate 
in the matrix which may be conjugated to amine-terminated siRNA through sulfo-NHS/EDC 
chemistry. Alkyne-containing acrylates may be implemented in particle matrices as well for 
conjugation with azide-terminated siRNAs through click chemistry.  
To conjugate siRNA to particles through degradable linkages post-particle 
fabrication, heterobifunctional monomers containing degradable linkages may be pursued. 
For example, disulfide-containing monomers with an acrylate and a functional group may be 
used as illustrated in Fig 3.38. The first monomer may be synthesized by reacting 3,3'-
dithiodipropionic acid with 2-aminoethylmethacrylate where this disulfide-containing 
monomer may be incorporated into the pre-particle solution. Subsequently, the carboxylic 
acid may be activated with EDC/sNHS for subsequent conjugation of amine-terminated 
siRNA. The second monomer may be prepared as described in section 3.2. As a control, the 
third monomer illustrated (an acrylamide, NHS-activated monomer) may be charged into the 
pre-particle solution for stable conjugation of siRNA. In case stability of the NHS carbonates 
179 
 
is compromised in particle fabrication, the alcohol precursors may be used as monomers 
followed by activation with disuccinimidyl carbonate (in large excess) post-particle 
fabrication for subsequent conjugation of siRNA.   
 
Figure 3.38 Structures of monomers that may be used to conjugate siRNA post-particle 
fabrication and corresponding bonds formed with siRNA. 
 
3.6.5 Delivery targets for RNAi 
Systemic delivery of siRNA through intravenous injection represents one of the most 
common modes of administration for liver and cancer therapies. For effective systemic 
delivery, generally stealthing and targeting ligands are required to passively reach the tissue 
and then target cell receptors for uptake. Targeting delivery vehicles to the RES (monocytes) 
should be easily accomplished by using ligands such as mannose to target the mannose 
receptor where GFP and therapeutic models may be investigated, e.g. chemokine receptor 
CCR2 in atherosclerosis.  
Conventional systemic therapy may involve tumor targets, which feature leaky 
vasculature that can be harnessed in the enhanced permeability and retention effect for 
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increased accumulation in tumor areas. Nanoparticles may be decorated with ligands 
targeting the tumor endothelium, such as the RGD peptide, and loaded with siRNA against 
vascular endothelial growth factor (VEGF) to suppress tumor growth. In targeting tumor 
cells, the identity of the ligand will depend on the type of cancer, e.g. prostate specific 
membrane antigens may be targeted with aptamers decorated on nanoparticles containing 
anticancer siRNA against KIF11, which can cause cellular apoptosis. Direct intratumoral 
injection of delivery vectors in xenograft models may enable increased transfection relative 
to systemic administration. Loading magnetite (iron oxide nanoparticles) into polymeric 
nanoparticles may enable tissue-specific delivery of siRNA as has been demonstrated by 
LipoMag, an oleic acid-coated magnetic core with a cationic lipid shell
35
 that is guided to 
tumors with a magnetic field.  
Iontophoretic delivery devices may be utilized to drive charged particles into the 
tissue of interest with greater accumulation. Prodrug approaches to siRNA delivery could be 
instrumental in iontophoresis of particles due to the use of an electric field that would most 
likely destroy the electrostatic association of physically-entrapped siRNA with cationic 
particles. Microneedles may be used separately or in combination with iontophoretic delivery 
devices to transport siRNA to relevant tissues through topical application. Inhalation of 
aerosolized nanoparticles containing siRNA could provide therapeutic value in treating cystic 
fibrosis, asthma, influenza, or the common cold. Different modes of delivering siRNA, 
harnessing PRINT technology, with optimized physicochemical properties of vectors, may 
enable RNAi in tissues not easily accessible through traditional nanoparticle formulations or 
local routes of administration to treat diseases that pose many challenges for conventional 
therapies. 
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APPENDIX 
 
BIODEGRADABLE POLY(ESTER)-BASED RICE-SHAPED NANOPARTICLES 
FOR GENE SILENCING IN CANCER CELLS 
 
A.1 Introduction to biodegradable poly(ester)s for delivery of siRNA 
 
Polyesters present attractive qualities as a matrix in the delivery of siRNA such as 
biocompatibility, lack of toxicity, bioabsorption (biodegradation), and high stability. The 
backbone of polyesters may be degraded hydrolytically or enzymatically to produce low 
molecular weight fragments and ultimately small molecule acids. Hydrophobic thermoplastic 
polyesters are melt-processable and water-insoluble materials, whose rate of hydrolytic 
degradation depends on morphology. Increased crystallinity leads to a slower rate of 
hydrolytic degradation due to limited access of water to attack the ester backbone. Chemical 
structures of three common polyesters, which are all FDA-approved materials, are illustrated 
in Figure A.1. As homopolymers, all materials are semicrystalline with poly(ε-caprolactone) 
(PCL) having the slowest rate of degradation due to its longer aliphatic chain length 
(hydrophobicity). Combining polyester homopolymers can produce amorphous 
thermoplastics, e.g. poly(lactic-co-glycolic acid) (PLGA), which is a commonly used 
copolymer of poly(glycolic acid) and poly(lactic acid) with relevant degradation times and 
processing properties toward drug delivery. 
 
Figure A.1 Structures of poly(glycolic acid), poly(lactic acid), and poly(ε-caprolactone). 
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PLGA nanoparticles have been prepared in a double emulsion solvent evaporation 
technique with siRNA and spermine, a biological polyamine that significantly enhanced 
encapsulation efficiency and enabled effective gene silencing in vitro.
1
 Steady release of 
siRNA from PLGA nanoparticles was observed under biologically relevant conditions and 
sustained gene silencing was elicited by vaginal instillation of particles into the reproductive 
tract of female mice. The double emulsion solvent evaporation technique has also been 
applied to prepare siRNA-loaded PLGA nanoparticles using acetylated bovine serum 
albumin to stabilize the primary emulsion and notably enhance encapsulation efficiency.
2
 
Slow release of siRNA from these PLGA nanoparticles was observed in buffer and released 
siRNA silenced gene expression in vitro when complexed with Lipofectamine
TM
 2000. 
Blends of polyethyleneimine, polyethylene glycol, and chitosan with PLGA and siRNA have 
been formulated to produce nanoparticles through nanoprecipitation to enable gene 
knockdown in vitro.
3
 In contrast to the requirement for additional materials to enhance 
encapsulation of siRNA in PLGA particles, PRINT allows for the direct encapsulation of 
siRNA within the PLGA matrix. Multiple siRNAs have been delivered in lipid-coated PLGA 
PRINT nanoparticles toward the treatment of prostate cancer.
4
 
A.2 PLGA and PCL particle matrices for gene silencing in cancer cells  
  
Two polyester particle matrices were evaluated for their ability to transfect cells with 
siRNA. PLGA and PCL, with different rates of degradation, were independently tested to 
prepare PRINT nanoparticles for gene silencing.  
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A.2.1 Experimental 
 
A.2.1.1 Materials 
 
PLGA (85:15 lactic acid:glycolic acid, MW = 50 kDa) was purchased from Sigma 
Aldrich. PCL (MW = 43-50 kDa) was purchased from Polysciences. Luciferase and control 
siRNA sequences used in these studies are listed in section 2.2.1.1 and 2.3.1.1. 
DOTAP:DOPE transfection lipid was obtained from Avanti Polar Lipids, Inc. 80x320 nm 
molds were graciously provided by Liquidia Technologies. Krosflow® MicroKros (X1-500S-
200) tangential flow filtration apparatus was obtained from Spectrum Labs.  
A.2.1.2 Fabrication of siRNA-containing, lipid-coated PLGA and PCL nanoparticles  
 
A 2 wt% solution of 95:5 (wt:wt) of PLGA or PCL:siRNA was prepared in DMF 
(using an aliquot of siRNA dissolved in DEPC-treated water at 50 mg/mL) from which a film 
was cast on a PET sheet using a #5 Mayer Rod while evaporating solvent with a heat gun. 
80x320 nm Liquidia molds were filled by lamination against PCL-siRNA and PLGA-siRNA 
films using a heated nip laminator at 270 ºF (80 psi) and 240 ºF. After cooling to room 
temperature wherein vitrification of PLGA and crystallization of PCL may occur, filled 
molds were laminated against PVA-coated PET under the same heated nip conditions. After 
delaminating the mold from the harvesting layer, particles were bead-harvested with DEPC-
treated water or a lipid-containing solution using 1 mL of solvent per ft of particles. Particles 
were subsequently purified through tangential flow filtration using ca. 15 mL of water for 2 
mg of particles. 
A.2.2 PLGA particles 
  
80x320 nm PLGA particles fabricated with luciferase or control siRNA were 
harvested with 0.25 mg of lipid per ft of particles and washed through tangential flow 
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filtration (TFF). Harvested 80x320 nm particles appear rice-shaped and monodisperse 
(Figure A.2). Zetasizer analysis of lipid-coated siRNA particles shows that particles are 
positively charged with diameters around 300 nm. When lipid-coated particles were dosed on 
HeLa cells stably transfected with luciferase firefly gene, sequence-specific and dose-
dependent gene silencing was observed. Specifically, control siRNA-loaded particles did not 
reduce luciferase expression significantly in comparison to luciferase-containing particles 
(Figure A.3). After confirming that lipid-coated particles could effectively transfect HeLa 
cells, PCL was evaluated as a slow-degrading particle matrix for gene silencing. 
 
Figure A.2 SEM micrographs of (a) control and (b) anti-luciferase siRNA-loaded lipidated 
PLGA rice. 
  
Table A.1 Zetasizer characterization of lipid-coated, PLGA rice. 
 
 
   
Figure A.3 Viability and luciferase expression of HeLa cells dosed with lipidated PLGA rice 
containing (a) control or (b) anti-luciferase siRNA for 4 h followed by 72 h incubation at  
37 ºC in media. 
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(a) Luciferase siRNA PLGA particles
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(b)
siRNA particle ζ-potential / mV Dz / nm 
Anti-luciferase +8.03 314.3 
Control +10.8 307.1 
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A.2.3 PCL particles 
 
Anti-luciferase and control siRNA-charged rice-shaped PCL nanoparticles were 
coated with increasing amounts of transfection lipid and purified through TFF to optimize 
biocompatibility and gene silencing efficiency. 80x320 nm lipid-coated particles appear 
monodisperse and to adopt the correct dimensions (Figure A.4). Diameters of all particles 
were around 220-240 nm, which is lower than PLGA particles due to the absence of a small 
aggregate peak (Table A.2). Lipid concentration-dependent ζ-potentials were observed for 
lipidated PCL rice.  
 
Figure A.4 SEM micrographs of (a) control and (b) anti-luciferase siRNA-containing 
lipidated PCL rice. 
 
Table A.2 Zetasizer analysis of PVA-harvested and lipid-coated PCL particles. 
 
*[Lipid] represents the DOTAP:DOPE stock solution concentration (mg/mL); A and C are 
anti-luciferase and control siRNA. 
(a) (b)
[Lipid], siRNA* ζ-potential / mV Dz / nm 
0 A -3.92 233.7 
0 C -3.01 229.3 
0.05 A -1.64 228.2 
0.05 C -0.64 227.4 
0.10 A +1.00 231.9 
0.10 C +0.81 239.8 
0.15 A +8.69 230.8 
0.15 C +8.91 234.7 
0.20 A +12.7 244.7 
0.20 C +11.7 225.8 
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 siRNA-containing, lipid-coated particles were dosed on luciferase-transfected HeLa 
cells for 4 h followed by 72 h incubation. Gene silencing efficiency increased with particle 
dose and mostly with lipid concentration, reaching an EC50 of ~ 64 nM for particles coated 
with 0.2 mg of lipid per ft of particle based on 100% encapsulation efficiency. However, 
cytotoxicity was noted at high doses of particles coated with lipid at 0.2 mg/ft.  
    
 
Figure A.5 (a) Luciferase expression and (b) viability of HeLa cells dosed with particles 
coated with increasing amounts of DOTAP:DOPE and at increasing particle concentration 
for 4 h followed by 72 h incubation at 37 ºC in media. EC50s were calculated based on 100% 
encapsulation efficiency. 
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A.2.4 Future Work 
 
To enable systemic delivery of PLGA nanoparticles in vivo, PEG lipids, e.g. 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG), may be mixed into the cationic 
lipid harvesting solution. Cells may be targeted with nanoparticles via use of ligand-
terminated lipids in addition to cationic and stealthing ligands. Alternatively, polyanions like 
poly(glutamic acid) may be electrostatically absorbed to cationic lipid-coated particles. 
Polyacid-tethered ligands may enable targeting to specific cellular receptors for selective 
internalization.  
Increased encapsulation of siRNA and retention in the particle matrix may be 
afforded by amine-containing end groups and main chain polyesters. For example, 
oligomeric or low molecular weight telechelic PLGA (dicarboxylic acid) may be reacted with 
diethylenetriamine to install secondary amines and amides into the backbone. Also, diacid 
end groups may be reacted with a variety of amines, e.g. 2-(4-isopropylpiperazin-1-
yl)ethanamine. Covalent attachment of siRNA to PCL may be achieved through acid- or 
reductively-labile bonds (Figure A.6). 
Efficacious polyester-based siRNA delivery vehicles for systemic administration 
would contribute to biodegradable, non-toxic platforms using FDA-approved materials in the 
treatment of diseases. 
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Figure A.6 Retrosynthetic schemes toward siRNA-PCL pro-drug conjugates for covalent 
incorporation and triggered release from the particle matrix. 
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